日本臨牀　別冊　呼吸器症候群（第3版）　II

出版社： 日本臨牀社
発行日： 2021-09-30
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 呼吸器症候群（第3版）　II
電子書籍版： 2021-09-30 （第3版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 特集　呼吸器症候群（第3版）　II　
    　　　―その他の呼吸器疾患を含めて―

    ◇序文：呼吸器症候群（第3版）の発刊にあたって

    IV．アレルギー性肺疾患
    １．喘息，気道疾患
    （１）慢性咳嗽：総論
    （２）咳喘息(CVA)
    （３）アトピー咳嗽
    （４）喉頭アレルギー
    （５）後鼻漏症候群
    （６）胃食道逆流による咳嗽
    （７）薬剤による咳嗽
    （８）難治性咳嗽
    （９）成人気管支喘息
    （10）小児気管支喘息
    （11）小児喘息性気管支炎、急性細気管支炎
    （12）難治性喘息/重症喘息：総論
    （13）重症喘息 (2型炎症：(Type 2炎症)
    （14）重症喘息(非Type2型炎症)
    （15）アレルギー性鼻炎合併喘息、慢性副鼻腔炎合併喘息
    （16）好酸球性多発血管炎性肉芽腫症
    （17）アレルギー性気管支肺アスペルギルス症
    （18）アレルギー性気管支肺真菌症（アスペルギルス以外）
    （19）N-ERD，NSAID-ERD，NSAIDs 過敏喘息 (旧AERD，アスピリン喘息）
    （20）運動誘発性気管支収縮
    （21）職業性喘息
    （22）高齢者(老年者）喘息
    （23）喘息COPDオーバラップ（ACO）
    （24）気道熱傷
    （25）吸入化学物質による肺・気道障害
    （26）金属ヒューム熱
    （27）非アトピー型喘息
    ２．過敏性肺炎
    （１）夏型過敏性肺炎
    （２）農夫肺
    （３）慢性過敏性肺炎
    （４）慢性鳥関連過敏性肺炎
    （５）薬剤性過敏症症候群
    ３．好酸球性肺疾患
    （１）急性好酸球性肺炎
    （２）慢性好酸球性肺炎
    （３）好酸球性気管支炎
    （４）感染性肺好酸球症
    （５）熱帯性肺好酸球増多症
    （６）薬剤性肺好酸球増多症

    V．肺循環の異常
    １．肺障害
    （１）SIRS(全身性炎症反応症候群)，sepsis
    （２）急性呼吸促迫症候群
    （３）虚血・再灌流性肺傷害
    （４）溺水による肺障害
    （５）輸血関連急性肺障害(TRALI)
    ２．肺水腫
    （１）心原性肺水腫
    （２）非心原性肺水腫
    （３）片側性肺水腫
    （４）高地肺水腫
    （５）再膨張性肺水腫
    （６）薬剤による肺水腫
    ３．肺高血圧症
    （１）原発性抗リン脂質抗体症候群
    （２）膠原病（SSｃ以外)に伴う肺動脈性肺高血圧症
    （３）特に強皮症に伴う肺動脈性肺高血圧症
    （４）新生児遷延性肺高血圧症
    （５）肺性心
    （６）特発性肺動脈性肺高血圧症(IPAH)
    （７）遺伝性肺動脈性肺高血圧症
    （８）肺分画症
    （９）肺毛細血管腫症
    （10）薬剤性肺高血圧症
    （11）左心性心疾患に伴う肺高血圧症
    （12）肺疾患に伴う肺高血圧症
    ４．肺塞栓症
    （１）ガス(空気)塞栓症
    （２）急性肺血栓塞栓症
    （３）脂肪塞栓症候群
    （４）がん関連血栓症 (腫瘍関連血栓症)
    （５）致死性肺血栓塞栓症
    （６）敗血症性肺塞栓症
    （７）慢性血栓塞栓性肺高血圧症
    （８）旅行者血栓症
    ５．肺血管異常
    （１）気管支動脈蔓状血管腫
    （２）気管支動脈瘤
    （３）先天性肺動脈，肺静脈発生異常
    （４）特発性気道出血
    （５）肺静脈還流異常
    （６）肺静脈閉塞性疾患（肺静脈閉塞症）
    （７）肺静脈瘤
    （８）肺底動脈体動脈起始症，肺底動脈下行大動脈起始症
    （９）肺動静脈瘻，Hereditary hemorrhagic telangiectasia（HHT)
    （10）片側肺動脈単独欠損症，片側肺静脈単独閉鎖症
    （11）薬剤による肺血管病変
    ６．肺血管炎
    （１）ANCA関連肺疾患
    （２）Behçet 病
    （３）小型血管炎
    （４）結節性多発動脈炎
    （５）顕微鏡的多発血管炎による肺血管炎
    （６）巨細胞性動脈炎
    （７）高安動脈炎

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

IV アレルギー性肺疾患

P.9 掲載の参考文献
1) 咳嗽・喀痰の診療ガイドライン 2019 (日本呼吸器学会 咳嗽・喀痰の診療ガイドライン2019作成委員会編), 日本呼吸器学会, 2019.
 
2) 新実彰男 : 慢性咳嗽の病態, 鑑別診断と治療-咳喘息を中心に-. 日本内科学会雑誌 105 : 1565-1577, 2016.
 
3) Niimi A : Natural language processing : A promising research tool of chronic cough for the big data era. Chest 159 : 2149-2150, 2021.
PubMed
4) Niimi A : Geography and cough aetiology. Pulm Pharmacol Ther 20 : 383-387, 2007.
PubMed
5) Kanemitsu Y, et al : Clinical impact of gastroesophageal reflux disease in patients with subacute/chronic cough. Allergol Int 68 : 478-485, 2019.
PubMed
6) Niimi A, et al : Cough variant and cough-predominant asthma are major causes of persistent cough : a multicenter study in Japan. J Asthma 50 : 932-937, 2013.
PubMed
7) Niimi A : Redefining "one airway, one disease" : Broader classification considering specific pathophysiology and treatment. Respir Invest, 2021. (DOI : 10.1016/j.resinv.2021.04.008)
 
8) Niimi A : Cough associated with gastro-oesophageal reflux disease (GORD) : Japanese experience. Pulm Pharmacol Ther 47 : 59-65, 2017.
PubMed
9) Tajiri T, et al : The causes of acute cough : a tertiary-care hospital study in Japan. J Asthma 17 : 1-7, 2020. (DOI : 10.1080/02770903.2020.1804576)
 
10) Watanabe H, et al : Forced oscillatory parameters in reversibility testing as predictors for chronic cough responsive to inhaled corticosteroid/long-acting β2 agonist. Ann Allergy Asthma Immunol 122 : 345-346.e1, 2019.
 
11) Asano T, et al : Diagnostic utility of fractional exhaled nitric oxide in prolonged and chronic cough according to atopic status. Allergol Int 66 : 344-350, 2017.
PubMed
12) Takeda N, et al : Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough : Implications of neurogenic and neutrophilic inflammation. J Asthma 57 : 1202-1210, 2020.
PubMed
13) Kurokawa R, et al : The diagnostic utility of the frequency scale for the symptoms of gastroesophageal reflux disease questionnaire (FSSG) for patients with subacute/chronic cough. J Asthma 12 : 1-10, 2020. (DOI : 10.1080/02770903.2020.1805750)
 
14) Niimi A : Narrative Review : How long should patients with cough variant asthma or non-asthmatic eosinophilic bronchitis be treated? J Thorac Dis 13 : 3197-3214, 2021.
PubMed
15) 新実彰男 : 咳嗽診療の心得「たかが咳, されど咳」. 日本内科学会雑誌 109 : 2091-2094, 2020.
 
16) 新実彰男 : 難治性慢性咳嗽の病態と新たな治療展開. アレルギー 70 : 112-117, 2021.
Medical*Online
P.13 掲載の参考文献
1) Niimi A, et al : Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough. Thorax 59 : 608-612, 2004.
PubMed
2) Matsumoto H, et al : Prevalence and clinical manifestations of gastro-oesophageal reflux-associated chronic cough in the Japanese population. Cough 3 : 1, 2007.
PubMed
3) 咳嗽・喀痰の診療ガイドライン 2019 (日本呼吸器学会 咳嗽・喀痰の診療ガイドライン2019作成委員会), メディカルレビュー社, 2019.
 
4) Niimi A, et al : Airway remodelling in cough-variant asthma. Lancet 356 : 564-565, 2000.
PubMed
5) Tajiri T, et al : Prevalence and clinical relevance of allergic rhinitis in patients with classic asthma and cough variant asthma. Respiration 87 : 211-218, 2014.
PubMed
6) Sugawara H, et al : Comparison of therapeutic effects of inhaled corticosteroids on three subtypes of cough variant asthma as classified by the impulse oscillometry system. Respir Res 20 : 41, 2019.
PubMed
7) Matsumoto H, et al : Features of cough variant asthma and classic asthma during methacholine-induced brochoconstriction : a cross-sectional study. Cough 5 : 3, 2009.
PubMed
8) Ohkura N, et al : Methacholine-induced cough as an indicator of bronchodilator-responsive cough. Pulm Pharmacol Ther 64 : 101962, 2020.
PubMed
9) Okazaki A, et al : Role of prostaglandin E2 in bronchoconstriction-triggered cough response in guinea pigs. Pulm Pharmacol Ther 48 : 62-70, 2018.
PubMed
10) Fukuhara A, et al : Clinical Characteristics of Cough Frequency Patterns in Patients with and without Asthma. J Allergy Clin Immunol Pract 8 : 654-661, 2020.
PubMed
11) Kanemitsu Y, et al : "Cold air" and/or "talking" as cough triggers, a sign for the diagnosis of cough variant asthma. Respir Investig 54 : 413-418, 2016.
PubMed
12) Asano T, et al : Diagnostic utility of fractional exhaled nitric oxide in prolonged and chronic cough according to atopic status. Allergol Int 66 : 344-350, 2017.
PubMed
13) Kanemitsu Y, et al : Gastroesophageal dysmotility is associated with the impairment of cough-specific quality of life in patients with cough variant asthma Allergol Int 65 : 320-326, 2016.
PubMed
14) 田尻智子, ほか : 当院呼吸器外来における急性咳嗽の原因疾患に関する検討. アレルギー 67 : 46-52, 2018.
 
15) Fukumitsu K, et al : Tiotropium Attenuates Refractory Cough and Capsaicin Cough Reflex Sensitivity in Patients with Asthma. J Allergy Clin Immunol Pract 6 : 1613-1620.e2, 2018.
 
16) Fujimura M, et al : Predictors for typical asthma onset from cough variant asthma. J Asthma 42 : 107-111, 2005.
PubMed
17) Matsumoto H, et al : Prognosis of cough variant asthma : a retrospective analysis. J Asthma 43 : 131-135, 2006.
PubMed
P.18 掲載の参考文献
1) 藤村政樹 : アトピー素因を有する咳嗽患者の臨床像-いわゆるアレルギー性気管支炎. アレルギーの臨床 9 : 66-69, 1989.
 
2) 咳嗽に関するガイドライン 第2版 (日本呼吸器学会 咳嗽に関するガイドライン作成委員会, 河野茂, ほか編), 社団法人日本呼吸器学会, 2012.
 
3) Corrao WM, et al : Chronic cough as the sole presenting manifestation of bronchial asthma. N Engl J Med 300 : 633-637, 1979.
PubMed
4) Fujimura M : Frequency of persistent cough and trends in seeking medical care and treatment-results of an internet survey. Allergol Int 61 : 573-581, 2012.
PubMed
5) Fujimura M, et al : Cough receptor sensitivity and bronchial responsiveness in patients with only chronic nonproductive cough : in view of effect of bronchodilator therapy. J Asthma 31 : 463-472, 1994.
PubMed
6) Ohkura N, et al : Heightened cough response to bronchoconstriction in cough variant asthma Respirology 17 : 964-968, 2012.
PubMed
7) Ohkura N, et al : Bronchoconstriction-triggered cough in atopic cough : A retrospective study. Exp Lung Res 42 : 227-231, 2016.
PubMed
8) Fujimura M, et al : Bronchial biopsy and sequential bronchoalveolar lavage in atopic cough : in view of effect of histamine H1-receptor antagonists. Allergology International 49 : 135-142, 2000.
 
9) 西耕一, ほか : アトピー咳嗽と気管支喘息の気管支生検所見と気管支洗浄所見の比較検討. アレルギー 43 (抄録) : 982, 1994.
 
10) Fujimura M, et al : Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough. Clin Exp Allergy 30 : 41-47, 2000.
PubMed
11) Fujimura M, et al : Exhaled nitric oxide levels in patients with atopic cough and cough variant asthma. Respirology 13 : 359-364, 2008.
PubMed
12) Fujimura M, et al : Comparison of atopic cough with cough variant asthma : is atopic cough a precursor of asthma? Thorax 58 : 14-18, 2003.
PubMed
13) Fujimura M, et al : Longitudinal decline in pulmonary function in atopic cough and cough variant asthma. Clin Exp Allergy 33 : 588-594, 2003.
PubMed
P.24 掲載の参考文献
1) 喉頭アレルギー. 咳嗽・喀痰の診療ガイドライン 2019 (日本呼吸器学会咳嗽・喀痰の診療ガイドライン2019作成委員会編), p78-80, メディカルレビュー社, 2019.
 
2) Anderson OE : Laryngeal obstruction due to antibiotic therapy. AMA Arch Otolaryngol 54 : 34-37, 1951.
PubMed
3) Williams RI : Allergic Laryngitis. Ann Otol Rhinol Laryngol 81 : 558-565, 1972.
PubMed
4) Pang LQ : Allergy of the larynx, trachea, and bronchial tree. Otolaryngol Clin North Am 7 : 719-734, 1974.
PubMed
5) 阪本浩一 : 耳鼻咽喉科外来における慢性咳嗽の臨床-喉頭アレルギー・後鼻漏症候群を中心に. 日本気管食道科学会会報 63 : 99-101, 2012.
Medical*Online
6) 増田佐和子 : 季節性喉頭アレルギーと診断された小児の一例. 喉頭 27 : 10-13, 2015.
Medical*Online
7) 片田彰博, ほか : シラカンバ花粉症患者における咽喉頭症状と喉頭アレルギー. 喉頭 23 : 12-18, 2011.
Medical*Online
8) Lee K, et al : Association of Sinonasal Factors With Chronic Laryngitis in Korean Adults. JAMA Otolaryngol Head Neck Surg 145 : 919-925, 2019.
PubMed
9) Naito K, et al : Laryngeal symptoms in patients exposed to Japanese cedar pollen : allergic reactions and environmental pollution. Eur Arch Otorhinolaryngol 256 : 209-211, 1999.
PubMed
10) Bucca CB, et al : Chronic cough and irritable larynx. J Allergy Clin Immunol 127 : 412-419, 2011.
PubMed
11) 阪本浩一 : 慢性咳嗽, 遷延性咳嗽. JOHNS 31 : 1334-1337, 2015.
Medical*Online
12) 内藤健晴 : 喉頭アレルギー. アレルギー 52 : 985-988, 2003.
Medical*Online
13) 山下利幸, ほか : 喉頭アレルギーの総合的研究. 耳鼻と臨床 41 (Suppl 2) : 871-877, 1995.
 
14) Sakurai K, et al : Influence of local antigen exposure dose in the upper respiratory tract on sensitization with cedar pollen. Allergol Int 51 : 9-12, 2002.
 
15) 内藤健晴 : 成人の慢性咳嗽診療におけるトピックス. 日本耳鼻咽喉科学会会報 122 : 1497-1501, 2019.
Medical*Online
16) Suzuki T, et al : Characteristics of laryngeal symptoms induced in patients with allergic rhinitis in an environmental challenge chamber. Ann Allergy Asthma Immumol 116 : 491-496, 2016.
 
17) 内藤健晴, ほか : 麦門冬湯を使用した持続性咳嗽症例. 漢方と免疫・アレルギー 17 : 54-65, 2003.
 
18) 馬場錬, ほか : 喉頭アレルギー症例に対する麻黄附子細辛湯の有用性について. アレルギーの臨床 8 : 640-644, 2001.
 
P.28 掲載の参考文献
1) 間島雄一 : 後鼻漏の病態生理. アレルギーの臨床 20 : 64-68, 2000.
 
2) Irwin RS, et al : Cough. A comprehensive review. Arch Intern Med 137 : 1186-1191, 1977.
PubMed
3) Pratter MR : Chronic Upper Airway Cough Syndrome Secondary to Rhinosinus Diseases (Previously Referred to as Postnasal Drip Syndrome) : ACCP Evidence-Based Clinical Practice Guidelines. Chest 129 (1 Suppl) : 63S-71S, 2006.
 
4) O'Hara J, Jones NS : "Post-nasal drip syndrome" : most patients with purulent nasal secretions do not complain of chronic cough. Rhinology 44 : 270-273, 2006.
 
5) Kaliner M : Medical management of sinusitis. Am J Med Sci 316 : 21-28, 1998.
PubMed
6) Bucca C, et al : Extrathoracic and intrathoracic airway responsiveness in sinusitis. J Allergy Clin Immunol 95 : 52-59, 1995.
PubMed
7) Irwin RS, et al : Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 141 : 640-647, 1990.
PubMed
8) 内藤健晴 : 成人の慢性咳嗽診療におけるトピックス. 日本耳鼻咽喉科学会会報 122 : 1497-1501, 2019.
Medical*Online
9) 後鼻漏症候群 (PNDS). 咳嗽・喀痰の診療ガイドライン 2019 (日本呼吸器学会咳嗽・喀痰の診療ガイドライン2019作成委員会編), p64-66, メディカルレビュー社, 2019.
 
10) 佐野正明, 塩谷隆信 : 上気道咳嗽症候群 (後鼻漏症候群). 呼吸器症候群 (第2版), p84-87, 日本臨牀社, 2009.
 
11) 内藤健晴 : 後鼻漏による咳嗽 (後鼻漏症候群) (耳鼻咽喉科からの見解). 慢性咳嗽の診断と治療に関する指針 2005年度版 (日本咳嗽研究会, アトピー咳嗽研究会, 藤村政樹監), p28-29, 前田書店, 2006.
 
12) 塩谷隆信, ほか : 慢性咳嗽発症のメカニズム. 医学のあゆみ 225 : 1135-1142, 2008.
Medical*Online
13) Greenberg SD, et al : Comparative morphology of chronic bronchitis and chronic sinusitis, with discussion of "Sinobronchial" syndrome. South Med J 59 : 64-74, 1966.
PubMed
14) 阪本浩一 : 耳鼻咽喉科外来における慢性咳嗽の臨床-咽頭アレルギー・後鼻漏症候群を中心に-. 日本気管食道科学会会報 63 : 99-101, 2012.
 
15) 藤枝重治, ほか : 好酸球性副鼻腔炎 ; 診断ガイドライン (JESREC Study). 日本耳鼻咽喉科学会会報 118 : 728-735, 2015.
Medical*Online
P.32 掲載の参考文献
1) Fujimura M : Frequency of persistent cough and trends in seeking medical care and treatment-results of an internet survey. Allergol Int 61 : 573-581, 2012.
PubMed
2) 田中勝巳, ほか : プライマリ・ケア診療所における症候および疾患の頻度順位の同定に関する研究. プライマリ・ケア 30 : 344-351, 2007.
 
3) Fujimura M, et al : Importance of atopic cough, cough variant asthma and sinobronchial syndrome as causes of chronic cough in the Hokuriku area of Japan. Respirology 10 : 201-207, 2005.
PubMed
4) Fujiwara Y, Arakawa T : Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 44 : 518-534, 2009.
PubMed
5) Niimi A, et al : Cough variant and cough-predominant asthma are major causes of persistent cough : a multicenter study in Japan. J Asthma 50 : 932-937, 2013.
PubMed
6) Jaspersen D, et al : Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease : an analysis based on the ProGERD Study. Aliment Pharmacol Ther 17 : 1515-1520, 2003.
PubMed
7) Irwin RS : Chronic cough due to gastroesophageal reflux disease : ACCP evidence-based clinical practice guidelines. Chest 129 : 80S-94S, 2006.
PubMed
8) Ing AJ, et al : Pathogenesis of chronic persistent cough associated with gastroesophageal reflux. Am J Respir Crit Care Med 149 : 160-167, 1994.
PubMed
9) 一般社団法人日本呼吸器学会 : 胃食道逆流症. 咳嗽・喀痰の診療ガイドライン 2019 (日本呼吸器学会咳嗽・喀痰の診療ガイドライン2019作成委員会), p81-84, メディカルレビュー社, 2019.
 
10) Fontana GA, Pistolesi M : Cough. 3 : chronic cough and gastro-oesophageal reflux. Thorax 58 : 1092-1095, 2003.
PubMed
11) Everett CF, Morice AH : Clinical history in gastroesophageal cough. Respir Med 101 : 345-348, 2007.
PubMed
12) Kusano M, et al : Development and evaluation of FSSG : frequency scale for the symptoms of GERD. J Gastroenterol 39 : 888-891, 2004.
PubMed
13) 日本消化器病学会 : 内科的治療, 胃食道逆流症 (GERD) 診療ガイドライン2015 (胃食道逆流症 (GERD) 診療ガイドライン委員会), p56-83, 南江堂, 2015.
 
14) Othman F, et al : Community acquired pneumonia incidence before and after proton pump inhibitor prescription : population based study. BMJ 355 : i5813, 2016.
PubMed
15) Ho SW, et al : Association of Proton Pump Inhibitors Usage with Risk of Pneumonia in Dementia Patients. Am Geriatr Soc 65 : 1441-1447, 2017.
PubMed
P.36 掲載の参考文献
1) Dicpinigaitis PV : Angiotensin-converting enzyme inhibitor-induced cough : ACCP evidence-based clinical practice guidelines. Chest 129 (1 Suppl) : 169S-173S, 2006.
 
2) 咳嗽・喀痰の診療ガイドライン 2019 (日本呼吸器学会「咳嗽・喀痰の診療ガイドライン 2019」作成委員会編), メディカルレビュー社, 2019.
 
3) 谷口正実, 関谷潔史 : 薬剤による咳. 日本医師会雑誌 142 : 1270, 2013.
 
4) McDowell SE, et al : Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332 : 1177-1181, 2006.
PubMed
5) Fox AJ, et al : Bradykinin-evoked sensitization of airway sensory nerves : a mechanism for ACE-inhibitor cough. Nat Med 2 : 814-817, 1996.
PubMed
6) Shim JS, et al : Drug-Induced Cough. Physiol Res 69 : S81-S92, 2020.
PubMed
7) 慢性咳嗽を診る-症例から学ぶ, 改訂版 (藤村正樹編), 医薬ジャーナル社, 2010.
 
8) Sekizawa K, et al : ACE inhibitors and pneumonia. Lancet 352 : 1069, 1998.
PubMed
9) O'Connell F, et al : Capsaicin cough sensitivity decreases with successful treatment of chronic cough. Am J Respir Crit Care Med 150 : 374-380, 1994.
PubMed
10) Li EC, et al : Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2014 : CD009096, 2014.
PubMed
11) Lacourciere Y, et al : Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens 12 : 1387-1393, 1994.
 
12) Baraniuk JN, Jamieson MJ : Rhinorrhea, cough and fatigue in patients taking sitagliptin. Allergy Asthma Clin Immunol 6 : 8, 2010.
PubMed
13) Reitan JA, et al : Central vagal control of fentanyl-induced bradycardia during halothane anesthesia. Anesth Analg 57 : 31-36, 1978.
PubMed
14) Yasuda I, et al : Tracheal constriction by morphine and by fentanyl in man. Anesthesiology 49 : 117-119, 1978.
PubMed
15) Lou YP : Regulation of neuropeptide release from pulmonary capsaicin-sensitive afferents in relation to bronchoconstriction. Acta Physiol Scand Suppl 612 : 1-88, 1993.
PubMed
16) Li CC, et al : Fentanyl-induced cough is a risk factor for postoperative nausea and vomiting. Br J Anaesth 115 : 444-448, 2015.
PubMed
17) Bang SR, et al : Comparison of the effectiveness of lidocaine and salbutamol on coughing provoked by intravenous remifentanil during anesthesia induction. Korean J Anesthesiol 59 : 319-322, 2010.
PubMed
18) Kim JE, et al : Pharmacological and nonpharmacological prevention of fentanyl-induced cough : a meta-analysis. J Anesth 28 : 257-266, 2014.
PubMed
19) 関谷潔史, ほか : NSAIDs過敏喘息. 内科 125 : 1375-1378, 2020.
 
P.41 掲載の参考文献
1) 咳嗽・喀痰の診療ガイドライン 2019 (日本呼吸器学会咳嗽・喀痰の診療ガイドライン2019作成委員会編), メディカルレビュー社. 2019.
 
2) Gibson P, et al : Treatrnent of Unexplained Chronic Cough : CHEST Guideline and Expert Panel Report. Chest 149 : 27-44, 2016.
 
3) Morice AH, et al : Cough hypersensitivity syndrome : a distinct clinical entity. Lung 189 : 73-79, 2011.
PubMed
4) Morice AH, et al : Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J 44 : 1132-1148, 2014.
PubMed
5) Song WJ, Morice AH : Cough Hypersensitivity Syndrome : A Few More Steps Forward. Allergy Asthma Immunol Res 9 : 394-402, 2017.
PubMed
6) Kanemitsu Y, et al : Clinical impact of gastroesophageal reflux disease in patients with subacute/chronic cough. Allergol Int 68 : 478-485, 2019.
PubMed
7) Smith JA, Woodcock A : Chronic Cough. N Engl J Med 375 : 1544-1551, 2016.
PubMed
8) 新実彰男 : 原因不明の慢性難治性咳嗽の概念と治療. 内科 121 : 1201-1205, 2018.
 
9) 新実彰男 : 難治性慢性咳嗽の病態と新たな治療展開. アレルギー 70 : 112-117, 2021.
Medical*Online
P.48 掲載の参考文献
1) 「喘息予防・管理ガイドライン 2018」作成委員 : 喘息予防・管理ガイドライン 2018 (日本アレルギー学会喘息ガイドライン専門部会監), 協和企画, 2018.
 
2) 難治性喘息 診断と治療の手引き 2019 (日本呼吸器学会「難治性喘息 診断と治療の手引き 2019」作成委員会編), 一般社団法人日本呼吸器学会, メディカルビュー社, 2019.
 
3) Wenzel SE : Asthma phenotypes : the evolution from clinical to molecular approaches. Nat Med 18 : 716-725, 2012.
PubMed
4) Hammad H, Lambrecht BN : Barrier Epithelial Cells and the Control of Type 2 Immunity. Immunity 43 : 29-40, 2015.
PubMed
5) Moore WC, et al : Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 133 : 1557-1563.e5, 2014.
 
6) Barczyk A, et al : Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med 97 : 726-733, 2003.
PubMed
7) Kerstjens HAM, et al : Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM) : a randomised, double-blind, controlled phase 3 study. Lancet Respir Med 8 : 1000-1012, 2020.
 
8) Lee LA, et al : Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN) : a double-blind, randomised, phase 3A trial. Lancet Respir Med 9 : 69-84, 2021.
 
9) Global Initiative for Asthma (GINA). [https://ginasthma.org/reports/]
 
P.56 掲載の参考文献
1) 日本小児アレルギー学会 : 小児気管支喘息治療・管理ガイドライン 2020 (足立雄一, ほか監), 2020.
 
2) 日本小児呼吸器学会・日本新生児成育医学会 : 小児RSウイルス呼吸器感染症診療ガイドライン 2021 (吉原重美, ほか監), 2021.
 
3) Yoshihara S, et al : Prevalence of childhood asthma in Ulaanbaatar, Mongolia in 2009. Allergol Int 65 : 62-67, 2016.
PubMed
4) Yamada Y, Yoshihara S : Creola bodies in infancy with respiratory syncytial virus bronchiolitis predict the development of asthma. Allergol Int 59 : 375-380, 2010.
PubMed
5) Yoshihara S, et al : Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics 132 : 811-818, 2013.
PubMed
6) Jackson DJ, et al : Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 178 : 667-672, 2008,
PubMed
7) 吉原重美 : 乳幼児喘息の診断と治療. アレルギー 69 : 652-657, 2020.
Medical*Online
8) 吉原重美 : 小児喘息診療の実際. アレルギー診療必携ハンドブック (永田真監), p111-128 中外医学社, 2021.
 
9) 吉原重美 : 乳幼児期の喘鳴症候群Reactive airway disease (RAD) の臨床像. 小児科 50 : 93-102, 2009.
 
10) 日本小児呼吸器学会 : 小児の咳嗽診療ガイドライン 2020 (吉原重美, ほか監), 2020.
 
11) 吉原重美 : 難治性喘息 診断と治療の手引き 2019～小児の難治性喘息～. アレルギー 70 : 95-99, 2021.
Medical*Online
P.62 掲載の参考文献
1) Martinez FD, et al : Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 332 : 133-138, 1995.
 
2) Stein RT, et al : Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood. Thorax 52 : 946-952, 1997.
PubMed
3) 小児気管支喘息治療・管理ガイドライン 2020 (日本小児アレルギー学会編), 協和企画, 2020.
 
4) 相澤昭 : 喘息性気管支炎. 日本医師会雑誌 102 : 91-92, 1989.
 
5) Brand PL, et al : Definition, assessment and treatment of wheezing disorders in preschool children : an evidence-based approach. Eur Respir J 32 : 1096-1110, 2008.
PubMed
6) Horsley A : Lung clearance index in the assessment of airways disease. Respir Med 103 : 793-799, 2009.
PubMed
7) Sonnappa S, et al : Symptom-pattern phenotype and pulmonary function in preschool wheezers. J Allergy Clin Immunol 126 : 519-526.e1-7, 2010.
 
8) Schultz A, et al : The transient value of classifying preschool wheeze into episodic viral wheeze and multiple trigger wheeze. Acta Paediatr 99 : 56-60, 2010.
PubMed
9) Van Wonderen KE, et al : Stability and predictiveness of multiple trigger and episodic viral wheeze in preschoolers. Clin Exp Allergy 46 : 837-847, 2016.
PubMed
10) Miyashita C, et al : Prevalence of childhood wheeze and modified DNA methylation at 7 years of age according to maternal folate levels during pregnancy in the Hokkaido Study. Pediatr Allergy Immunol 32 : 514-523, 2021.
PubMed
11) Kawamoto T, et al : Maternal prenatal stress and infantile wheeze and asthma : The Osaka Maternal and Child Health Study. J Psychosom Res 135 : 110143, 2020.
PubMed
12) Okabe Y, et al : Association between obesity and asthma in Japanese preschool children. Pediatr Allergy Immunol 23 : 550-555, 2012.
PubMed
13) Heymann PW, et al : Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol 114 : 239-247, 2004.
PubMed
14) Cavallaro EC, et al : Neutrophil infiltration and activation in bronchiolitic airways are independent of viral etiology. Pediatr Pulmonol 52 : 238-246, 2017.
PubMed
15) De Steenhuijsen Piters WA, et al : Nasopharyngeal Microbiota, Host Transcriptome, and Disease Severity in Children with Respiratory Syncytial Virus Infection. Am J Respir Crit Care Med 194 : 1104-1115, 2016.
PubMed
16) Mansbach JM, et al : Respiratory syncytial virus and rhinovirus severe bronchiolitis are associated with distinct nasopharyngeal microbiota. J Allergy Clin Immunol 137 : 1909-1913.e4, 2016.
 
17) Mansbach JM, et al : Haemophilus-Dominant Nasopharyngeal Microbiota Is Associated With Delayed Clearance of Respiratory Syncytial Virus in Infants Hospitalized for Bronchiolitis. J Infect Dis 219 : 1804-1808, 2019.
PubMed
18) Stewart CJ, et al : Serum Metabolome Is Associated With the Nasopharyngeal Microbiota and Disease Severity Among Infants With Bronchiolitis. J Infect Dis 219 : 2005-2014, 2019.
PubMed
19) Everard ML, et al : Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 71 : 428-432, 1994.
PubMed
20) Cortjens B, et al : Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease. J Pathol 238 : 401-411, 2016.
 
21) Anthracopoulos MB, Everard ML : Asthma : A Loss of Post-natal Homeostatic Control of Airways Smooth Muscle With Regression Toward a Pre-natal State. Front Pediatr 8 : 95, 2020.
 
22) Kantor DB, et al : Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children. J Allergy Clin Immunol 138 : 1467-1471.e9, 2016.
 
23) Papadopoulos NG, et al : Viruses and bacteria in acute asthma exacerbations-a GA2 LENDARE systematic review. Allergy 66 : 458-468, 2011.
PubMed
24) Van Ly D, et al : Characterising the mechanism of airway smooth muscle β2 adrenoceptor desensitization by rhinovirus infected bronchial epithelial cells. PLoS One 8 : e56058, 2013.
 
25) Rueter K, et al : Symptomatic viral infection is associated with impaired response to treatment in children with acute asthma. J Pediatr 160 : 82-87, 2012.
PubMed
26) Vathenen AS, et al : Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 143 : 1317-1321, 1991.
PubMed
27) Holden NS, et al : β2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids. Proc Natl Acad Sci USA 108 : 19713-19718, 2011.
 
28) Goldsmith AM, et al : Regulation of airway smooth muscle alpha-actin expression by glucocorticoids. Am J Physiol Lung Cell Mol Physiol 292 : L99-L106, 2007.
PubMed
29) Tran MU, et al : Smooth muscle development during postnatal growth of distal bronchioles in infant rhesus monkeys. J Appl Physiol (1985) 97 : 2364-2371 ; discussion 2354, 2004.
PubMed
30) Prendiville A, et al : Airway responsiveness in wheezy infants : evidence for functional beta adrenergic receptors. Thorax 42 : 100-104, 1987.
PubMed
31) Castro-Rodriguez JA, et al : A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 162 : 1403-1406, 2000.
PubMed
32) Guilbert TW, et al : Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol 114 : 1282-1287, 2004.
PubMed
33) Leonardi NA, et al : Validation of the Asthma Predictive Index and comparison with simpler clinical prediction rules. J Allergy Clin Immunol 127 : 1466-1472.e6, 2011.
 
34) Teague WG, et al : Novel Treatment-Refractory Preschool Wheeze Phenotypes Identified by Cluster Analysis of Lung Lavage Constituents. J Allergy Clin Immunol Pract 9 : 2792-2801.e4, 2021.
 
35) Rubner FJ, et al : Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence. J Allergy Clin Immunol 139 : 501-507, 2017.
PubMed
36) Caliskan M, et al : Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med 368 : 1398-1407, 2013.
PubMed
37) Simoes EA, et al : Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 151 : 34-42, 42.e1, 2007.
 
P.68 掲載の参考文献
1) 難治性喘息 診断と治療の手引き 2019 (日本呼吸器学会難治性喘息診断と治療の手引き2019作成委員会編), メディカルレビュー社, 2018.
 
2) Chung KF, et al : International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 : 343-373, 2014.
PubMed
3) Kupczyk M, et al : Frequent exacerbators-a distinct phenotype of severe asthma. Clin Exp Allergy 44 : 212-221, 2014.
PubMed
4) To Y, et al : Real-world treatment and health care resource use among severe asthma patients in Japan. Respir Investig 59 : 467-477, 2021.
 
5) Hekking PW, et al : The prevalence of severe refractory asthma. J Allergy Clin Immunol 135 : 896-902, 2015.
PubMed
6) 喘息予防・管理ガイドライン 2018 (日本アレルギー学会喘息ガイドライン専門部会監), 協和企画, 2018.
 
7) Opina MT, Moore WC : Phenotype-Driven Therapeutics in Severe Asthma. Curr Allergy Asthma Rep 17 : 10, 2017.
PubMed
8) Wenzel SE, et al : Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160 : 1001-1008, 1999.
PubMed
9) The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 22 : 470-477, 2003.
 
10) Haldar P, et al : Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 : 973-984, 2009.
PubMed
11) Nair P, et al : Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J med 360 : 985-993, 2009.
PubMed
12) Ortega HG, et al : Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 : 1198-1207, 2014.
PubMed
13) Bel EH, et al : Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371 : 1189-1197, 2014.
PubMed
14) Bleecker ER, et al : Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO) : a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388 : 2115-2127, 2016.
 
15) アレルギー総合ガイドライン 2019 (日本アレルギー学会), 協和企画, 2019.
 
16) 岩永賢司, 東田有智 : 重症喘息治療の現在-生物学的製剤を活用した症状コントロール-, 生物学的製剤overview JGLにおける位置づけ. Progress in Medicine 40 : 361-365, 2020.
 
17) Cox G, et al : Asthma control during the year after bronchial thermoplasty. N Engl J Med 356 : 1327-1337, 2007.
PubMed
18) Pavord ID, et al : Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 176 : 1185-1191, 2007.
PubMed
19) Castro M, et al : Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma : a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 181 : 116-124, 2010.
PubMed
P.73 掲載の参考文献
1) 長瀬洋之 : 専門医のためのアレルギー学講座 免疫・アレルギー疾患の分子標的 喘息における分子標的薬の可能性. アレルギー 64 : 14-22, 2015.
 
2) Nagase H, et al : Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int 69 : 53-60, 2020.
PubMed
3) Denton E, et al : Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract 9 : 2680-2688.e7, 2021.
 
4) Frossing L, et al : The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma. J Allergy Clin Immunol Pract 9 : 1267-1275, 2021.
 
5) Matsusaka M, et al : Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract 6 : 274-276.e2, 2018.
 
6) Heijink IH, et al : Epithelial cell dysfunction, a major driver of asthma development. Allergy 75 : 1902-1917, 2020.
 
7) Kraft M, et al : Patient characteristics, biomarkers, and exacerbation risk in severe, uncontrolled asthma. Eur Respir J, 2021. (DOI : 10.1183/13993003.00413-2021)
 
8) van Veen IH, et al : Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 32 : 344-349, 2008.
PubMed
9) Lee LA, et al : Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN) : a double-blind, randomised, phase 3A trial. Lancet Respir Med 9 : 69-84, 2021.
 
10) Ortega HG, et al : Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 : 1198-1207, 2014.
PubMed
11) Castro M, et al : Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 378 : 2486-2496, 2018.
PubMed
12) 三好昭暉, ほか : 重症喘息における4種の分子標的薬の適応症例の比率と臨床背景の比較. アレルギー 68 : 523, 2019.
Medical*Online
13) Nagase H, et al : The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases : Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol Int 69 : 178-186, 2020.
PubMed
P.78 掲載の参考文献
1) The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 22 : 470-477, 2003.
 
2) Wenzel S : Severe asthma : from characteristics to phenotypes to endotypes. Clin Exp Allergy 42 : 650-658, 2012.
PubMed
3) Moore WC, et al : Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 133 : 1557-1563.e5, 2014.
 
4) Hastie AT, et al : Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 132 : 72-80, 2013.
 
5) Gibson PG, et al : Heterogeneity of airway inflammation in persistent asthma : evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 119 : 1329-1336, 2001.
PubMed
6) Lemiere C, et al : Airway inflammation assessed by invasive and noninvasive means in severe asthma : eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 118 : 1033-1039, 2006.
PubMed
7) Simpson JL, et al : Inflammatory subtypes in asthma : assessment and identification using induced sputum. Respirology 11 : 54-61, 2006.
PubMed
8) Schleich F, et al : Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 108 : 1723-1732, 2014.
PubMed
9) Soma T, et al : Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma. Allergol Int 67S : S3-S11, 2018.
PubMed
10) Takaku Y, et al : CXC chemokine superfamily induced by Interferon-γ in asthma : a cross-sectional observational study. Asthma Res Pract 2 : 6, 2016.
 
11) Kikuchi S, et al : Neutrophilic inflammation and CXC chemokines in patients with refractory asthma. Int Arch Allergy Immunol 149 (Suppl 1) : 87-93, 2009.
 
12) Nishihara F, et al : Trans-basement membrane migration of eosinophils induced by LPS-stimulated neutrophils from human peripheral blood in vitro. ERJ Open Res 1 : 00003-2015, 2015.
PubMed
13) Nakagome K, et al : Dopamine D1-like receptor antagonist attenuates Th17-mediated immune response and ovalbumin antigen-induced neutrophilic airway inflammation. J Immunol 186 : 5975-5982, 2011.
PubMed
14) Kikuchi I, et al : Eosinophil trans-basement membrane migration induced by interleukin-8 and neutrophils. Am J Respir Cell Mol Biol 34 : 760-765, 2006.
PubMed
15) Chung KF, et al : International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 : 343-373, 2014.
PubMed
16) Sze E, et al : Mechanisms and therapeutic strategies for non-T2 asthma. Allergy 75 : 311-325, 2020.
PubMed
17) Iwamoto H, et al : Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J 31 : 1379-1380, 2008.
PubMed
18) Simpson JL, et al : Clarithromycin targets neutrophilic airway inflamrnation in refractory asthma. Am J Respir Crit Care Med 177 : 148-155, 2008.
PubMed
19) Brusselle GG, et al : Azithromycin for prevention of exacerbations in severe asthma (AZISAST) : a multicentre randomised double-blind placebo-controlled trial. Thorax 68 : 322-329, 2013.
PubMed
20) Gibson PG, et al : Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES) : a randomised, double-blind, placebo-controlled trial. Lancet 390 : 659-668, 2017.
PubMed
21) Taylor SL, et al : Long-Term Azithromycin Reduces Haemophilus influenzae and Increases Antibiotic Resistance in Severe Asthma. Am J Respir Crit Care Med 200 : 309-317, 2019.
PubMed
22) Corren J, et al : Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med 377 : 936-946, 2017.
PubMed
P.83 掲載の参考文献
1) 鼻アレルギー診療ガイドライン-通年性鼻炎と花粉症-2020年版 [改訂第9版] (日本耳鼻咽喉科免疫アレルギー学会鼻アレルギー診療ガイドライン作成委員会編), ライフ・サイエンス, 2020.
 
2) Fokkens WJ, et al : European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 58 (Suppl S29) : 1-464, 2020.
 
3) 副鼻腔炎. 難治性喘息診断と治療の手引き 2019 (日本呼吸器学会難治性喘息診断と治療の手引き2019作成委員会編), p53-56, メディカルレビュー社, 2018.
 
4) Brozek JL, et al : Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 140 : 950-958, 2017.
PubMed
5) Tiotiu A, et al : Manifesto on united airways diseases (UAD) : an Interasma (global asthma association-GAA) document. J Asthma, 2021. (DOI : 10.1080/02770903.2021.1879130)
 
6) Ohta K, et al : Prevalence and impact of rhinitis in asthma. SACRA, a cross-sectional nation-wide study in Japan. Allergy 66 : 1287-1295, 2011.
 
7) Tokunaga T, et al : Novel scoring system and algorithm for classifying chronic rhinosinusitis : the JESREC Study. Allergy 70 : 995-1003, 2015.
PubMed
8) Ryu G, et al : Bidirectional association between asthma and chronic rhinosinusitis : Two longitudinal follow-up studies using a national sample cohort. Sci Rep 10 : 9589, 2020.
PubMed
9) Moore WC, et al : Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 181 : 315-323, 2010.
PubMed
10) Shaw DE, et al : Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 46 : 1308-1321, 2015.
PubMed
11) 喘息予防・管理ガイドライン 2018 (日本アレルギー学会喘息ガイドライン専門部会監, 「喘息予防・管理ガイドライン 2018」作成委員作成), 協和企画, 2018.
 
12) Maeda Y, et al : A clinical study of Japanese cedar (Cryptomeria japonica) pollen-induced asthma. Allergol Int 57 : 413-417, 2008.
PubMed
13) 鈴木賢二, ほか : 第6回耳鼻咽喉科領域感染症臨床分離菌全国サーベイランス結果報告. 日耳鼻感染症・エアロゾル会誌8 : 193-211, 2020.
 
14) 好酸球性副鼻腔炎における治療指針作成とその普及に関する研究班 : 306好酸球性副鼻腔炎概要・診断基準等. 難病情報センター. [https://www.nanbyou.or.jp/entry/5462#306adf]
 
P.88 掲載の参考文献
1) Jennette JC : Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17 : 603-606, 2013.
 
2) 難病情報センターHP : 平成30年度 衛生行政報告例 平成30年度末現在. [https://www.nanbyou.or.jp/wp-content/uploads/upload_files/koufu20191.pdf.]
 
3) Wechsler ME, Drazen JM : Zafirlukast and Churg-Strauss syndrome. Chest 116 : 266-267, 1999.
PubMed
4) Basta F, et al : Omalizumab in eosinophilic granulomatosis with polyangiitis : friend or foe? A systernatic literature review. Clin Exp Rheumatol 38 (Suppl 124) : 214-220, 2020.
PubMed
5) Hocevar A, et al : Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab. J Allergy Clin Immunol Pract 8 : 2448-2449, 2020.
PubMed
6) Vaglio A, et al : HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 56 : 3159-3166, 2007.
PubMed
7) Wieczorek S, et al : Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides : comment on the article by Vaglio et al. Arthritis Rheum 58 : 329-330, 2008.
 
8) Wieczorek S, et al : Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum 58 : 1839-1848, 2008.
 
9) Alberici F, et al : FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis. Rheumatogy (Oxford) 59 : 3563-3566, 2020.
 
10) Tsurikisawa N, et al : Familial Churg-Strauss syndrome in two sisters. Chest 131 : 592-594, 2007.
PubMed
11) Ueki Y, et al : Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother. Intern Med 59 : 991-995, 2020.
 
12) Harmanci K, et al : Familial eosinophilic granulomatosis with polyangiitis in a mother and daughter. BMJ Case Rep 2014. (DOI : 10.1136/bcr-2014-206934)
 
13) Tsurikisawa N, et al : A retrospective study of bronchial hyperresponsiveness in patients with asthma before the onset of Churg-Strauss syndrome. Allergy Asthma Proc 28 : 336-343, 2007.
PubMed
14) Cottin V, et al : Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J 48 : 1429-1441, 2016.
PubMed
15) Latorre M, et al : Asthma Control and Airway Inflammation in Patients with Eosinophilic Granulomatosis with Polyangiitis. J Allergy Clin Immunol Pract 4 : 512-519, 2016.
PubMed
16) Berti A, et al : Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respir Med 142 : 66-72, 2018.
PubMed
17) Berti A, et al : Eosinophilic Granulomatosis With Polyangiitis : Clinical Predictors of Long-term Asthma Severity. Chest 157 : 1086-1099, 2020.
PubMed
18) Mukherjee M, et al : Sputum Antineutrophil Cytoplasmic Antibodies in Serum Antineutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis with Polyangiitis. Am J Respir Crit Care Med 199 : 158-170, 2019.
PubMed
19) Sinico RA, et al : Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52 : 2926-2935, 2005.
PubMed
20) Sable-Fourtassou R, et al : Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143 : 632-638, 2005.
PubMed
21) Chang HC, et al : Antineutrophil Cytoplasmic Antibodies and Organ-Specific Manifestations in Eosinophilic Granulomatosis with Polyangiitis : A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract 9 : 445-452.e6, 2021.
 
22) Samson M, et al : Long-term outcomes of l18 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 43 : 60-69, 2013.
 
23) Durel CA, et al : Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). Arthritis Care Res (Hoboken) 68 : 374-387, 2016.
PubMed
24) Tsurikisawa N, et al : Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis. Clin Exp Allergy 48 : 1305-1316, 2018.
PubMed
25) Tsurikisawa N, et al : Th17 cells reflect colon submucosal pathologic changes in active eosinophilic granulomatosis with polyangiitis. BMC Immunoi 16 : 75, 2015.
 
26) Raffray L, Guillevin L : Treatment of Eosinophilic Granulomatosis with Polyangiitis : A Review. Drugs 78 : 809-821, 2018.
PubMed
27) Tsurikisawa N, et al : Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol 122 : 610-616, 2008.
PubMed
28) Tsurikisawa N, et al : An increase of CD83+ dendritic cells ex vivo correlates with increased regulatory T cells in patients with active eosinophilic granulomatosis and polyangiitis. BMC Immunol 15 : 32, 2014.
PubMed
29) Lanham JG, et al : Systemic vasculitis with asthma and eosinophilia : a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63 : 65-81, 1984.
 
30) Masi AT, et al : The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33 : 1094-1100, 1990.
PubMed
31) Ozaki S : ANCA-associated vasculitis : diagnostic and therapeutic strategy. Allergol Int 56 : 87-96, 2007.
PubMed
32) Silva CI, et al : Churg-Strauss syndrome : high resolution CT and pathologic findings. J Thorac Imaging 20 : 74-80, 2005.
PubMed
33) Duran E, et al : Vital corner of diagnostic challenge : eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia? Ann Rheum Dis, 2020. (DOI : 10.1136/annrheumdis-2020-218533)
PubMed
34) Hashizume H, et al : Eosinophilic granulomatosis with polyangiitis mimicking coronavirus disease 2019 : a case report. J Eur Acad Dermatol Venereol 34 : e557-e559, 2020.
PubMed
35) Schramm MA, et al : COVID-19 in a severely immunosuppressed patient with life-threatening eosinophilic granulomatosis with polyangiitis. Front immunol 11 : 2086, 2020. (DOI : 10.3389/fimmu.2020.02086)
 
36) Guillevin L, et al : The Five-Factor Score revisited : assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90 : 19-27, 2011.
 
37) Moosig F, et al : A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA) : monocentric experiences in 150 patients. Ann Rheum Dis 72 : 1011-1017, 2013.
PubMed
38) Tsurikisawa N, et al : Longterm Prognosis of 121 Patients with Eosinophilic Granulomatosis with Polyangiitis in Japan. J Rheumatol 44 : 1206-1215, 2017.
PubMed
39) Jardel S, et al : Mortality in systemic necrotizing vasculitides : A retrospective analysis of the French Vasculitis Study Group registry. Autoimmun Rev 17 : 653-659, 2018.
 
40) Comarmond C, et al : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) : clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65 : 270-281, 2013.
 
41) Samson M, et al : Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmun Rev 13 : 945-953, 2014.
PubMed
42) Springer JM, et al : Eosinophilic Granulomatosis with Polyangiitis : A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatol 3 : 101-110, 2021.
PubMed
43) Berti A, et al : Eosinophilic granulomatosis with polyangiitis : the multifaceted spectrum of clinical manifestations at different stages of the disease. Expert Rev Clin Immunol 16 : 51-61, 2020.
PubMed
44) Tsurikisawa N, et al : Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92 : 80-87, 2004.
PubMed
45) Tsurikisawa N, et al : High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol 39 : 1019-1025, 2012.
PubMed
46) Tsurikisawa N, et al : High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis. Clin Transl Allergy 4 : 38, 2014.
PubMed
47) Thiel J, et al : Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment : A 36-Month Follow-Up Analysis. J Allergy Clin Immunol Pract 5 : 1556-1563, 2017.
PubMed
48) Fanouriakis A, et al : Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy : Case report and review of current clinical evidence. Semin Arthritis Rheum 45 : 60-66, 2015.
PubMed
49) Akiyalna M, et al : Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis : A systematic literature review. Autoimmun Rev 20 : 102737, 2021.
PubMed
50) Teixeira V, et al : Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open 5 : e000905, 2019.
PubMed
51) Moura MC, et al : Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. Clin Rheumatol 39 : 1581-1590, 2020.
 
52) Trivioli G, et al : Eosinophilic granulomatosis with polyangiitis : understanding the disease and its management. Rheumatology (Oxford) 59 : iii84-iii94, 2020.
PubMed
53) Wechsler ME, et al : Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 376 : 1921-1932, 2017.
 
54) Ennis D, et al : Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Expert Opin Biol Ther 19 : 617-630, 2019.
 
55) Ueno M, et al : Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Res Ther 23 : 86, 2021.
PubMed
56) Kitamura N, et al : The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients. Allergol Int 70 : 148-149, 2021.
PubMed
57) Tsurikisawa N, et al : Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab. Int Arch Allergy Immunol, 2021. (DOI : 10.1159/000514505).
 
58) Canzian A, et al : Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis : Data From a European Collaborative Study. Arthritis Rheumatol 73 : 498-503, 2021.
 
59) Vultaggio A, et al : Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis. Allergy Asthma Immunol Res 12 : 885-893, 2020.
PubMed
60) Jachiet M, et al : Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) : Data on Seventeen Patients. Arthritis Rheumatol 68 : 2274-2282, 2016.
PubMed
61) Guntur VP, et al : Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis. J Allergy Clin Immunol Pract 9 : 1186-1193.e1, 2021.
 
62) Carrillo-Martin I, et al : An alternative approach against eosinophils for the treatment of eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract 8 : 2079-2080, 2020.
PubMed
63) Galant-Swafford J, et al : Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab. J Allergy Clin Immunol Pract 8 : 3643-3646.e1, 2020.
 
64) Kent BD, et al : Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Res 6 : 00311-2019, 2020.
PubMed
65) Tsurikisawa N, et al : Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol 33 : 965-976, 2013.
PubMed
P.94 掲載の参考文献
1) アレルギー性気管支肺真菌症の診療の手引き (日本アレルギー学会, 日本呼吸器学会監, アレルギー性気管支肺真菌症研究班編), 医学書院, 2019.
 
2) Denning DW, et al : Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 51 : 361-370, 2013.
PubMed
3) Asano K, et al : Allergic bronchopulmonary mycosis-pathophysiology, histology, diagnosis, and treatment. Asia Pac Allergy 8 : e24, 2018.
PubMed
4) Oguma T, et al : Allergic bronchopulmonary aspergillosis in Japan : Anationwide survey. Allergol Int 67 : 79-84, 2018.
 
5) Asano K, et al : New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol 147 : 1261-1268.e5, 2021.
 
6) 浅野浩一郎 : 真菌関連喘息とその重症化機序. 医学のあゆみ 265 : 827-831, 2018.
Medical*Online
7) Ueki S, et al : Allergic bronchopulmonary aspergillosis-a luminal hypereosinophilic disease with extracellular trap cell death. Front Immunol 9 : 2346, 2018.
PubMed
8) Muniz VS, et al : Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus. J Allergy Clin Immunol 141 : 571-585.e7, 2018.
 
9) Rosenberg M, et al : Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 86 : 405-414, 1977.
PubMed
10) Agarwal R, et al : Allergic bronchopulmonary aspergillosis : review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 43 : 850-873, 2013.
PubMed
11) Agarwal R, et al : A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J 47 : 490-498, 2016.
 
12) Agarwal R, et al : A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. Chest 153 : 656-664, 2018.
 
13) Tomomatsu K, et al : Effectiveness and Safety of Omalizumab in Patients with Allergic Bronchopulmonary Aspergillosis Complicated by Chronic Bacterial Infection in the Airways. Int Arch Allergy Immunol 181 : 499-506, 2020.
PubMed
14) Tomomatsu K, et al : Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment. Allergol Int 69 : 636-638, 2020.
PubMed
15) Okada N, et al : Repeated exacerbation by environmental exposure and spontaneous resolution of allergic bronchopulmonary mycosis. J Allergy Clin Immunol Pract 9 : 558-560.e1, 2021.
 
P.99 掲載の参考文献
1) 新しいABPM診断基準. アレルギー性気管支肺真菌症の診療の手引き (「アレルギー性気管支肺真菌症」研究班編), p57-61, 医学書院2019.
 
2) 非アスペルギルスABPMの臨床像. アレルギー性気管支肺真菌症の診療の手引き (「アレルギー性気管支肺真菌症」研究班編), p22-25, 医学書院, 2019.
 
3) Chowdhary A, et al : Allergic bronchopulmonary mycosis due to fungi other than Aspergillus : a global overview. Crit Rev Microbiol 40 : 30-48, 2014.
PubMed
4) Asano K, et al : New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol 147 : 1261-1268.e5, 2021.
 
5) Matsuse H, et al : Dissociation between sensitizing and colonizing fungi in patients with allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 111 : 190-193, 2013.
PubMed
P.104 掲載の参考文献
1) Kowalski ML, et al : Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD) -a EAACI position paper. Allergy 74 : 28-39, 2019.
 
2) Szczeklik A, Stevenson DD : Aspirin-induced asthma : advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 111 : 913-921 ; quiz 922, 2003.
PubMed
3) 谷口正実 : 喘息の亜型・特殊型・併存症アスピリン喘息 (NSAIDs過敏喘息). 日本内科学会雑誌 102 : 1426-1432, 2013.
 
4) Taniguchi M, et al : Aspirin-exacerbated respiratory disease (AERD) : Current understanding of AERD. Allergol Int 68 : 289-295, 2019.
PubMed
5) Laidlaw TM, Cahill KN : Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs. J Allergy Clin Immunol Pract 5 : 537-545, 2017.
PubMed
6) Asano K, et al : Adult-onset eosinophilic airway diseases. Allergy 75 : 3087-3099, 2020.
PubMed
7) Morales DR, et al : NSAID-exacerbated respiratory disease : a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy 70 : 828-835, 2015.
PubMed
8) 福冨友馬, ほか : 本邦における病院通院成人喘息患者の実態調査国立病院機構ネットワーク共同研究. アレルギー 59 : 37-46, 2010.
 
9) Fukutomi Y, et al : Time trend in the prevalence of adult asthma in Japan : findings from population-based surveys in Fujieda City in 1985, 1999, and 2006. Allergol Int 60 : 443-448, 2011.
PubMed
10) Sekiya K, et al : Severe or life-threatening asthma exacerbation : patient heterogeneity identified by cluster analysis. Clin Exp Allergy 46 : 1043-1055, 2016.
 
11) Szczeklik A, et al : Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma, Eur Respir J 16 : 432-436, 2000.
PubMed
12) Perez-Novo CA, et al : Aspirin sensitivity and IgE antibodies to Staphylococcus aureus enterotoxins in nasal polyposis : studies on the relationship. Int Arch Allergy Immunol 133 : 255-260, 2004.
PubMed
13) Hayashi H, et al : Smoking Cessation as a Possible Risk Factor for the Development of Aspirin-Exacerbated Respiratory Disease in Smokers. J Allergy Clin Immunol Pract 6 : 116-125.e3, 2018.
 
14) Boyce JA : Aspirin sensitivity : Lessons in the regulation (and dysregulation) of mast cell function. J Allergy Clin Immunol 144 : 875-881, 2019.
PubMed
15) Cahill KN, et al : Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial. Am J Respir Crit Care Med 200 : 704-711, 2019.
 
16) White AA, Doherty TA : Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis. Am J Rhinol Allergy 32 : 7-11, 2018.
PubMed
17) Cavagnero KJ, Doherty TA : Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 126 : 135-142, 2021.
PubMed
18) Taniguchi M, et al : Hyperleukotrieneuria in patients with allergic and inflammatory disease. Allergol Int 57 : 313-320, 2008.
PubMed
19) Higashi N, et al : Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria) : Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 113 : 277-283, 2004.
PubMed
20) Higashi N, et al : Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites. Allergol Int 61 : 393-403, 2012.
PubMed
21) Mitsui C, et al : Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 137 : 400-411, 2016.
PubMed
22) Mascia K, et al : Aspirin sensitivity and severity of asthma : evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 116 : 970-975, 2005.
PubMed
23) Fukutomi Y, et al : Obesity and aspirin intolerance are risk factors for difficult-to-treat asthma in Japanese non-atopic women. Clin Exp Allergy 42 : 738-746, 2012.
PubMed
24) Cahill KN, et al : Prostaglandin D2 : adominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 135 : 245-252, 2015.
 
25) Shah NH, et al : Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 4 : 1215-1219, 2016.
PubMed
26) 谷口正実 : アレルギー実践講座 気道過敏性検査とアスピリン負荷試験の実際. アレルギー 58 : 87-96, 2009.
 
27) Settipane RA, et al : Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 96 : 480-485, 1995.
PubMed
28) 谷口正実 : アスピリン喘息における点滴静注ステロイド薬の使い方. アレルギーの臨床 23 : 87-89, 2003.
 
29) Hayashi H, et al : Omalizumab reduces cysteinyl leukotriene and 9α, 11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 137 : 1585-1587.e4, 2016.
 
30) Hayashi H, et al : Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial. Am J Respir Crit Care Med 201 : 1488-1498, 2020.
PubMed
31) 妹川史朗, ほか : クロモグリク酸ナトリウムは発作寛解期のアスピリン喘息患者に対して急性気管支拡張効果を有する. アレルギー 41 : 1515-1520, 1992.
Medical*Online
32) Laidlaw TM, et al : Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract 7 : 2462-2465.e1, 2019.
 
33) Mustafa SS, Vadamalai K : Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 126 : 738-739, 2021.
PubMed
P.110 掲載の参考文献
1) Parsons Jp, et al : An official American Thoracic Society clinical practice guideline : exercise-induced bronchoconstriction. Am J Respir Crit Care Med 187 : 1016-1027, 2013.
PubMed
2) Carlsen KH, et al : Exercise-induced asthma, respiratory and allergic disorders in elite athletes : epidemiology, mechanisms and diagnosis : part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy 63 : 387-403, 2008.
PubMed
3) Kippelen P, et al : Mechanisms and Biomarkers of Exercise-Induced Bronchoconstriction. Immunol Allergy Clin North Am 38 : 165-182, 2018.
PubMed
4) Couto M, et al : Mechanisms of exercise-induced bronchoconstriction in athletes : Current perspectives and future challenges. Allergy 73 : 8-16, 2018.
PubMed
5) Bonini M, Silvers W : Exercise-Induced Bronchoconstriction : Background, Prevalence, and Sport Considerations. Immunol Allergy Clin North Am 38 : 205-214, 2018.
PubMed
6) Helenius I, Haahtela T : Allergy and asthma in elite summert sport athletes. J Allergy Clin Immunol 106 : 444-452, 2000.
PubMed
7) Del Giacco SR, et al : Exercise and asthma : an overview. Eur Clin Respir J 2 : 27984, 2015.
PubMed
8) Rundell KW, et al : Air quality and temperature effects on exercise-induced bronchoconstriction. Compr Physiol 5 : 579-610, 2015.
PubMed
9) Holzer K, et al : Exercise in elite summer athletes : Challenges for diagnosis. J Allergy Clin Immunol 110 : 374-380, 2002.
PubMed
10) Weiler JM, et al : Exercise-induced bronchoconstriction update-2016. J Allergy Clin Immunol 138 : 1292-1295.e36, 2016.
 
11) Rundell KW, et al : Exercise-induced asthma screening of elite athletes : field versus laboratory exercise challenge. Med Sci Sports Exerc 32 : 309-316, 2000.
PubMed
12) Anderson SD, et al : Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics. J Allergy Clin Immunol 117 : 767-773, 2006.
PubMed
13) Hancox RJ, et al : Beta2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med 165 : 1068-1070, 2002.
PubMed
14) TUE Physician Guidelines-Asthma-Version 7.0-December 2020. WAPA World Anti-Doping Program. [http://www.wada-ama.org/sites/default/files/resources/files/asthma_version_7.0_december_2020.pdf] (2021年7月閲覧)
 
P.114 掲載の参考文献
1) 職業性アレルギー疾患診療ガイドライン 2016 (日本職業・環境アレルギー学会監), 協和企画, 2016.
 
2) Tarlo SM, Lemiere C : Occupational asthma. N Engl J Med 370 : 640-649, 2014.
PubMed
3) Banauch GI, et al : Persistent hyperreactivity and reactive airway dysfunction in firefighters at the World Trade Center. Am J Respir Crit Care Med 168 : 54-62, 2003.
PubMed
4) Balmes J, et al : American Thoracic Society Statement : Occupational contribution to the burden of airway disease. Am J Respir Crit Care Med 167 : 787-797, 2003.
 
5) Blanc PD, et al : The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement. Am J Respir Crit Care Med 199 : 1312-1334, 2019.
PubMed
6) Blomme EE, et al : Innate lymphoid cells in isocyanate-induced asthma : role of microRNA-155. Eur Respir J 56 : 1901289, 2020.
PubMed
7) Kim SH, et al : Alpha-T-catenin (CTNNA3) gene was identified as a risk variant for toluene diisocyanate-induced asthma by genome-wide association analysis. Clin Exp Allergy 39 : 203-212, 2009.
 
8) Yucesoy B, et al : Genome-Wide Association Study Identifies Novel Loci Associated With Diisocyanate-Induced Occupational Asthma. Toxicol Sci 146 : 192-201, 2015.
PubMed
9) Bernstein DI, et al : Genetic variants with gene regulatory effects are associated with diisocyanate-induced asthma. J Allergy Clin Immunol 142 : 959-969, 2018.
PubMed
10) Redlich CA : Skin exposure and asthma : is there a connection? Proc Am Thorac Soc 7 : 134-137, 2010.
 
11) Vandenplas O, et al : Specific inhalation challenge in the diagnosis of occupational asthma : consensus statement. Eur Respir J 43 : 1573-1587, 2014.
PubMed
12) Nicholson PJ, et al : Concise guidance : diagnosis, management and prevention of occupational asthma. Clin Med (Lond) 12 : 156-159, 2012.
PubMed
13) Olivieri M, et al : Omalizumab in persistent severe bakers' asthma. Allergy 63 : 790-791, 2008.
PubMed
14) Lavaud F, et al : Usefulness of omalizumab in ten patients with severe occupational asthma. Allergy 68 : 813-815, 2013.
PubMed
15) Nicholson PJ, et al : Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med 62 : 290-299, 2005.
PubMed
P.119 掲載の参考文献
1) Connolly MJ, et al : Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax 47 : 410-413, 1992.
PubMed
2) National Heart, Lung and Blood Institute : NAEPP Working Group Report : Considerations for Diagnosing and Managing Asthma in the Elderly. National Institutes of Health pub. No. 96-3662, Bethesda, 1996.
 
3) GINA, GOLD : Diagnosis of Diseases of Chronic Airflow Limitation : Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS), 2014.
 
4) Matsunaga K, et al : Importance of assistance by caregivers for inhaled corticosteroid therapy in elderly patients with asthma. J Am Geriatr Soc 54 : 1626-1627, 2006.
PubMed
5) Lipworth BJ : Systemic adverse effects of inhaled corticosteroid therapy : A systematic review and meta-analysis. Arch Intern Med 159 : 941-955, 1999.
PubMed
6) Newman SP : Inhaler treatment option in COPD. Eur Respir Rev 14 : 102-108, 2005.
 
7) Global Initiative for Asthma Management and Prevention. NHLBI/WHO Workshop Report. National Institutes Heart, Lung, and Blood Instite 56, 2006.
 
8) Marcus P, et al : Use of nebulized inhaled corticosteroids among older adult patients : an assessment of outcomes. Ann Allergy Asthma Immunol 96 : 736-743, 2006.
PubMed
9) 堀口高彦, ほか : 高齢者喘息の特徴を考慮した治療ナビゲーション-吸入薬の手技確認と理解度に関する検討-. アレルギー・免疫 17 : 1086-1093, 2010.
 
10) 東田有智, ほか : 正しい吸入方法を身につけよう. 独立行政法人環境再生保全機構, 2015. [https://www.erca.go.jp/yobou/pamphlet/form/00/archives_26714.html] (2021年7月閲覧)
 
11) Takita K, et al : Effectiveness of training patients using DVD in the accurateuse of inhalers for the treatment of bronchial asthma. Allergol Int 66 : 545-549, 2017.
PubMed
12) Yoshida T, et al : A comparison of posterior pharyngeal wall areas between different tongue positions during inhalation. J Allergy Clin Immunol Pract 7 : 743-745.e1, 2019.
 
13) Horiguchi T, Kondo R : Determination of the preferred tongue position for optimal inhaler use. J Allergy Clin Immunol Pract 6 : 1039-1041.e3, 2018.
 
14) Yokoi T, et al : Residual fluticasone in the oral cavity after inhalation with different tongue positions. J Allergy Clin Immunol Pract 7 : 1668-1670, 2019.
PubMed
15) Lim R, et al : Cardiac arrhythmias during acute exacerbations of chronic airflow limitation : effect of fall in plasma potassium concentration induced by nebulised beta 2-agonist therapy. Postgrad Med J 65 : 449-452, 1989.
PubMed
16) Price D, et al : Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 364 : 1695-1707, 2011.
PubMed
17) Nielsen-Kudsk JE, et al : Effects of pinacidil on guinea-pig airway smooth muscle contracted by asthma mediators. Eur J Pharmacol 157 : 221-226, 1988.
PubMed
18) 喘息予防・管理ガイドライン 2018 (日本アレルギー学会 喘息ガイドライン専門部会監), 協和企画, 2018.
 
19) Ullah MI, et al : Influence of age on response to ipratropium and salbutamol in asthma. Thorax 36 : 523-529, 1981.
PubMed
20) Stoodley RG, et al : The role of ipratropium bromide in the emergency management of acute asthma exacerbation : a metaanalysis of randomized clinical trials. Ann Emerg Med 34 : 8-18, 1999.
PubMed
21) Gross NJ, et al : Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis 139 : 1188-1191, 1989.
PubMed
22) Barros MJ, Rees PJ : Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction. Respir Med 84 : 371-375, 1990.
PubMed
23) Gong H, et al : Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 85 : 632-641, 1990.
PubMed
24) Simons FE, Simons KJ : The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 330 : 1663-1670, 1994.
PubMed
P.124 掲載の参考文献
1) Global Initiative for Asthma (GINA), Global Initiative for Chronic Obstructive Lung Disease (GOLD) : Diagnosis and initial treatment of asthma, COPD, and asthma-COPD overlap : A joint project of GINA and GOLD, updated April 2017. [https://ginasthma.org/wp-content/uploads/2019/11/GINA-GOLD-2017-overlap-pocket-guide-wms-2017-ACO.pdf] (2021年8月閲覧)
 
2) Global Initiative for Chronic Obstructive Lung Disease (GOLD) : Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. [https://www.goldcopd.org] (2021年8月閲覧)
 
3) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management, and Prevention. GINA Full Report 2021. [http://www.ginasthma.org] (2021年8月閲覧)
 
4) Alshabanat A, et al : Asthma and COPD Overlap Syndrome (ACOS) : A Systematic Review and Meta Analysis. PLoS One 10 : e0136065, 2015.
PubMed
5) De Marco R, et al : The coexistence of asthma and chronic obstructive pulmonary disease (COPD) : prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One 8 : e62985, 2013.
PubMed
6) Hashimoto S, et al : Asthma and Chronic Obstructive Pulmonary Disease Overlap According to the Japanese Respiratory Society Diagnostic Criteria : The Prospective, Observational ACO Japan Cohort Study. Adv Ther 38 : 1168-1184, 2021.
 
7) Lee H, et al : Characteristics of Specialist-Diagnosed Asthma-COPD Overlap in Severe Asthma : Observations from the Korean Severe Asthma Registry (KoSAR). Allergy 76 : 223-232, 2021.
PubMed
8) Stocks J, et al : Early lung development : lifelong effect on respiratory health and disease. Lancet Respir Med 1 : 728-742, 2013.
PubMed
9) McGeachie MJ, et al : Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. N Engl J Med 374 : 1842-1852, 2016.
PubMed
10) Lange P, et al : Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med 373 : 111-122, 2015.
PubMed
11) Brightling C, Greening N : Airway inflammation in COPD : progress to precision medicine. Eur Respir J 54 : 1900651, 2019.
PubMed
12) 喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き 2018 (日本呼吸器学会編), 日本呼吸器学会, 2017.
 
13) Takayama Y, et al : Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma-COPD overlap. Int J Chron Obstruct Pulmon Dis 13 : 2525-2532, 2018.
PubMed
P.129 掲載の参考文献
1) 熱傷用語集 2015 [改訂版]. (日本熱傷学会 熱傷用語集改訂検討特別委員会編), p60-62, 日本熱傷学会, 2015.
 
2) The evidence-based guidelines group and A. B. Association. J Burn Care Rehabil (Suppl) : 19-22, 2001.
 
3) Cox RA, et al : Airway obstruction in sheep with burn and smoke inhalation inj uries. Am J Respir Cell Mol Biol 29 : 295-302, 2003.
 
4) Endorf FW, Gamelli RL : Inhalation injury, pulmonary perturbations, and fluid resuscitation. J Burn Care Res 28 : 80-83, 2007.
PubMed
5) Chou SH, et al : Fiber-optic bronchoscopic classification of inhalation injury : prediction of acute lung injury. Surg Endosc 18 : 1377-1379, 2004.
PubMed
6) Bingham HG, et al : Early bronchoscopy as a predictor of ventilatory support for burned patients. J Trauma 27 : 1286-1288, 1987.
PubMed
7) Yamamura H, et al : Chest computed tomography performed on admission helps predict the severity of smoke-inhalation injury. Crit Care 17 : R95, 2013.
PubMed
8) 久保飛鳥, ほか : 初療時胸部CT画像検査における気管支壁厚を用いた気道熱傷の重症度予測の有効性の検討. 日本集中治療医学会雑誌 25 : 179-184, 2018,
 
9) Sheridan RL : Fire-Related Inhalation Injury. N Engl J Med 375 : 464-469, 2016.
PubMed
10) 熱傷診療ガイドライン [改訂第2版] (日本熱傷学会学術委員会編), p19-25, 日本熱傷学会, 2015.
 
11) Cioffi WG, et al : Prophylactic use of high-frequency percussive ventilation in patients with inhalation injury. Ann Surg 213 : 575-580 ; discussion 580-582, 1991.
 
12) Reper P, et al : High frequency percussive ventilation and conventional ventilation after smoke inhalation : a randomised study. Burns 28 : 503-508, 2002.
PubMed
13) Hall JJ, et al : Use of high-frequency percussive ventilation in inhalation injuries. J Burn Care Res 28 : 396-400, 2007.
PubMed
14) Greenhalgh DG : Management of Burns. N Engl J Med 380 : 2349-2359, 2019.
 
15) American Burn Association : Advanced Burn Life Support Course Provider's Manual. American Burn Association, Chicago, 2011.
 
16) Navar PD, et al : Effect of inhalation injury on fluid resuscitation requirements after thermal injury. Am J Surg 150 : 716-720, 1985.
PubMed
P.132 掲載の参考文献
1) Takano H, Inoue K : Environmental pollution and allergies. J Toxicol Pathol 30 : 193-199, 2017.
PubMed
2) 日本呼吸器学会 : 大気・室内環境関連疾患 予防と対策の手引き 2019 (日本呼吸器学会大気・室内環境関連疾患 予防と対策の手引き2019作成委員会編), メディカルビュー社, 2019.
 
3) 国立環境研究所 : SPM, PM2.5, PM10, …, さまざまな粒子状物質. [https://www.nies.go.jp/kanko/news/20/20-5/20-5-05.html] (2021年7月閲覧)
 
4) 中本啓太郎, ほか : 大気汚染と呼吸器疾患. 呼吸 33 : 953-960, 2014.
Medical*Online
5) 本田晶子, 高野裕久 : 気道炎症と環境汚染物質. 炎症と免疫 24 : 548-552, 2016.
Medical*Online
6) 市瀬孝道 : 3. 大気汚染 (PM2.5, 黄砂等) とアレルギーに関する研究の進展. アレルギー 63 : 1085-1094, 2014.
Medical*Online
7) 小田嶋博 : 大気汚染 (PM2.5, 黄砂など) とアレルギー疾患. 医療 70 : 89-94, 2016.
Medical*Online
8) Kloog I, et al : Acute and chronic effects of particles on hospital admissions in New-England. PLoS One 7 : e34664, 2012.
PubMed
9) Asano K, Yabuta T : The role of thymic stromal lymphopoietin (TSLP) in asthma. Jpn Open J Respir Med 5 : e00120, 2021.
 
10) Watanabe M, et al : Cigarette smoke-induced plasma extravasation is inhibited by C99.994, but not HOE104. Biomed Res 19 : 309-314, 1998.
 
11) 日本禁煙学会 ; 松崎道幸 (訳) : 電子タバコに関する世界保健機関報告書, 2016年8月. [http://www.jstc.or.jp/uploads/uploads/files/%20DTWHO.pdf] (2021年7月閲覧)
 
12) Meng Z, Lu B : Dust events as a risk factor for daily hospitalization for respiratory and cardiovascular diseases in Minqin, China. Atoms Environ 41 : 7048-7058, 2007.
 
13) Ihrie MD, Bonner JC : The Toxicology of Engineered Nanomaterials in Asthma. Curr Environ Health Rep 5 : 100-109, 2018.
PubMed
14) Journeay WS, Goldman RH : Occupational handling of nickel nanoparticles : a case report. Am J Ind Med 57 : 1073-1076, 2014.
PubMed
15) Roach KA, et al : Metal nanomaterials : Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease. J Immunotoxicol 16 : 87-124, 2019.
 
P.136 掲載の参考文献
1) Kelleher P, et al : Inorganic dust pneumonias : the metal-related parenchymal disorders. Environ Health Perspect 108 (Suppl 4) : 685-696, 2000.
 
2) Greenberg MI, Vearrier D : Metal fume fever and polymer fume fever. Clin Toxicol (Phila) 53 : 195-203, 2015.
PubMed
3) 川波敏則, 迎寛 : 金属ヒューム熱. 呼吸 30 : 810-813, 2011.
Medical*Online
4) 戸島洋一, ほか : 亜鉛フューム吸入により化学性肺臓炎をおこした溶接工の1例. 日本呼吸器学会雑誌 36 : 394-398, 1998.
Medical*Online
5) Wong A, et al : Metal fume fever-a case review of calls made to the Victorian Poisons Information Centre. Aust Fam Physician 41 : 141-143, 2012.
 
6) 宮崎洋生, ほか : 亜鉛溶接工に発症した過敏性肺臓炎の1例. 日本呼吸器学会雑誌 44 : 985-989, 2006.
Medical*Online
7) Schraufnagel DE : The health effects of ultrafine particles. Exp Mol Med 52 : 311-317, 2020.
PubMed
8) McNeilly JD, et al : Soluble transition metals in welding fumes cause infiammation via activation of NF-κB and AP-1. Toxicol Lett 158 : 152-157, 2005.
 
9) Bleidorn J et al : The pro-inflammatory stimulus of zinc-and copper-containing welding fumes in whole blood assay via protein tyrosine phosphatase 1B inhibition. Sci Rep 9 : 1315, 2019.
PubMed
10) Wesselkamper SC, et al : Development of pulmonary tolerance in mice exposed to zinc oxide fumes. Toxicol Sci 60 : 144-151, 2001.
PubMed
11) Wardhana, Datau EA : Metal fume fever among galvanized welders. Acta Med Indones 46 : 256-262, 2014.
PubMed
12) Christensen SW, et al : A prospective study of decline in lung function in relation to welding emissions. J Occup Med Toxicol 3 : 6, 2008.
PubMed
13) El-Zein M, et al : Prevalence and association of welding related systemic and respiratory symptoms in welders. Occup Environ Med 60 : 655-661, 2003.
PubMed
14) 赤池公孝, ほか : アーク溶接時に生じた金属ヒューム吸入が原因と考えられた肺胞出血の1例. 日本呼吸器学会雑誌 6 : 244-248, 2017.
 
15) 谷口浩和, ほか : 酸化亜鉛ヒューム吸入により生じたびまん性肺胞傷害の1例. 日本呼吸器学会雑誌 41 : 447-450, 2003.
Medical*Online
P.140 掲載の参考文献
1) 日本喘息学会 : 喘息診療実践ガイドライン 2021 (相良博典, ほか監), 2021.
 
2) 日本小児アレルギー学会 : 小児気管支喘息治療・管理ガイドライン 2020 (足立雄一, ほか監), 2020.
 
3) 日本小児呼吸器学会・日本新生児成育医学会 : 小児RSウイルス呼吸器感染症診療ガイドライン 2021 (吉原重美, ほか監), 2021.
 
4) Yoshihara S, et al : Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics 132 : 811-818, 2013.
PubMed
5) Mochizuki H, et al : Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. six-year follow-up study. Am J Respir Crit Care Med 196 : 29-38, 2017.
PubMed
P.144 掲載の参考文献
1) Ando M, et al : Japanese summer-type hypersensitivity pneumonitis. Geographic distribution, home environment, and clinical characteristics of 621 cases. Am Rev Respir Dis 144 : 765-769, 1991.
PubMed
2) Raghu G, et al : Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 202 : e36-e69, 2020.
PubMed
3) 宮崎泰成 : 過敏性肺炎 診断と治療のアップデート. アレルギー 69 : 329-333, 2020
Medical*Online
4) Inase N, et al : Chronic summer-type hypersensitivity pneumonitis : clinical similarities to idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 24 : 141-147, 2007.
PubMed
5) Okamoto T, et al : Nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 51 : 191-199, 2013.
PubMed
6) Onishi Y, et al : Clinical features of chronic summer-type hypersensitivity pneumonitis and proposition of diagnostic criteria Respir Investig 58 : 59-67, 2020.
PubMed
7) 安藤正幸 : 夏型過敏性肺炎の研究を顧みて-原因抗原の探求-. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 37 : 19-24, 2017.
 
8) 大西康貴, ほか : 冬季発症の急性過敏性肺炎の特徴と抗原回避の有用性に関する検討. 日本呼吸器学会誌 9 : 425-431, 2020.
Medical*Online
9) Ando M, et al : HLA-DQw3 in Japanese summer-type hypersensitivity pneumonitis induced by Trichosporon cutaneum. Am Rev Respir Dis 140 : 948-950, 1989.
PubMed
10) 溝部孝則, ほか : 夏型過敏性肺炎のEnzyme-Linked Immunosorbent Assayによる血清診断の有効性の検討. アレルギー 51 : 20-23, 2002.
Medical*Online
11) 吉澤靖之, 澤田めぐみ : 過敏性肺炎. 日本醫事新報 3982 : 33-36, 2000.
 
12) Ohtani Y, et al : Inhalation provocation tests in chronic bird fancier's lung. Chest 118 : 1382-1389, 2000.
PubMed
13) Yoshida K, et al : Prevention of summer-type hypersensitivity pneumonitis : effect of elimination of Trichosporon cutaneum from the patients' homes. Arch Environ Health 44 : 317-322, 1989.
 
14) Fernandez Perez ER, et al : Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 144 : 1644-1651, 2013.
PubMed
15) Stern EJ, et al : CT mosaic pattern of lung attenuation : distinguishing different causes. AJR Am J Roentgenol 165 : 813-816, 1995.
PubMed
P.148 掲載の参考文献
1) Campbell JM : Acute symptoms following work with hay. Br Med J 2 : 1143-1144, 1932.
 
2) 南須原康行 : 農夫肺. 日本胸部臨床 64 : 603-609, 2005.
Medical*Online
3) 小岩弘明, ほか : 禁煙後に発症した農夫肺の1例. 日本呼吸器学会誌 42 : 319-323, 2004.
 
4) 米田良蔵 : 過敏性肺炎診断の手引きと診断基準. 厚生省特定疾患びまん性肺疾患調査研究班平成2年度報告書, p13-15, 1990.
 
5) 吉澤靖之, ほか : 過敏性肺炎の診断基準・病型分類・重症度. 内科 85 : 1061-1065, 2000.
 
6) Fernandez Perez ER, et al : Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 144 : 1644-1651, 2013.
PubMed
7) Raghu G, et al : Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 202 : e36-e69, 2020.
PubMed
8) Ohtani Y, et al : Chronic bird fancier's lung : histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 60 : 665-671, 2005.
PubMed
P.154 掲載の参考文献
1) Costabel U, et al : Hypersensitivity pneumonitis. Nat Rev Dis Primers 6 : 65, 2020.
PubMed
2) Raghu G, et al : Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 202 : e36-e69, 2020.
PubMed
3) Okamoto T, et al : Nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 51 : 191-199, 2013.
PubMed
4) Inase N, et al : A clinical study of hypersensitivity pneumonitis presumably caused by feather duvets. Ann Allergy Asthma Immunol 96 : 98-104, 2006.
PubMed
5) Ohtani Y, et al : Clinical features of recurrent and insidious chronic bird fancier's lung. Ann Allergy Asthma Immunol 90 : 604-610, 2003.
 
6) Ohtani Y, et al : Chronic bird fancier's lung : histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 60 : 665-671, 2005.
PubMed
7) Takemura T, et al : Pathology of hypersensitivity pneumonitis. Curr Opin Pulm Med 14 : 440-454, 2008.
PubMed
8) Suhara K, et al : Utility of immunological tests for bird-related hypersensitivity Pneumonitis. Respir Investig 53 : 13-21, 2015.
PubMed
9) Ishizuka M, et al : Validation of inhalation provocation test in chronic bird-related hypersensitivity pneumonitis and new prediction score. Ann Am Thorac Soc 12 : 167-173, 2015.
PubMed
10) Okamoto T, et al : The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respir Med 109 : 1576-1581, 2015.
PubMed
11) Tsutsui T, et al : Antigen avoidance tests for diagnosis of chronic hypersensitivity pneumonitis. Respir Investig 53 : 217-224, 2015.
PubMed
12) Flaherty KR, et al : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381 : 1718-1727, 2019.
PubMed
13) Tsutsui T, et al : The amount of avian antigen in household dust predicts the prognosis of chronic bird-related hypersensitivity pneumonitis. Ann Am Thorac Soc 12 : 1013-1021, 2015.
PubMed
14) Inase N, et al : Chronic summer-type hypersensitivity pneumonitis : clinical similarities to idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 24 : 141-147, 2007.
PubMed
15) Miyazaki Y, et al : Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest 134 : 1265-1270, 2008.
PubMed
P.158 掲載の参考文献
1) Lacasse Y, et al : Classification of hypersensitivity pneumonitis : ahypothesis. Int Arch Allergy Immunol 149 : 161-166, 2009.
 
2) Ohtani Y, et al : Clinical features of recurrent and insidious chronic bird fancier's lung. Ann Allergy Asthma Immunol 90 : 604-610, 2003.
 
3) Raghu G, et al : Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 202 : e36-e69, 2020.
PubMed
4) Perez ERF, et al : Diagnosis and Evaluation of Hypersensitivity Pneumonitis : CHEST Guideline and Expert Panel Report. Chest, 2021. (DOI : 10.1016/j.chest.2021.03.066)
 
5) 宮崎泰成 : 過敏性肺炎 診断と治療のアップデート. アレルギー 69 : 329-333, 2020.
Medical*Online
6) Lacasse Y, et al : Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 168 : 952-958, 2003.
PubMed
7) Ando M, et al : Japanese summer-type hypersensitivity pneumonitis. Geographic distribution, home environment, and clinical characteristics of 621 cases. Am Rev Respir Dis 144 : 765-769, 1991.
PubMed
8) Okamoto T, et al : Nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 51 : 191-199, 2013.
PubMed
9) Kishi M, et al : Pathogenesis of cBFL in common with IPF? Correlation of IP-10/TARC ratio with histological patterns. Thorax 63 : 810-816, 2008.
PubMed
10) Costabel U, et al : Hypersensitivity pneumonitis. Nat Rev Dis Primers 6 : 65, 2020.
PubMed
11) Shirai T, et al : Screening and diagnosis of acute and chronic bird-related hypersensitivity pneumonitis by serum IgG and IgA antibodies to bird antigens with ImmunoCAP(R). Allergol Int 70 : 208-214, 2021.
 
12) Salisbury ML, et al : Hypersensitivity Pneumonitis : Radiologic Phenotypes Are Associated With Distinct Survival Time and Pulmonary Function Trajectory. Chest 155 : 699-711, 2019.
PubMed
13) Fernandez Perez ER, et al : Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 144 : 1644-1651, 2013.
PubMed
14) Tsutsui T, et al : The amount of avian antigen in household dust predicts the prognosis of chronic bird-related hypersensitivity pneumonitis. Ann Am Thorac Soc 12 : 1013-1021, 2015.
PubMed
15) Kokkarinen JI, et al : Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. Am Rev Respir Dis 145 : 3-5, 1992.
PubMed
16) De Sadeleer LJ, et al : Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis : a retrospective cohort study. Eur Respir J 55 : 1901983, 2020.
PubMed
17) Morisset J, et al : Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest 151 : 619-625, 2017.
 
18) Flaherty KR, et al : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381 : 1718-1727, 2019.
PubMed
P.161 掲載の参考文献
1) Bocquet H, et al : Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms : DRESS). Semin Cutan Med Surg 15 : 250-257, 1996.
PubMed
2) Takahashi R, et al : Defective regulatory T cells in patients with severe drug eruptions : timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 182 : 8071-8079, 2009.
PubMed
3) Ogawa K, et al : Elevated serum thymus and activation-regulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS) /drug-induced hypersensitivity syndrome (DIHS). Br J Dermatol 171 : 425-427, 2014.
PubMed
4) Mizukawa Y, et al : Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score : A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol 80 : 670-678.e2, 2019.
 
5) Taweesedt PT, et al : Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome : A Systematic Review. Biomed Res Int 2019 : 7863815, 2019.
PubMed
6) Sawata T, et al : Drug-induced Hypersensitivity Syndrome Accompanied by Pulmonary Lesions Exhibiting Centrilobular Nodular Shadows. Intern Med 55 : 1159-1163, 2016.
PubMed
7) Hase I, et al : Bronchoscopic Investigation of Atypical Drug-induced Hypersensitivity Syndrome Showing Viral Lung Involvement. Intern Med 55 : 2691-2696, 2016.
PubMed
8) Oyama B, et al : Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer. Intern Med 60 : 441-444, 2021.
 
9) Ros J, Munoz-Couselo E : DRESS syndrome due to vemurafenib treatment : switching BRAF inhibitor to solve a big problem. BMJ Case Rep, 2018. (DOI : 10.1136/bcr-2018-224379)
 
10) Takimoto R, et al : DIHS/DRESS-like eruption possibly induced by amoxicillin during treatment with nivolumab. Eur J Dermatol 29 : 228-229, 2019.
PubMed
P.164 掲載の参考文献
1) De Giacomi F, et al : Acute Eosinophilic Pneumonia. Causes, Diagnosis, and Management. Am J Respir Crit Care Med 197 : 728-736, 2018,
PubMed
2) Crofton JW, et al : Pulmonary eosinophilia. Thorax 7 : 1-35, 1952.
PubMed
3) Allen JN, et al : Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 321 : 569-574, 1989.
PubMed
4) Takei R, et al : Traction bronchiectasis on high-resolution computed tomography may predict fatal acute eosinophilic pneumonia. Respir Investig 57 : 67-72, 2019.
PubMed
5) Rhee CK, et al : Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia. Eur Respir J 41 : 402-409, 2013.
PubMed
6) Kawayama T, et al : Fatal idiopathic acute eosinophilic pneumonia with acute lung injury. Respirology 7 : 373-375, 2002.
PubMed
7) Philit F, et al : Idiopathic acute eosinophilic pneumonia : a study of 22 patients. Am J Respir Crit Care Med 166 : 1235-1239, 2002.
PubMed
8) Shorr AF, et al : Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. JAMA 292 : 2997-3005, 2004.
PubMed
9) Yoon CG, et al : Clinical Characteristics and Factors Influencing the Occurrence of Acute Eosinophilic Pneumonia in Korean Military Personnel. J Korean Med Sci 31 : 247-253, 2016.
PubMed
10) Suzuki Y, Suda T : Eosinophilic pneumonia : A review of the previous literature, causes, diagnosis, and management. Allergol Int 68 : 413-419, 2019.
PubMed
11) Ota K et al : Age distribution and seasonality in acute eosinophilic pneumonia : analysis using a national inpatient database. BMC Pulm Med 19 : 38, 2019.
 
12) De Giacomi F, et al : Acute Eosinophilic Pneumonia : Correlation of Clinical Characteristics With Underlying Cause. Chest 152 : 379-385, 2017.
PubMed
13) Cottin V, Cordier JF : Eosinophilic pneumonias. Allergy 60 : 841-857, 2005.
PubMed
14) Uchiyama H, et al : Alterations in smoking habits are associated with acute eosinophilic pneumonia. Chest 133 : 1174-1180, 2008.
PubMed
15) Thota D, Latham E : Case report of electronic cigarettes possibly associated with eosinophilic pneumonitis in a previously healthy active-duty sailor. J Emerg Med 47 : 15-17, 2014.
 
16) Arter ZL, et al : Acute eosinophilic pneumonia following electronic cigarette use. Respir Med Case Rep 27 : 100825, 2019.
PubMed
17) Harada HA, et al : A 20-Year-Old Man with e-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI) and Thrombotic Coagulopathy. Am J Case Rep 22 : e929915, 2021.
PubMed
18) Daimon T, et al : KL-6 and surfactant proteins A and D in serum and bronchoalveolar lavage fluid in patients with acute eosinophilic pneumonia. Intern Med 44 : 811-817, 2005.
 
19) Fujimura M, et al : Bronchoalveolar lavage cell findings in three types of eosinophilic pneumonia : acute, chronic and drug-induced eosinophilic pneumonia. Respir Med 92 : 743-749, 1998.
PubMed
20) Daimon T, et al : Acute eosinophilic pneumonia : Thin-section CT findings in 29 patients. Eur J Radiol 65 : 462-467, 2008.
PubMed
21) Johkoh T, et al : Eosinophilic lung diseases : diagnostic accuracy of thin-section CT in 111 patients. Radiology 216 : 773-780, 2000.
PubMed
22) Tazelaar HD, et al : Acute eosinophilic pneumonia : histopathologic findings in nine patients. Am J Respir Crit Care Med 155 : 296-302, 1997.
PubMed
23) Jhun BW, et al : Outcomes of rapid corticosteroid tapering in acute eosinophilic pneumonia patients with initial eosinophilia. Respirology 20 : 1241-1247, 2015.
PubMed
P.169 掲載の参考文献
1) Cottin V, Cordier JF : Eosinophilic lung diseases. Immunol Allergy Clin North Am 32 : 557-586, 2012.
PubMed
2) Carrington CB, et al : Chronic eosinophilic pneumonia. N Engl J Med 280 : 787-798, 1969.
PubMed
3) Thomeer MJ, et al : Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl 32 : 114s-118s, 2001.
PubMed
4) Suzuki Y, Suda T : Eosinophilic pneumonia : A review of the previous literature, causes, diagnosis, and management. Allergol Int 68 : 413-419, 2019.
PubMed
5) Allen J, Wert M : Eosinophilic Pneumonias. J Allergy Clin Immunol Pract 6 : 1455-1461, 2018.
PubMed
6) Kobayashi Y, et al : Critical role of CCL4 in eosinophil recruitment into the airway. Clin Exp Allergy 49 : 853-860, 2019.
PubMed
7) Marchand E et al : Idiopathic chronic eosinophilic pneumonia and asthma : how do they influence each other? Eur Respir J 22 : 8-13, 2003.
PubMed
8) Crowe M, et al : Chronic eosinophilic pneumonia : clinical perspectives. Ther Clin Risk Manag 15 : 397-403, 2019.
PubMed
9) Nogawa H, et al : An unusual case of eosinophilic lung disease with multiple cyst formation. Respir Med Case Rep 31 : 101300, 2020.
PubMed
10) Matsuse H, et al : Diagnostic problems in chronic eosinophilic pneumonia. J Int Med Res 25 : 196-201, 1997.
PubMed
11) Minakuchi M, et al : Chronic eosinophilic pneumonia : treatment with inhaled corticosteroids. Respiration 70 : 362-366, 2003.
PubMed
12) Cottin V : Eosinophilic Lung Diseases. Clin Chest Med 37 : 535-556, 2016.
PubMed
13) Oyama Y, et al : Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia. Eur Respir J 45 : 1624-1631, 2015.
PubMed
14) Ishiguro T, et al : The Long-term Clinical Course of Chronic Eosinophilic Pneumonia. Intern Med 55 : 2373-2377, 2016.
 
15) Sarkis E, et al : Anti-interleukin (IL) -5 as a steroid-sparing agent in chronic eosinophilic pneumonia. J Asthma 57 : 82-86, 2020.
PubMed
P.174 掲載の参考文献
1) Gibson PG, et al : Chronic cough : eosinophilic bronchitis without asthma. Lancet 1 : 1346-1348, 1989.
PubMed
2) Gonlugur U, Gonlugur ET : Eosinophilic bronchitis without asthma. Int Arch Allergy Immunol 147 : 1-5, 2008.
PubMed
3) Morice AH, et al : ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 55 : 2020.
PubMed
4) Lai K, et al : Response to bronchodilator and clinical, pathophysiological features in patients with nonasthmatic eosinophilic bronchitis. Clin Respir J 14 : 242-249, 2020.
PubMed
5) Niimi A, et al : Eosinophilic airway disorders associated with chronic cough. Pulm Pharmacol Ther 22 : 114-120, 2009.
PubMed
6) Lai K, et al : A prospective, multicenter survey on causes of chronic cough in China. Chest 143 : 613-620, 2013.
 
7) Irwin SR, et al : Classification of Cough as a Symptom in Adults and Management Algorithms : CHEST Guideline and Expert Panel Report. Chest 153 : 196-209, 2018.
 
8) Barber CM, Fishwick D : Chronic cough-occupational considerations. Chron Respir Dis 5 : 211-221, 2008.
PubMed
9) Lai K, et al : Non-asthmatic eosinophilic bronchitis and its relationship with asthma. Pulm Pharmacol Ther 47 : 66-71, 2017.
PubMed
10) Saunders R, et al : Fibrocyte localisation to the ASM bundle in asthma : bidirectional effects on cell phenotype and behaviour. Clin Transl Immunology 9 : e1205, 2020.
 
11) Song WJ, et al : Diagnostic accuracy of fractional exhaled nitric oxide measurement in predicting cough-variant asthma and eosinophilic bronchitis in adults with chronic cough : A systematic review and meta-analysis. J Allergy Clin Immunol 140 : 701-709, 2017.
PubMed
12) Berlyne GS, et al : A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. J Allergy Clin Immunol 106 : 638-644, 2000.
PubMed
13) Zhan W, et al : Duration of treatment with inhaled corticosteroids in nonasthmatic eosinophilic bronchitis : a randomized open label trial. Ther Adv Respir Dis 13 : 1753466619891520, 2019.
PubMed
14) Cho J, et al : Clinical Outcome of Eosinophilic Airway Inflammation in Chronic Airway Diseases Including Nonasthmatic Eosinophilic Bronchitis. Sci Rep 8 : 146, 2018.
PubMed
15) Lai K, et al : Will nonasthmatic eosinophilic bronchitis develop into chronic airway obstruction? : a prospective, observational study. Chest 148 : 887-894, 2015.
PubMed
P.179 掲載の参考文献
1) Fraser RS, et al : Eosinophilic Lung Disease. In : Fraser and Pare's Diagnosis of Diseases of the Chest (ed by Fraser RS, et al), 4th ed, p1743-1756, WB Saunders, Philadelphia, 1999.
 
2) Yasuda K, Kuroda E : Role of eosinophils in protective immunity against secondary nematode infections. Immunol Med 42 : 148-155, 2019.
PubMed
3) Kurt-Jones EA, et al : Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1 : 398-401, 2000.
PubMed
4) Odhiambo PO, et al : The Contribution of Host Cells to Pneumocystis Immunity : An Update. Pathogens 8 : 52, 2019.
 
5) Marcy TW : Eosinophilia in patients presenting with pulmonary infiltrates and fever. Semin Respir Infect 3 : 247-257, 1988.
PubMed
6) 大西健児 : 肺炎 : 診断と治療の進歩. V. 寄生虫性肺疾患. 日本内科学会雑誌 94 : 2307-2312, 2005.
 
7) 床島眞紀, ほか : ブタ回虫幼虫移行症による好酸球性肺炎の1例. 感染症学雑誌 78 : 1036-1040, 2004.
 
8) Rom WN, et al : Persistent lower respiratory tract infiammation associated with interstitial lung disease in patients with tropical pulmonary eosinophilia following conventional treatment with diethylcarbamazine. Am Rev Respir Dis 142 : 1088-1092, 1990.
 
9) Allen JN, Davis WB : Eosinophilic lung diseases. Am J Respir Crit Care Med 150 : 1423-1438, 1994.
 
10) 片桐佐和子, ほか : 移動性浸潤影にて発症し, ELISA法が診断治療に有用であった宮崎肺吸虫の1例. 日本呼吸器学会誌 40 : 225-229, 2002.
 
11) Kormos WA, et al : Case records of the Massachusetts General Hospital. Case 35-2010. A 56-year-old man with cough, hypoxemia, and rash. N Engl J Med 363 : 2046-2054, 2010.
 
12) Miyazaki E, et al : A case of acute eosinophilic pneumonia caused by inhalation of Trichosporon terrestre. Am J Respir Crit Care Med 151 : 541-543, 1995.
 
13) Allen JN, et al : Diagnostic significance of increased bronchoalveolar lavage fluid eosinophils. Am Rev Respir Dis 142 : 642-647, 1990.
PubMed
14) Vijayan VK, et al : Pulmonary eosinophilia in pulmonary tuberculosis. Chest 101 : 1708-1709, 1992.
PubMed
15) Garofalo R, et al : Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 120 : 28-32, 1992.
PubMed
P.184 掲載の参考文献
1) Citro LA, et al : Eosinophilic lung disease (or how to slice P. I. E). Am J Roentgenol Radium Ther Nucl Med 117 : 787-797, 1973.
PubMed
2) Fraser RG, et al : Eosinophilic Lung Disease. In : Diagnosis of Disease of the Chest, 3rd ed, p1290-1300, W. B. Saunders, Philadelphia, 1989.
 
3) Cottin V, Cordier JF : Eosinophilic pneumonias. Allergy 60 : 841-857, 2005.
PubMed
4) Mullerpattan JB, et al : Tropical pulmonary eosinophilia-a review. Indian J Med Res 138 : 295-302, 2013.
PubMed
5) Ong RK, Doyle RL : Tropical Pulmonary Eosinophilia. Chest 113 : 1673-1679, 1998.
PubMed
6) Frimodt-Moller C, Barton RM : A Pseudo-tuberculosis condition associated with eosinophilia. The Ind Med Gaz : 75 : 607-613, 1940.
PubMed
7) Weingarten RJ, Cologne MD : Tropical Eosinophilia. The Lancet 241 : 103-105, 1943.
 
8) Ball JD : Tropical Pulmonary Eosinophilia. Trans R Soc Trop Med Hyg 44 : 237-258, 1950.
PubMed
9) 小山田吉孝, ほか : 胸水貯留をきたした熱帯性好酸球増多症の1例. 日本胸部疾患学会雑誌 33 : 451-455, 1995.
 
10) Mehlotra RK, et al : Reciprocal immunomodulatory effects of gamma interferon and interleukin-4 on filaria-induced airway hyperresponsiveness. Infect Immun 69 : 1463-1468, 2001.
PubMed
11) Hall LR, et al : An essential role for interleukin-5 and eosinophils in helminth-induced airway hyperresponsiveness. Infect Immun 66 : 4425-4430, 1998.
PubMed
12) Madan M, et al : Tropical pulmonary eosinophilia : effect of addition of corticosteroids after failure of diethylcarbamazine therapy. Adv Respir Med 85 : 51-54, 2017.
PubMed
13) World Health Organization : Weekly epidemiological record 95 : 509-524, 2020.
 
14) 一盛和世, ほか : 世界フィラリア症制圧プログラム-日本への期待. 医学のあゆみ 247 : 370-374, 2013.
Medical*Online
15) 佐野ありさ, ほか : 空洞形成と胸水をきたした肺犬糸状虫症の1例. 日本呼吸器学会誌 38 : 490-493, 2000.
 
P.188 掲載の参考文献
1) Allen JN, Davis WB : Eosinophilic lung diseases. Am J Respir Crit Care Med 150 : 1423-1438, 1994.
 
2) Bain GA, Flower CD : Pulmonary eosinophilia. Eur J Radiol 23 : 3-8, 1996.
PubMed
3) Umeki S : Reevaluation of eosinophilic pneumonia and its diagnostic criteria. Arch Intern Med 152 : 1913-1919, 1992.
PubMed
4) 薬剤性好酸球性肺炎 (EP). 薬剤性肺障害の診断・治療の手引き 第2版 2018 (日本呼吸器学会薬剤性肺障害の診断・治療の手引き第2版作成委員会編), p58-61, メディカルレビュー社, 2018.
 
5) Camus P : The Drug-induced Respiratory Disease Website. [https://www.pneumotox.com/drug/index/] (2021年5月閲覧)
 
6) Fujimura M, et al : Bronchoalveolar lavage cell findings in three types of eosinophilic pneumonia : acute, chronic and drug-induced eosinophilic pneumonia. Respir Med 92 : 743-749, 1998.
PubMed
7) Camus P : Drug-induced interstitial lung disease. In : Interstitial Lung Disease, 4th ed (ed by Schwarz MI, King TE Jr), p485-534, B. C. Decker, Hamilton, 2003.
 
8) Meyer KC, et al : An official American Thoracic Society clinical practice guideline : the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 185 : 1004-1014, 2012.
PubMed
9) 早稲田優子, ほか : 気管支肺胞洗浄液 (BALF) 細胞分画の解析方法の違いが治療方針に与える影響. 日本呼吸器学会誌 8 (増刊号) : 157, 2019.
 
10) 桑野和善 : 正常所見と喫煙による変化. 気管支肺胞洗浄 (BAL) 法の手引き 改訂第3版 (日本呼吸器学会びまん性肺疾患学術部会, 厚生労働省難治性疾患政策研究事業びまん性肺疾患に関する調査研究班編), p65-70, 克誠堂出版, 2017.
 
11) Allen JN, et al : Diagnostic significance of increased bronchoalveolar lavage fluid eosinophils. Am Rev Respir Dis 142 : 642-647, 1990.
PubMed
12) Nabeya D, et al : Yellow Broncho-alveolar Lavage Fluid in Eosinophilic Pneumonia. Intern Med 55 : 3227-3228, 2016.
PubMed
13) 小倉高志 : 好酸球性肺炎 (急性好酸球性肺炎・慢性好酸球性肺炎) と気管支鏡. 気管支学 27 : 32-36, 2005.
Medical*Online
14) 石本裕士, ほか : プラセンタによる薬剤性好酸球性肺炎の1例. 日本呼吸器学会誌 4 : 464-467, 2015.
Medical*Online
15) 横山彰仁 : 2. 診断へのアプローチ (特集 : 薬剤性肺疾患 : 診断と治療の進歩. II. 発生機序と診断). 日本内科学会雑誌 96 : 1097-1103, 2007.
 

V 肺循環の異常

P.196 掲載の参考文献
1) Balk RA, Bone RC : The septic syndrome : definition and clinical implications. Crit Care Clin 5 : 1-8, 1989.
PubMed
2) Bone RC, et al : Sepsis syndrome : a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 17 : 389-393, 1989.
 
3) Bone RC, et al : Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 : 1644-1655, 1992.
PubMed
4) Levy MM, et al : 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 : 1250-1256, 2003.
PubMed
5) Singer M, et al : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 : 801-810, 2016.
PubMed
6) Vincent JL, et al : The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22 : 707-710, 1996.
 
7) Bernard GR, et al : The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336 : 912-918, 1997.
 
8) Bone RC : Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome : what we do and do not know about cytokine regulation. Crit Care Med 24 : 163-172, 1996.
 
9) Matsuda N, et al : Priming by lipopolysaccharide exaggerates acute lung injury and mortality in responses to peptidoglycan through up-regulation of Toll-like receptor-2 expression in mice. Biochem Pharmacol 75 : 1065-1075, 2008.
PubMed
10) Ferrer R, et al : Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour : results from a guideline-based performance improvement program. Crit Care Med 42 : 1749-1755, 2014.
PubMed
11) Rhodes A, et al : Surviving Sepsis Campaign : International Guidelines for Management of Sepsis and Septic Shock : 2016. Intensive Care Med 43 : 304-377, 2017.
PubMed
12) Ferreira FL, et al : Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill Patients. JAMA 286 : 1754-1758, 2001.
PubMed
P.200 掲載の参考文献
1) Thompson BT, et al : Acute Respiratory Distress Syndrome. N Engl J Med 377 : 562-572, 2017.
PubMed
2) ARDS Definition Task Force ; Ranieri VM, et al : Acute respiratory distress syndrome : the Berlin Definition. JAMA 307 : 2526-2533, 2012.
PubMed
3) Bellani G, et al : Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA 315 : 788-800, 2016.
PubMed
4) Tasaka S, Tatsumi K : Clinical practice of acute respiratory distress syndrome in Japan : A nationwide survey and scientific evidences. Respir Investig 55 : 257-263, 2017.
PubMed
5) Thille AW, et al : Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage : a prospective cohort study of clinical autopsies. Lancet Respir Med 1 : 395-401, 2013.
 
6) Piantadosi CA, Schwartz DA : The acute respiratory distress syndrome. Ann Intern Med 141 : 460-470, 2004.
PubMed
7) Ichikado K, et al : Fibroproliferative changes on high-resolution CT in the acute respiratory distress syndrome predict mortality and ventilator dependency : a prospective observational cohort study. BMJ Open 2 : e000545, 2012.
PubMed
8) Kamo T, et al : Prognostic values of the Berlin definition criteria, blood lactate level, and fibroproliferative changes on high-resolution computed tomography in ARDS patients. BMC Pulm Med 19 : 37, 2019.
 
9) Acute Respiratory Distress Syndrome Network, et al : Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342 : 1301-1308, 2000.
PubMed
10) Lamontagne F, et al : Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia : a meta-analysis of randomized controlled trials. J Crit Care 25 : 420-435, 2010.
PubMed
11) Walkey AJ, Wiener RS : Macrolide antibiotics and survival in patients with acute lung injury. Chest 141 : 1153-1159, 2012.
PubMed
12) Kawamura K, et al : Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome : a retrospective, propensity score-matching analysis of prospectively collected data at a single center. Int J Antimicrob Agents 51 : 918-924, 2018.
 
P.204 掲載の参考文献
1) ISHLTホームページ. [http://www.ishlt.org/] (2021年7月閲覧)
 
2) Den Hengst WA, et al : Lung ischemia-reperfusion injury : a molecular and clinical view on a complex pathophysiological process. Am J Physiol Heart Circ Physiol 299 : H1283-1299, 2010.
PubMed
3) Christie JD, et al : Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II : definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 24 : 1454-1459, 2005.
 
4) Snell GI, et al : Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I : Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 36 : 1097-1103, 2017.
 
5) Arnaoutakis GJ, et al : Low potassium dextran is superior to University of Wisconsin solution in high-risk lung transplant recipients. J Heart Lung Transplant 29 : 1380-1387, 2010.
PubMed
6) Okada Y, et al : Clinical application of an extracellular phosphate-buffered solution (EP-TU) for lung preservation : preliminary results of a Japanese series. Surg Today 42 : 152-156, 2012.
PubMed
7) Ikeda M, et al : Clinical application of ET-Kyoto solution for lung transplantation. Surg Today 45 : 439-443, 2015.
PubMed
P.208 掲載の参考文献
1) 救急診療指針 [改訂第5版] (日本救急医学会指導医・専門医制度委員会, 日本救急医学会専門医認定委員会編), p545-546, へるす出版, 2018.
 
2) Idris AH, et al : Recommended guidelines for uniform reporting of data from drowning : the "Utstein style". Resuscitation 59 : 45-57, 2003.
PubMed
3) 辻岡三南子 : 溺水・溺死. 慶應保健研究 18 : 71-75, 2000.
 
4) Modell JH, Davis JH : Electrolyte changes in human drowning victims. Anesthesiology 30 : 414-420, 1969.
PubMed
5) Bierens JJ, et al : Drowning. Curr Opin Crit Care 8 : 578-586, 2002.
PubMed
6) ARDS診療ガイドライン 2016 (日本呼吸器学会, 日本呼吸療法医学会, 日本集中治療医学会編), 総合医学社, 2016.
 
7) Miyake M, et al : Rapidly progressive pneumonia due to Aeromonas hydrophila shortly after near-drowning. Intern Med 39 : 1128-1130, 2000.
PubMed
8) 下地法明, ほか : 腸管外からAeromonas属菌が検出された症例の基礎的解析. 医学検査 64 : 295-301, 2015.
Medical*Online
9) 塩田量子, ほか : 温泉浴槽内溺水後の肺炎患者から検出されたLegionella pneumophila SG3について. 感染症学雑誌 69 : 1356-1364, 1995.
 
10) 粟屋禎一, ほか : ボリコナゾールが著効した肺Pseudallescheria症の1例. 日本呼吸器学会誌 45 : 788-792, 2007.
 
11) Iwata K, et al : Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) : a systematic review and meta-analysis. Intern Med 49 : 2423-2432, 2010.
PubMed
12) 岩下義明, ほか : 温泉水誤嚥によるARDSの一例. 人工呼吸 28 : 83-88, 2011.
Medical*Online
13) 笠松哲司, ほか : 溺水による急性肺障害にシベレスタットナトリウムが有効と考えられた1例. 新薬と臨牀 56 : 150-152, 2007.
Medical*Online
14) Staudinger T, et al : Exogenous surfactant therapy in a patient with adult respiratory distress syndrome after near drowning. Resuscitation 35 : 179-182, 1997.
 
15) Szpilman D, et al : Drowning. N Engl J Med 366 : 2102-2110, 2012.
PubMed
P.213 掲載の参考文献
1) Popovsky MA, Moore SB : Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 25 : 573-577, 1985.
PubMed
2) Toy P, et al : Transfusion-related acute lung injury : incidence and risk factors. Blood 119 : 1757-1767, 2012.
PubMed
3) Serious Hazards of Transfusion : ANNUAL SHOT REPORT 2015. [https://www.shotuk.org/wp-content/uploads/myimages/SHOT-2015-Annual-Report-Web-Edition-Final-bookmarked.pdf] (2021年7月閲覧)
 
4) Nakazawa H, et al : Impact of fresh-frozen plasma from male-only donors versus mixed-sex donors on postoperative respiratory function in surgical patients : a prospective case-controlled study. Transfusion 49 : 2434-2441, 2009.
PubMed
5) Muller MC, et al : Low-risk transfusion-related acute lung injury donor strategies and the impact on the onset of transfusion-related acute lung injury : a meta-analysis. Transfusion 55 : 164-175, 2015.
PubMed
6) Gajic O, et al : Transfusion-related acute lung injury in the critically ill : prospective nested casecontrol study. Am J Respir Crit Care Med 176 : 886-891, 2007.
PubMed
7) Kleinman S, et al : Toward an understanding of transfusion-related acute lung injury : statement of a consensus panel. Transfusion 44 : 1774-1789, 2004.
PubMed
8) ARDS Definition Task Force ; Ranieri VM, et al : Acute respiratory distress syndrome : the Berlin Definition. JAMA 307 : 2526-2533, 2012.
PubMed
9) Vlaar APJ, et al : A consensus redefinition of transfusion-related acute lung injury. Transfusion 59 : 2465-2476, 2019.
PubMed
10) 日本赤十字社 : 日本赤十字社におけるTRALI及びTACOの評価基準変更のお知らせ. 令和3年3月. [https://www.jrc.or.jp/mr/product/information/pdf/info_202103.pdf] (2021年7月閲覧)
 
11) Zhou L, et al : Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion 45 : 1056-1063, 2005.
PubMed
12) Roubinian NH, et al : NT-proBNP levels in the identification and classification of pulmonary transfusion reactions. Transfusion 60 : 2548-2556, 2020.
PubMed
13) Klanderman RB, et al : Transfusion-associated circulatory overload-a systematic review of diagnostic biomarkers. Transfusion 59 : 795-805, 2019.
PubMed
14) ARDS診療ガイドライン 2016, (日本呼吸器学会, 日本呼吸療法医学会, 日本集中治療医学会, 3学会合同ARDS診療ガイドライン2016作成委員会編), 2016.
 
15) 岡崎仁, ほか : 科学的根拠に基づいた輸血有害事象対応ガイドライン. 日本輸血細胞治療学会誌 65 : 1-9, 2019.
Medical*Online
P.218 掲載の参考文献
1) 日本循環器学会循環器疾患診療実態調査IT/Database部会 : 循環器疾患診療実態調査報告書 (2019年度実施・公表). [http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2018web.pdf] (2021年7月閲覧)
 
2) 急性・慢性心不全診療ガイドライン [2017年改訂版] (日本循環器学会・日本心不全学会, ほか編). [https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf] (2021年7月閲覧)
 
3) Abramov D, Kittleson MM : The Universal Definition of Heart Failure : Strengths and Opportunities. J Card Fail 27 : 622-624, 2021.
PubMed
4) Mebazaa A, et al : Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36 : S129-139, 2008.
PubMed
5) Hope JA : A Treatise on the Diseases of the Heart and Great Vessels, William Kidd, London, 1832.
 
6) Shapiro BP, et al : Acute and chronic ventricular-arterial coupling in systole and diastole : insights from an elderly hypertensive model. Hypertension 50 : 503-511, 2007.
PubMed
7) MacIver DH, et al : The vital role of the right ventricle in the pathogenesis of acute pulmonary edema. Am J Cardiol 115 : 992-1000, 2015.
PubMed
8) Nugent K, et al : Lung morphology and surfactant function in cardiogenic pulmonary edema : a narrative review. J Thorac Dis 11 : 4031-4038, 2019.
PubMed
9) Ricci F, et al : Role and importance of ultrasound lung comets in acute cardiac care. Eur Heart J Acute Cardiovasc Care 4 : 103-112, 2015.
PubMed
10) Light RW, George RB : Serial pulmonary function in patients with acute heart failure. Arch Intern Med 143 : 429-433, 1983.
PubMed
11) Sharp JT, et al : Ventilatory mechanics in pulmonary edema in man. J Clin Invest 37 : 111-117, 1958.
 
12) Frat JP, et al : High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 372 : 2185-2196, 2015.
PubMed
13) Jardin F, et al : Influence of positive end-expiratory pressure on left ventricular performance. N Engl J Med 304 : 387-392, 1981.
PubMed
14) Plaisance P, et al : A randomized study of out-of-hospital continuous positive airway pressure for acute cardiogenic pulmonary oedema : physiological and clinical effects. Eur Heart J 28 : 2895-2901, 2007.
PubMed
15) Herrero-Puente P, et al : Influence of Intravenous Nitrate Treatment on Early Mortality Among Patients With Acute Heart Failure. NITRO-EAHFE Study. Rev Esp Cardiol (Engl Ed) 68 : 959-967, 2015.
PubMed
P.222 掲載の参考文献
1) Ware LB, et al : Clinical practice. Acute pulmonary edema. N Engl J Med 353 : 2788-2796, 2005.
PubMed
2) Milne EN, et al : The radiologic distinction of cardiogenic and noncardiogenic edema. AJR Am J Roentgenol 144 : 879-894, 1985.
PubMed
3) Karmpaliotis D, et al : Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 131 : 964-971, 2007.
 
4) Acute Respiratory Distress Syndrome Network ; Brower RG, et al : Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342 : 1301-1308, 2000.
PubMed
5) Ware LB, Matthay MA : The acute respiratory distress syndrome. N Engl J Med 342 : 1334-1349, 2000.
PubMed
6) Meduri GU, et al : Methylprednisolone infusion in early severe ARDS : results of a randomized controlled trial. Chest 131 : 954-963, 2007.
PubMed
P.227 掲載の参考文献
1) Calenoff L, et al : Unilateral pulmonary edema. Radiology 126 : 19-24, 1978.
 
2) Givertz MM : Noncardiogenic pulmonary edema. UpToDate [https://www.uptodate.com/contents/noncardiogenic-pulmonary-edema?search=pulmonary%20edema&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1] (2021年7月閲覧)
 
3) Cherian SV, et al : Unilateral Pulmonary Edema after Visiting High Altitude. Ann Am Thorac Soc 14 : 589-593, 2017.
PubMed
4) Durga P, et al : Unilateral neurogenic pulmonary oedema : An unusual cause for post-operative respiratory dysfunction following clipping of ruptured intracranial aneurysm. Indian J Anaesth 56 : 58-61, 2012.
PubMed
5) Komatsu T, et al : Unilateral re-expansion pulmonary edema following treatment of pneumothorax with exceptionally massive sputum production, followed by circulatory collapse. Can Respir J 17 : 53-55, 2010.
PubMed
6) Reynes AN, et al : Acute unilateral edema of the lung in patient with heroin overdose and treated with intravenous naloxone. Med Clin (Barc) 94 : 637, 1990.
 
7) Giuliano JS, et al : Unilateral pulmonary edema and acute rheumatic fever. Eur J Pediatr 167 : 465-467, 2008.
PubMed
8) Attias D, et al : Prevalence, characteristics, and outcomes of patients presenting with cardiogenic unilateral pulmonary edema. Circulation 122 : 1109-1115, 2010.
PubMed
9) Gurney JW, Goodman LR : Pulmonary edema localized in the right upper lobe accompanying mitral regurgitation. Radiology 171 : 397-399, 1989.
PubMed
10) Marom EM, et al : Variations in pulmonary venous drainage to the left atrium : implications for radiofrequency ablation. Radiology 230 : 824-829, 2004.
 
11) Shin JH, et al : Unilateral pulmonary edema : a rare initial presentation of cardiogenic shock due to acute myocardial infarction. J Korean Med Sci 27 : 211-214, 2012.
PubMed
12) 阿部聖裕, 西村一孝 : 片側性肺水腫. 別冊日本臨牀 新領域症候群シリーズ No. 9. 呼吸器症候群 (第2版) II, p221-223, 日本臨牀社, 2009.
 
13) Inotani S, et al : Unilateral cardiogenic pulmonary edema. J Cardiol Cases 17 : 85-88, 2018.
PubMed
P.231 掲載の参考文献
1) 高山病と関連疾患の診療ガイドライン (日本登山医学会 高山病と関連疾患の診療ガイドライン作成委員会編), 中外医学社, 2017.
 
2) Hanaoka M, et al : Association of high-altitude pulmonary edema with the major histocompatibility complex. Circulation 97 : 1124-1128, 1998.
PubMed
3) Maggiorini M, et al : High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation 103 : 2078-2083, 2001.
PubMed
4) Hanaoka M, et al : Hypoxia-induced pulmonary blood redistribution in subjects with a history of high-altitude pulmonary edema. Circulation 101 : 1418-1422, 2000.
PubMed
5) Scherrer U, et al : Inhaled nitric oxide for high-altitude pulmonary edema. N Engl J Med 334 : 624-629, 1996.
PubMed
6) Droma Y, et al : Positive association of the endothelial nitric oxide synthase gene polymorphisms with high-altitude pulmonary edema. Circulation 106 : 826-830, 2002.
PubMed
7) West JB, et al : Stress failure in pulmonary capillaries. J Appl Physiol (1985) 70 : 1731-1742, 1991.
PubMed
8) Swenson ER, et al : Pathogenesis of high-altitude pulmonary edema : inflammation is not an etiologic factor. JAMA 287 : 2228-2235, 2002.
 
9) Kubo K, et al : Cytokines in bronchoalveolar lavage fluid in patients with high altitude pulmonary oedema at moderate altitude in Japan. Thorax 51 : 739-742, 1996.
PubMed
10) Basnyat B, Murdoch DR : High-altitude illness. Lancet 361 : 1967-1974, 2003.
PubMed
11) 花岡正幸 : 高地肺水腫. 別冊「医学のあゆみ」最新ARDSのすべて (石井芳樹編), p206-210, 医歯薬出版, 2010.
 
12) Droma Y, et al : Pathological features of the lung in fatal high altitude pulmonary edema occurring at moderate altitude in Japan. High Alt Med Biol 2 : 515-523, 2001.
PubMed
13) Hultgren HN, Marticorena EA : High altitude pulmonary edema. Epidemiologic observations in Peru. Chest 74 : 372-376, 1978.
PubMed
14) Luks AM, et al : Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness : 2014 update. Wilderness Environ Med 25 : S4-14, 2014.
PubMed
15) 花岡正幸 : 高地肺水腫. 呼吸器疾患最新の治療 2019-2020 (門田淳一, ほか編), p184-186, 南江堂, 2019.
 
P.236 掲載の参考文献
1) Rozenman J, et al : Re-expansion pulmonary oedema following spontaneous pneumothorax. Respir Med 90 : 235-238, 1996.
PubMed
2) Matsuura Y, et al : Clinical analysis of reexpansion pulmonary edema Chest 100 : 1562-1566, 1991.
PubMed
3) Ault MJ, et al : Thoracentesis outcomes : a 12-year experience. Thorax 70 : 127-132, 2015.
PubMed
4) Sunderland N, et al : Re-expansion pulmonary oedema : a novel emergency therapeutic option. BMJ Case Rep 2016 : bcr2016215076, 2016.
PubMed
5) Mahfood S, et al : Reexpansion pulmonary edema. Ann Thorac Surg 45 : 340-345, 1988.
PubMed
6) Jackson RM, et al : Re-expansion pulmonary edema. A potential role for free radicals in its pathogenesis. Am Rev Respir Dis 137 : 1165-1171, 1988.
PubMed
7) McCord JM : Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312 : 159-163, 1985.
PubMed
8) Saito S, et al : Pulmonary reexpansion causes xanthine oxidase-induced apoptosis in rat lung. Am J Physiol Lung Cell Mol Physiol 289 : L400-406, 2005.
PubMed
9) Suzuki S, et al : Evidence of acute inflammatory response in reexpansion pulmonary edema. Chest 101 : 275-276, 1992.
PubMed
10) Nakamura H, et al : Elevated levels of interleukin-8 and leukotriene B4 in pulmonary edema fluid of a patient with reexpansion pulmonary edema. Am J Respir Crit Care Med 149 : 1037-1040, 1994.
PubMed
11) Sakao Y, et al : Association of IL-8 and MCP-1 with the development of reexpansion pulmonary edema in rabbits. Ann Thorac Surg 71 : 1825-1832, 2001.
PubMed
12) Nakamura M, et al : Importance of interleukin-8 in the development of reexpansion lung injury in rabbits. Am J Respir Crit Care Med 161 : 1030-1036, 2000.
PubMed
13) Sawafuji M, et al : Role of Rho-kinase in reexpansion pulmonary edema in rabbits. Am J Physiol Lung Cell Mol Physiol 289 : L1946-1953, 2005.
 
14) Pavlin DJ, et al : Hemodynamic effects of rapidly evacuating prolonged pneumothorax in rabbits. J Appl Physiol (1985) 62 : 477-484, 1987.
PubMed
15) Oyarzun MJ, et al : Effect of lung collapse on alveolar surfactant in rabbits subjected to unilateral pneumothorax. Exp Lung Res 15 : 909-924, 1989.
PubMed
16) Sewell RW, et al : Experimental evaluation of reexpansion pulmonary edema. Ann Thorac Surg 26 : 126-132, 1978.
PubMed
17) Miller WC, et al : Experimental pulmonary edema following re-expansion of pneumothorax. Am Rev Respir Dis 108 : 664-666, 1973.
 
18) Pavlin J, Cheney FW Jr : Unilateral pulmonary edema in rabbits after reexpansion of collapsed lung. J Appl Physiol Respir Environ Exerc Physiol 46 : 31-35, 1979.
PubMed
19) Ravin CE, Dahmash NS : Re-expansion pulmonary edema. Chest 77 : 709-710, 1980.
PubMed
20) Havelock T, et al : Pleural procedures and thoracic ultrasound : British Thoracic Society Pleural Disease Guideline 2010. Thorax 65 (Suppl 2) : ii61-76, 2010.
 
21) Pavlin DJ, et al : Reexpansion hypotension. A complication of rapid evacuation of prolonged pneumothorax. Chest 89 : 70-74, 1986.
PubMed
22) Light RW, et al : Observations on pleural fluid pressures as fluid is withdrawn during thoracentesis. Am Rev Respir Dis 121 : 799-804, 1980.
PubMed
23) Feller-Kopman D, et al : Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 84 : 1656-1661, 2007.
PubMed
24) Feller-Kopman D, et al : The relationship of pleural pressure to symptom development during therapeutic thoracentesis. Chest 129 : 1556-1560, 2006.
PubMed
25) Ragozzino MW, Greene R : Bilateral reexpansion pulmonary edema following unilateral pleurocentesis. Chest 99 : 506-508, 1991.
PubMed
26) 水原敬洋, 倉橋清泰 : 腹腔内巨大腫瘍摘出後に再膨張性肺水腫を来した1症例. 麻酔 57 : 191-196, 2008.
Medical*Online
27) Henry M, et al : BTS guidelines for the management of spontaneous pneumothorax. Thorax 58 (Suppl 2) : ii39-52, 2003.
 
28) Cho SR, et al : New treatment method for reexpansion pulmonary edema : differential lung ventilation. Ann Thorac Surg 80 : 1933-1934, 2005.
PubMed
P.242 掲載の参考文献
1) 日本呼吸器学会 : 薬剤性肺障害の診断・治療の手引き 2018 [第2版], メディカルレビュー社, 2018.
 
2) 立石秀彦ほか : ホスゲン吸入による肺障害の1例. 呼吸 32 : 372-373, 2013.
Medical*Online
3) 山崎啓, ほか : セファドロキシルが原因と考えられた薬剤性非心原性肺水腫の1例. 日本呼吸器学会誌 1 : 207-212, 2012.
Medical*Online
4) Camus P, et al : Interstitial lung disease induced by drugs and radiation. Respiration 71 : 301-326, 2004.
PubMed
5) 田村昌士 : 薬剤誘起性肺臓炎. 内科Mook 22, p262-270, 金原出版, 1983.
 
P.246 掲載の参考文献
1) Miyakis S, et al : International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 : 295-306, 2006.
 
2) Parthvi R, et al : Pulmonary hypertension associated with antiphospholipid antibody : Call for a screening tool? Intractable Rare Dis Res 6 : 163-171, 2017.
PubMed
3) Vianna JL, et al : Comparison of the primary and secondary antiphospholipid syndrome : a European Multicenter Study of 114 patients. Am J Med 96 : 3-9, 1994.
PubMed
4) Fujieda Y, et al : Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 21 : 1506-1514, 2012.
PubMed
5) 慢性血栓塞栓性肺高血圧症 (CTEPH) 診療ガイドライン (日本肺高血圧・肺循環器学会編), 2018. [http://jpcphs.org/pdf/guideline/cteph_guideline.pdf.]
 
6) Pepke-Zaba J, et al : Chronic thromboembolic pulmonary hypertension : role of medical therapy. Eur Respir J 41 : 985-990, 2013.
PubMed
7) Lang IM, et al : Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension. Clin Chest Med 42 : 81-90, 2021.
PubMed
8) Cheng CY, et al : Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension : a systematic review and meta-analysis. Intern Emerg Med 14 : 521-527, 2019.
PubMed
9) Wolf M, et al : Thrombotic risk factors in pulmonary hypertension. Eur Respir J 15 : 395-399, 2000.
PubMed
10) Jiang X, et al : Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension : A Well-Defined Subgroup of Patients. Thromb Haemost 119 : 1403-1408, 2019.
PubMed
11) Oku K, et al : Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. Rheumatology (Oxford) 52 : 1775-1784, 2013.
PubMed
12) Bohgaki M, et al : The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2 Glycoprotein I antibodies. Int Immunol 16 : 1633-1641, 2004.
 
13) Oku K, et al : Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68 : 1030-1035, 2009.
PubMed
14) Oku K, et al : Complement and thrombosis in the antiphospholipid syndrome. Autoirnmun Rev 15 : 1001-1004, 2016.
PubMed
15) Oku K, et al : Autoantibodies against a complement component 1q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome. Rheumatology (Oxford) 55 : 1403-1411, 2016.
PubMed
16) Otomo K, et al : Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64 : 504-512, 2012.
PubMed
17) Abe N, et al : Potential therapeutics for antiphospholipid antibody associated thrombocytopenia : A systematic review and meta-analysis. Mod Rheumatol 30 : 116-124, 2020.
PubMed
18) Habe K, et al : Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura. Intern Med 55 : 589-595, 2016.
PubMed
19) Ogawa A, Matsubara H : After the Dawn-Balloon Pulmonary Angioplasty for Patients With Chronic Thromboembolic Pulmonary Hypertension. Circ J 82 : 1222-1230, 2018.
PubMed
20) Li C, et al : Pulmonary thromboendarterectomy is a curative resolution for chronic thromboembolic pulmonary hypertension associated with antiphospholipid syndrome : a retrospective cohort study. Lupus 27 : 2206-2214, 2018.
PubMed
21) D'Armini AM, et al : Impact of high titre of antiphospholipid antibodies on postoperative outcome following pulmonary endarterectomy. Interact Cardiovasc Thorac Surg 10 : 418-422, 2010.
PubMed
22) Sato T, et al : Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome : a longitudinal cohort study. Lupus 28 : 1577-1582, 2019.
PubMed
23) 抗リン脂質抗体症候群・好酸球性多発血管炎性肉芽腫症・結節性多発動脈炎・リウマトイド血管炎の治療の手引き 2020 (厚生労働科学研究費補助金 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究, 針谷正祥編), 診断と治療社, 2021.
 
P.253 掲載の参考文献
1) Shirai Y, et al : Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension : a single-centre cohort. Rheumatology (Oxford) 51 : 1846-1854, 2012.
PubMed
2) Tselios K, et al : Systemic lupus erythematosus and pulmonary arterial hypertension : links, risks, and management strategies. Open Access Rheumatol 9 : 1-9, 2017.
PubMed
3) Sato T, et al : Prevalence of primary Sjogren's syndrome in patients undergoing evaluation for pulmonary arterial hypertension. PLoS One 13 : e0197297, 2018.
PubMed
4) Frost A, et al : Diagnosis of pulmonary hypertension. Eur Respir J 53 : 1801904, 2019.
PubMed
5) Tamura Y, et al : Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. Circ J 82 : 275-282, 2017.
PubMed
6) 白井悠一郎 : 強皮症における肺高血圧症-その多様性と治療戦略. リウマチ科 57 : 430-436, 2017.
 
7) Chung L, et al : Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 146 : 1494-1504, 2014.
PubMed
8) Galie N, et al : Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med 373 : 834-844, 2015.
PubMed
9) Kuwana M, et al : Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study : post hoc analysis. Ann Rheum Dis 79 : 626-634, 2020.
PubMed
10) Sanchez O, et al : Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130 : 182-189, 2006.
PubMed
11) 結合組織病に伴う肺動脈性肺高血圧症診療ガイドライン (日本肺高血圧・肺循環学会編), 2019. [http://jpcphs.org/pdf/guideline/ketugou_guideline.pdf]
 
12) Yasuoka H, et al : Predictors for favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease. Circ J 82 : 546-554, 2018.
PubMed
13) 肺高血圧症治療ガイドライン [2017年改訂版] (日本循環器学会編) [www.j-circ.or.jp/guideline/pdf/JCS2017_fukuda_h.pdf]
 
14) Miyamichi-Yamamoto S, et al : Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J 75 : 2668-2674, 2011.
PubMed
P.258 掲載の参考文献
1) Simonneau G, et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53 : 1801913, 2019.
PubMed
2) 東條毅, ほか : 膠原病4疾患における肺高血圧症の頻度に関する全国疫学調査. 厚生省特定疾患皮膚・結合組織疾患調査研究班, 混合性結合組織病分科会, 平成10年度研究報告書, p3-6, 1999.
 
3) Allcock RJ, et al : A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 43 : 596-602, 2004.
PubMed
4) Mayes MD : Scleroderma epidemiology. Rheum Dis Clin North Am 29 : 239-254, 2003.
PubMed
5) Avouac J, et al : Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 37 : 2290-2298, 2010.
PubMed
6) Perez-Penate GM, et al : Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus : Prevalence and Predictors. J Rheumatol 43 : 323-329, 2016.
PubMed
7) Coghlan JG, et al : Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis : the DETECT study. Ann Rheum Dis 73 : 1340-1349, 2014.
PubMed
8) 結合組織病に伴う肺動脈性肺高血圧症 診療ガイドライン (日本肺高血圧・肺循環学会編), レタープレス, 2019.
 
9) Yasuoka H, et al : Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Circ J 82 : 546-554, 2018.
PubMed
10) Pulido T, et al : Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369 : 809-818, 2013.
PubMed
11) Humbert M, et al : Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease : results from PATENT-1 and PATENT-2. Ann Rheum Dis 76 : 422-426, 2017.
PubMed
12) Gaine S, et al : Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 50 : 1602493, 2017.
PubMed
13) Xanthouli P, et al : Haemodynamic phenotypes and survival in patients with systemic sclerosis : the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis 79 : 370-378, 2020.
PubMed
14) Lei Y, et al : The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension : A systematic review and meta-analysis. Mod Rheumatol 31 : 151-161, 2021.
PubMed
15) Coghlan JG, et al : Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) : subgroup analysis from the AMBITION trial. Ann Rheum Dis 76 : 1219-1227, 2017.
PubMed
P.264 掲載の参考文献
1) Pedersen J, et al : Current and Future Treatments for Persistent Pulmonary Hypertension in the Newborn. Basic Clin Pharmacol Toxicol 123 : 392-406, 2018.
PubMed
2) Martinho S, et al : Persistent pulmonary hypertension of the newborn : pathophysiological mechanisms and novel therapeutic approaches. Front Pediatr 8 : 342, 2020.
PubMed
3) Simonneau G, et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53 : 1801913, 2019.
PubMed
4) Ivy DD, et al : Pediatric pulmonary hypertension. J Am Coll Cardiol 62 : D117-126, 2013.
PubMed
5) Mathew B, Lakshminrusimha S : Persistent Pulmonary Hypertension in the Newborn. Children 4 : 63, 2017.
PubMed
6) 肺高血圧症治療ガイドライン (2017年改訂版) (日本循環器学会, 合同研究班参加学会・研究会・研究班編), 2018.
 
7) 佐地勉 : Down症候群に合併する肺高血圧の意義. 日本小児循環器学会雑誌 29 : 3-10, 2013.
Medical*Online
8) De Boode WP, et al : Application of neonatologist performed echocardiography in the assessment and management of persistent pulmonary hypertension of the newborn. Pediatr Res 84 : S68-S77, 2018.
 
9) Lai MY, et al : Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Pediatr Neonatol 59 : 15-23, 2018.
PubMed
10) 石戸博隆 : 新生児遷延性肺高血圧症. 小児・成育循環器学 (日本小児循環器学会編), p344-346, 診断と治療社, 2018.
 
11) 鈴木悟 : NO吸入療法の現状と可能性. Medical Gases 18 : 58-62, 2016.
Medical*Online
12) Kimura T, et al : Inhaled nitric oxide for preterm infants with persistent pulmonary hypertension. Ann Clin Epidemiol 1 : 18-27, 2019.
 
13) 北田里華, ほか : 新生児特定集中治療室での使用を目的としたシルデナフィル錠に対する粉砕調剤の最適化. 薬剤学 80 : 307-314, 2020.
Medical*Online
14) 小金澤征也, ほか : 新生児遷延性肺高血圧症 (PPHN) を合併した一過性骨髄異常増殖症候群 (TAM) の4例. 日本周産期・新生児医学会雑誌 56 : 174-181, 2020.
Medical*Online
15) 久松千恵子, ほか : 新生児MASに対してECMOを施行し, 13年後に右中下葉切除を行った気管支拡張症の1例. 日本小児外科学会雑誌 43 : 780-783, 2007.
 
P.268 掲載の参考文献
1) 石橋正義, 吉田稔 : I-1 概念と発生機序 (特集 : 肺性心 : 診断と治療の進歩). 日本内科学会雑誌 82 : 789-793, 1993.
 
2) Hambraeus-Jonzon K, et al : Hypoxic pulmonary vasoconstriction in human lungs. A stimulus-response study. Anesthesiology 86 : 308-315, 1997.
PubMed
3) Weir EK, et al : Acute oxygen-sensing mechanisms. N Engl J Med 353 : 2042-2055, 2005.
PubMed
4) Simonneau G, et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53 : 2019.
PubMed
5) Chaouat A, et al : Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 : 189-194, 2005.
PubMed
6) Piazza G, Goldhaber SZ : The Acutely Decompensated Right Ventricle : Pathways for Diagnosis and Management. Chest 128 : 1836-1852, 2005.
PubMed
7) 相澤義房 : 診断学・検査の進歩 心電図. 日本臨牀 65 (増刊号 4 : 心不全 (上)) : 381-386, 2007.
 
8) 坂巻文雄, 石坂彰敏 : 肺性心とBNP・hANP. 綜合臨牀 56 : 1963-1964, 2007.
Medical*Online
9) Migueres M, et al : Pulsed Doppler echocardiography in the diagnosis of pulmonary hypertension in COPD. Chest 98 : 280-285, 1990.
 
10) 平賀俊尚, ほか : 慢性呼吸不全患者における低酸素血症の肺循環に及ぼす影響-動脈血酸素分圧・基礎疾患別検討-. 厚生省特定疾患呼吸不全調査研究班, 昭和62年度研究報告書. p135-140, 1988.
 
11) Ambrosy A, et al : Tolvaptan for the treatment of heart failure : a review of the literature. Expert Opin Pharmacother 12 : 961-976, 2011.
PubMed
12) Nathan SD, et al : Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 53 : 1801914, 2019.
PubMed
13) Tanabe N, et al : Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. Circ J 85 : 333-342, 2021.
PubMed
14) Waxman A, et al : Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 384 : 325-334, 2021.
PubMed
15) Salvaterra CG, Rubin LJ : Investigation and management of pulmonary hypertension in chronic obstructive pulmonary disease. Am Rev Respir Dis 148 : 1414-1417, 1993.
PubMed
P.274 掲載の参考文献
1) Simonneau G, et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53 : 1801913, 2019.
PubMed
2) Loyd JE : Genetics and pulmonary hypertension. Chest 122 : 284S-286S, 2002.
PubMed
3) 肺高血圧症治療ガイドライン [2017年改訂版] (日本循環器病学会, ほか編) [http://www.j-circ.or.jp/guideline/pdf/JCS2017_fukuda_h.pdf]
 
P.277 掲載の参考文献
1) 肺高血圧症治療ガイドライン (2017年改訂版) (日本循環器学会/日本肺高血圧・肺循環学会, ほか編), 2017.
 
2) Morrell NW, et al : Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 53 : 1801899, 2019.
PubMed
3) International PPH Consortium ; Lane KB, et al : Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat Genet 26 : 81-84, 2000.
 
4) Evans JD, et al : BMPR2 mutations and survival in pulmonary arterial hypertension : an individual participant data meta-analysis. Lancet Respir Med 4 : 129-137, 2016.
PubMed
5) Gamou S, et al : Genetics in pulmonary arterial hypertension in a large homogeneous Japanese population. Clin Genet 94 : 70-80, 2018.
 
6) Graf S, et al : Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun 9 : 1416, 2018.
PubMed
7) Andruska A, Spiekerkoetter E : Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond : Contributions to Pulmonary Arterial Hypertension. Int J Mol Sci 19 : 2499, 2018.
 
8) Long L, et al : Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med 21 : 777-785, 2015.
PubMed
9) Trembath RC, et al : Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345 : 325-334, 2001.
PubMed
10) Minai OA, et al : Long-term outcome in a patient with pulmonary hypertension and hereditary hemorrhagic telangiectasia. Chest 131 : 984-987, 2007.
 
11) Li W, et al : The clinical characteristics and long-term prognosis of pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia. Pulm Circ 8 : 2045894018759918, 2018.
PubMed
12) Evans JD, et al : BMPR2 mutations and survival in pulmonary arterial hypertension : an individual participant data meta-analysis. Lancet Respir Med 4 : 129-137, 2016.
PubMed
13) Isobe S, et al : Improved Survival of Patients with Pulmonary Arterial Hypertension with BMPR2 Mutations in the Last Decade. Am J Respir Crit Care Med 193 : 1310-1314, 2016.
PubMed
14) Suzuki H, et al : Genomic Comparison With Supercentenarians Identifies RNF213 as a Risk Gene for Pulmonary Arterial Hypertension. Circ Genom Precis Med 11 : e002317, 2018.
PubMed
15) Hiraide T, et al : Poor outcomes in carriers of the RNF213 variant (p.Arg4810Lys) with pulmonary arterial hypertension. J Heart Lung Transplant 39 : 103-112, 2020.
PubMed
P.280 掲載の参考文献
1) Pryce DM : Lower accessory pulmory artery with intralobar sequestration of lung ; a report of seven cases. J Pathol Bacteriol 58 : 457-467, 1946.
 
2) 進藤剛毅, ほか : 肺葉内肺分画症12例の臨床と病理-特に成因の病理的検索. 日本胸部臨床 32 : 9-22, 1973.
 
3) Savic B, et al : Lung sequestration : report of seven cases and review of 540 published cases. Thorax 34 : 96-101, 1979.
PubMed
4) Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery ; Shimizu H, et al : Thoracic and cardiovascular surgery in Japan in 2016 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 67 : 377-411, 2019.
PubMed
5) Corbett HJ, Humphrey GM : Pulmonary sequestration. Paediatr Respir Rev 5 : 59-68, 2004.
PubMed
6) Smith RA : Atheory of the origin of intralobar sequestration of lung. Thorax 11 : 10-24, 1956.
 
7) Sade RM, et al : The spectrum of pulmonary sequestration. Ann Thorac Surg 18 : 644-658, 1974.
PubMed
8) Hall NJ, Stanton MP : Long-term outcomes of congenital lung malformations. Semin Pediatr Surg 26 : 311-316, 2017.
PubMed
P.283 掲載の参考文献
1) 肺静脈閉塞症 (PVOD) 肺毛細血管腫症 (PCH) 診療ガイドライン (日本肺高血圧・肺循環学会編), 2017.
 
2) Simonneau G, et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53 : 1801913, 2019.
PubMed
3) O'Keefe MC, Post MD : Pulmonary capillary hemangiomatosis : a rare cause of pulmonary hypertension. Arch Pathol Lab Med 139 : 274-277, 2015.
PubMed
4) Almagro P, et al : Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension : report of 2 new cases and review of 35 cases from the literature. Medicine (Baltimore) 81 : 417-424, 2002.
PubMed
5) Ma L, Bao R : Pulmonary capillary hemangiomatosis : a focus on the EIF2AK4 mutation in onset and pathogenesis. Appl Clin Genet 8 : 181-188, 2015.
PubMed
6) 肺高血圧症治療ガイドライン [2017年改訂版] (日本循環器学会, ほか編), 2018.
 
7) Anazawa R, et al : Features of radiological and physiological findings in pulmonary capillary hemangiomatosis : an updated pooled analysis of confirmed diagnostic cases. Pulm Circ 9 : 2045894019896696, 2019. (DOI : 10.1177/2045894019896696)
 
8) Wada H, et al : Pulmonary capillary hemangiomatosis diagnosed by pathology of explanted lungs : a unique etiology serves as a key of clinical diagnosis. Gen Thorac Cardiovasc Surg 67 : 332-335, 2019.
PubMed
9) Frazier AA, et al : From the Archives of the AFIP : pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Radiographics 27 : 867-882, 2007.
PubMed
10) Lantuejoul S, et al : Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis : aclinicopathologic study of 35 cases. Am J Surg Pathol 30 : 850-857, 2006.
 
11) Ogawa A, et al : Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis : A systematic review. Respir Investig 57 : 183-190, 2019.
PubMed
12) Umezu H, et al : An autopsy case of pulmonary capillary hemangiomatosis without evidence of pulmonary hypertension. Virchows Arch 439 : 586-592, 2001.
PubMed
P.287 掲載の参考文献
1) 金澤實 : 治療方針. 薬剤性肺疾患 : 診断と治療の進歩. 日本内科学会雑誌 96 : 1156-1162, 2007.
 
2) Simonneau G, et al : Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62 : D34-41, 2013.
PubMed
3) Montani D, et al : Drug-induced pulmonary arterial hypertension : a recent outbreak. Eur Respir Rev 22 : 244-250, 2013.
PubMed
4) Seferian A, et al : Drugs induced pulmonary arterial hypertension. Presse Med 42 : e303-310, 2013.
PubMed
5) Daccord C, et al : First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. Eur Respir J 51 : 1701694, 2018.
PubMed
6) Herrmann J : Common Vascular Toxicities of Cancer Therapies. Cardiol Clin 37 : 365-384, 2019.
PubMed
7) Starakis I, et al : Drug-induced thromboembolic events in patients with malignancy. Cardiovasc Hematol Disord Drug Targets 10 : 94-102, 2010.
PubMed
8) Ranchoux B, et al : Chemotherapy-induced pulmonary hypertension : role of alkylating agents. Am J Pathol 185 : 356-371, 2015.
PubMed
9) Li A, et al : The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma. Ann Hematol 99 : 121-126, 2020.
PubMed
10) Liu M, et al : Risk of severe pulmonary embolism in cancer patients receiving bevacizumab : Results from a meta-analysis of published and unpublished data. Tumour Biol 39 : 1010428317714897, 2017.
PubMed
11) Mari F, et al : Acute massive pulmonary thromboembolism due to acute intoxication by duloxetine : a case report. Cardiovasc Toxicol 12 : 258-262, 2012.
PubMed
12) Ohnishi Y, et al : Pulmonary Hypertension Following Increased Dosing of Diazoxide in an Infant. Int Heart J 61 : 1084-1087, 2020.
 
13) Orcholski ME, et al : Drug-induced pulmonary arterial hypertension : a primer for clinicians and scientists, Am J Physiol Lung Cell Mol Physiol 314 : L967-L983, 2018.
PubMed
P.291 掲載の参考文献
1) Simonneau G, et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53 : 1801913, 2019.
PubMed
2) Kozu K, et al : Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. Int J Cardiol 300 : 228-235, 2020.
PubMed
3) Tatebe S, et al : Clinical significance of reactive post-capillary pulmonary hypertension in patients with left heart disease. Circ J 76 : 1235-1244, 2012.
PubMed
4) Caravita S, et al : Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease : a meta-analysis. Eur Respir J 51 : 1702427, 2018.
PubMed
5) Rich S, Rabinovitch M : Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation 118 : 2190-2199, 2008.
PubMed
6) Hunt JM, et al : Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease. Am J Physiol Lung Cell Mol Physiol 305 : L725-736, 2013.
PubMed
7) Delgado JF, et al : Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 7 : 1011-1016, 2005.
PubMed
8) Vachiery JL, et al : Pulmonary hypertension due to left heart disease. Eur Respir J 53 : 1801897, 2019.
PubMed
9) Kovacs G, et al : Pulmonary arterial pressure during rest and exercise in healthy subjects : a systematic review. Eur Respir J 34 : 888-894, 2009.
PubMed
10) Naeije R, et al : Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure. Circ Heart Fail 10 : e004082, 2017.
PubMed
11) Califf RM, et al : A randomized controlled trial of epoprostenol therapy for severe congestive heart failure : The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 : 44-54, 1997.
PubMed
12) Packer M, et al : Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure : results of a pilot study. J Card Fail 11 : 12-20, 2005.
PubMed
13) Packer M et al : Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure : Primary Results of the ENABLE Trials. JACC Heart Fail 5 : 317-326, 2017.
PubMed
14) Anand I, et al : Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH) : randomised, double-blind, placebo-controlled trial. Lancet 364 : 347-354, 2004.
PubMed
15) Vachiery JL, et al : Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 51 : 1701886, 2018.
PubMed
16) Guazzi M : Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. Circ Heart Fail 1 : 272-280, 2008.
PubMed
17) Redfield MM, et al : Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction : a randomized clinical trial. JAMA 309 : 1268-1277, 2013.
PubMed
18) Bonderman D, et al : Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction : a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128 : 502-511, 2013.
PubMed
P.296 掲載の参考文献
1) Subias PE, et al : Comments on the 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) 69 : 102-108, 2016.
PubMed
2) Kovacs G, et al : Pulmonary arterial pressure during rest and exercise in healthy subjects : a systematic review. Eur Respir J 34 : 888-894, 2009.
PubMed
3) Nathan SD, et al : Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 53 : 1801914, 2019.
PubMed
4) Chaouat A, et al : Pulmonary hypertension in COPD. Eur Respir J 32 : 1371-1385, 2008.
PubMed
5) Andersen KH, et al : Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 31 : 373-380, 2012.
PubMed
6) Raghu G, et al : Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J 46 : 1370-1377, 2015.
PubMed
7) Kimura M, et al : Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 85 : 456-463, 2013.
PubMed
8) Shorr AF, et al : Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 30 : 715-721, 2007.
PubMed
9) Tanabe N, et al : Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology 20 : 805-812, 2015.
PubMed
10) Ruffenach G, et al : Pulmonary hypertension secondary to pulmonary fibrosis : clinical data, histopathology and molecular insights. Respir Res 21 : 303, 2020.
PubMed
11) 国枝武義 : 肺高血圧症の概念, 病態, 治療体制の確立に向けて. Therapeutic Research 26 : 2012-2021, 2005.
Medical*Online
12) Ullah W, et al : Comparative accuracy of non-invasive imaging versus right heart catheterization for the diagnosis of pulmonary hypertension : A systematic review and metaanalysis. Int J Cardiol Heart Vasc 29 : 100568, 2020.
PubMed
13) Weitzenblum E, et al : Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 131 : 493-498, 1985.
PubMed
14) Waxman A, et al : Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 384 : 325-334, 2021.
PubMed
P.302 掲載の参考文献
1) U. S. Navy Diving Manual, Rev7, Naval Sea Systems Command Publication, 0910-LP-115-1921, CHANGE A, 30 APRIL, 2018.
 
2) Francis TJR, Mitchell SJ : Manifestations of decompression disorders. In : Bennett and Elliott's Physiology and Medicine of Diving, 5th edition (ed by Brubakk AO, Neuman TS), p578-599, Saunders, Edinburgh, 2003.
 
3) Ryles MT, Pilmanis AA : The initial signs and symptoms of altitude decompression sickness. Aviat Space Environ Med 67 : 983-989, 1996.
PubMed
4) Vik A, et al : Venous air embolism in swine : transport of gas bubbles through the pulmonary circulation. J Appl Physiol (1985) 69 : 237-244, 1990.
PubMed
5) 鈴木信哉 : 潜水による障害, 再圧治療. 高気圧酸素治療法入門 第6版 (鈴木信哉編), p147-174, 日本高気圧環境・潜水医学会, 2017.
 
6) Moon RE : Hyperbaric treatment of air or gas embolism : current recommendations. Undersea Hyperb Med 46 : 673-683, 2019.
 
7) UHMS Best Practice Guidelines, Prevention and Treatment of Decompression Sickness and Arterial Gas Embolism, 2011. [https://www.uhms.org/images/DCS-AGE-Committee/dcsandage_prevandmgt_uhms-fi.pdf] (2021年7月閲覧)
 
8) Moon RE, Mitchell SJ : Hyperbaric treatment for decompression sickness : current recommendations. Undersea Hyperb Med 46 : 685-693, 2019.
 
9) Thom SR, et al : Association of microparticles and neutrophil activation with decompression sickness. J Appl Physiol (1985) 119 : 427-434, 2015.
PubMed
10) Yu X, et al : Bubble-Induced Endothelial Microparticles Promote Endothelial Dysfunction. PLoS One 12 : e0168881, 2017.
PubMed
11) Pearson RR, Goad RF : Delayed cerebral edema complicating cerebral arterial gas embolism : case histories. Undersea Biomed Res 9 : 283-296, 1982.
PubMed
12) Edmonds C : The evolution of scuba divers pulmonary edema. Undersea Hyperb Med 43 : 83-91, 2016.
PubMed
13) Morishima R, et al : A diver with immersion pulmonary oedema and prolonged respiratory symptorns. Diving Hyperb Med 48 : 259-261, 2018.
PubMed
14) Thom SR, et al : Inhibition of human neutrophil beta2-integrin-dependent adherence by hyperbaric O2. Am J Physiol 272 : C770-777, 1997.
PubMed
15) Thom SR, et al : Microparticles initiate decompression-induced neutrophil activation and subsequent vascular injuries. J Appl Physiol (1985) 110 : 340-351, 2011.
PubMed
16) 日本高気圧環境・潜水医学会 : 減圧症に対する高気圧酸素治療 (再圧治療) と大気圧下酸素吸入. 日本高気圧環境・潜水医学会雑誌 53 : 109-112, 2018.
 
17) Ball R : Effect of severity, time to recompression with oxygen, and re-treatment on outcome in forty-nine cases of spinal cord decompression sickness. Undersea Hyperb Med 20 : 133-145, 1993.
PubMed
18) Ziser A, et al : Hyperbaric oxygen therapy for massive arterial air embolism during cardiac operations. J Thorac Cardiovasc Surg 117 : 818-821, 1999.
PubMed
19) Benson J, et al : Hyperbaric oxygen therapy of iatrogenic cerebral arterial gas embolism. Undersea Hyperb Med 30 : 117-126, 2003.
PubMed
20) 鈴木信哉, ほか : 第1種装置で応急治療後に転院し第2種装置で再圧治療し軽快した内耳型減圧障害の一例. 日本高気圧環境・潜水医学会雑誌 53 : 260, 2018.
 
21) 鈴木信哉 : 減圧障害に対する治療-補助療法について-. 日本高気圧環境・潜水医学会雑誌 45 : 41-48, 2010.
Medical*Online
P.305 掲載の参考文献
1) Nakamura M, et al : Current management of venous thromboembolism in Japan : Current epidemiology and advances in anticoagulant therapy. J Cardiol 66 : 451-459, 2015.
PubMed
2) Kuroiwa M, et al : Changes in the incidence, case fatality rate, and characteristics of symptomatic perioperative pulmonary thromboembolism in Japan : Results of the 2002-2011 Japanese Society of Anesthesiologists Perioperative Pulmonary Thromboembolism (JSA-PTE) Study. J Anesth 29 : 433-441, 2015.
PubMed
3) Nakamura M, et al : Current venous thromboembolism management and outcomes in Japan. Circ J 78 : 708-717, 2014.
PubMed
4) 中村真潮 : 血栓性素因保有者の血栓症予防と治療. 血液フロンティア 25 : 37-43, 2014.
 
5) 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版) (日本循環器学会, ほか編), 2018 [https://www.j-circ.or.jp/old/guideline/pdf/JCS2017_ito_h.pdf]
 
6) Ota M, et al : Prognostic significance of early diagnosis in acute pulmonary thromboembolism with circulatory failure. Heart Vessels 17 : 7-11, 2002.
PubMed
P.309 掲載の参考文献
1) Bulger EM, et al : Fat embolism syndrome. A 10-year review. Arch Surg 132 : 435-439, 1997.
PubMed
2) Gurd AR, Wilson RI : The fat embolism syndrome. J Bone Joint Surg Br 56B : 408-416, 1974.
PubMed
3) Schonfeld SA, et al : Fat embolism prophylaxis with corticosteroids. A prospective study in high-risk patients. Ann Intern Med 99 : 438-443, 1983.
PubMed
P.313 掲載の参考文献
1) Walker AJ, et al : Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases. Eur J Cancer 49 : 1404-1413, 2013.
 
2) Khorana AA, et al : Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5 : 632-634, 2007.
PubMed
3) Sakuma M, et al : Venous thromboembolism : deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J 73 : 305-309, 2009.
PubMed
4) Sakamoto J, et al : Cancer-Associated Venous Thromboembolism in the Real World-From the COMMAND VTE Registry. Circ J 83 : 2271-2281, 2019.
PubMed
5) Blom JW, et al : Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 : 715-722, 2005.
PubMed
6) Prandoni P, et al : Cancer and venous thromboembolism. Lancet Oncol 6 : 401-410, 2005.
PubMed
7) Alahmari AK, et al : Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer : A Meta-Analysis of Randomized Controlled Trials. Am Health Drug Benefits 9 : 221-232, 2016.
PubMed
8) Khorana AA, et al : Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111 : 4902-4907, 2008.
PubMed
9) Lee AY, et al : Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 : 146-153, 2003.
PubMed
10) Raskob GE, et al : Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 378 : 615-624, 2018.
PubMed
11) Young AM, et al : Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism : Results of a Randomized Trial (SELECT-D). J Clin Oncol 36 : 2017-2023, 2018.
 
12) Agnelli G, et al : Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med 382 : 1599-1607, 2020.
PubMed
13) Key NS, et al : Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer : ASCO Clinical Practice Guideline Update. J Clin Oncol 38 : 496-520, 2020.
PubMed
14) Streiff MB, et al : NCCN Guidelines Insights : Cancer-Associated Venous Thromboembolic Disease, Version 1. 2021.
 
15) Prandoni P, et al : Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 : 3484-3488, 2002.
PubMed
P.318 掲載の参考文献
1) 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). (日本循環器学会, ほか編), 2018. [https://j-circ.or.jp/old/guideline/pdf/JCS2017-ito_h.pdf]
 
2) Jaff MR, et al : Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension : a scientific statement from the American Heart Association. Circulation 123 : 1788-1830, 2011.
PubMed
3) Konstantinides SV, et al : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41 : 543-603, 2020.
PubMed
4) 日本医療安全調査機構 (医療事故調査・支援センター) : 急性肺血栓塞栓症に係る死亡事例の分析 医療事故の再発防止に向けた提言 第2号, 2017. [https://www.medsafe.or.jp/uploads/uploads/files/teigen-02.pdf]
 
5) Tajima H, et al : Manual aspiration thrombectomy with a standard PTCA guiding catheter for treatment of acute massive pulmonary thromboembolism. Radiat Med 22 : 168-172, 2004.
PubMed
6) Kasper W, et al : Management strategies and determinants of outcome in acute major pulmonary embolism : results of a multicenter registry. J Am Coll Cardiol 30 : 1165-1171, 1997.
PubMed
7) Sakuma M, et al : Inferior vena cava filter is a new additional therapeutic option to reduce mortality from acute pulmonary embolism. Circ J 68 : 816-821, 2004.
PubMed
8) Nakamura M, et al : Clinical characteristics of acute pulmonary thromboembolism in Japan : results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol 24 : 132-138, 2001.
PubMed
9) Goldhaber SZ, et al : Acute pulmonary embolism : clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) Lancet 353 : 1386-1389, 1999.
 
10) Ota M, et al : Prognostic significance of early diagnosis in acute pulmonary thromboembolism with circulatory failure. Heart Vessels 17 : 7-11, 2002.
PubMed
P.322 掲載の参考文献
1) Cook RJ, et al : Septic pulmonary embolism : presenting features and clinical course of 14 patients. Chest 128 : 162-166, 2005.
PubMed
2) MacMillan JC, et al : Clinical spectrum of septic pulmonary embolism and infarction. J Thorac Cardiovasc Surg 75 : 670-679, 1978.
PubMed
3) Jiang J, et al : Septic pulmonary embolism in China : clinical features and analysis of prognostic factors for mortality in 98 cases. BMC Infect Dis 19 : 1082, 2019.
 
4) 佐野剛, 本間栄 : Septic pulmonary emboli. 呼吸 32 : 58-61, 2013.
Medical*Online
5) Ye R, et al : Clinical characteristics of septic pulmonary embolism in adults : a systematic review. Respir Med 108 : 1-8, 2014.
PubMed
6) Goswami U, et al : Associations and outcomes of septic pulmonary embolism. Open Respir Med J 8 : 28-33, 2014.
PubMed
7) Lee SJ, et al : Septic pulmonary embolism in Korea : microbiology, clinicoradiologic features, and treatment outcome. J Infect 54 : 230-234, 2007.
PubMed
8) Chou DW, et al : Septic Pulmonary Embolism Requiring Critical Care : Clinicoradiological Spectrum, Causative Pathogens and Outcomes. Clinics (Sao Paulo) 71 : 562-569, 2016.
PubMed
9) Ufuk F, et al : Non-thrombotic pulmonary embolism in emergency CT. Emerg Radiol 27 : 343-350, 2020.
PubMed
P.326 掲載の参考文献
1) 巽浩一郎, ほか : 慢性血栓塞栓性肺高血圧症 (CTEPH) 診療ガイドライン (日本肺高血圧・肺循環学会 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性呼吸器疾患・肺高血圧症に関する調査研究」班編), 2018.
 
2) Riedel M, et al : Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81 : 151-158, 1982.
PubMed
3) 福田恵一, ほか : 肺高血圧症治療ガイドライン [2017年改訂版] (日本循環器学会, ほか編). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_fukuda_h.pdf] (2021年7月閲覧)
 
4) Pengo V, et al : Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 : 2257-2264, 2004.
PubMed
5) Lang IM, Madani M : Update on chronic thromboembolic pulmonary hypertension. Circulation 130 : 508-518, 2014.
PubMed
6) Tanabe N, et al : Association of clinical features with HLA in chronic pulmonary thromboembolism. Eur Respir J 25 : 131-138, 2005.
PubMed
7) Galie N, Kim NHS : Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3 : 571-576, 2006.
 
8) Jujo T, et al : Evaluation of the Microcirculation in Chronic Thromboembolic Pulmonary Hypertension Patients : The Impact of Pulmonary Arterial Remodeling on Postoperative and Follow-Up Pulmonary Arterial Pressure and Vascular Resistance. PLoS One 10 : e0133167, 2015.
 
9) Kasai H, et al : Mosaic attenuation pattern in non-contrast computed tomography for the assessment of pulmonary perfusion in chronic thromboembolic pulmonary hypertension. Respir Investig 55 : 300-307, 2017.
PubMed
10) Rengier F, et al : Advanced imaging in pulmonary hypertension : emerging techniques and applications. Int J Cardiovasc Imaging 35 : 1407-1420, 2019.
 
11) Bunclark K, et al : A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 18 : 114-122, 2020.
PubMed
12) Ordi-Ros J, et al : Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome : A randomized non-inferiority trial. Ann Intern Med 171 : 685-694, 2019.
PubMed
13) Tanabe N, et al : Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice : interim data from post-marketing surveillance in Japan. Pulm Circ 10 : 1-9, 2020. (DOI : 10.1177/2045894020938986)
 
14) Karyofyllis P, et al : Balloon Pulmonary Angioplasty as a Treatment in Chronic Thromboembolic Pulmonary Hypertension : Past, Present, and Future. Curr Treat Options Cardiovasc Med 22 : 7, 2020.
PubMed
P.330 掲載の参考文献
1) Chandra D, et al : Meta-analysis : travel and risk for venous thromboembolism. Ann Intern Med 151 : 180-190, 2009.
PubMed
2) Sarvesvaran R : Sudden natural deaths associated with commercial air travel. Med Sci Law 26 : 35-38, 1986.
PubMed
3) Lapostolle F, et al : Severe pulmonary embolism associated with air travel. N Engl J Med 345 : 779-783, 2001.
PubMed
4) Dalen JE : Economy class syndrome : too much flying or too much sitting? Arch Intern Med 163 : 2674-2676, 2003.
PubMed
5) Watanabe H, et al : Impact of earthquakes on risk for pulmonary embolism. Int J Cardiol 129 : 152-154, 2008.
PubMed
6) Sueta D, et al : Venous thromboembolism caused by spending a night in a vehicle after an earthquake (night in a vehicle after the 2016 Kumamoto earthquake). Can J Cardiol 34 : 813.e9-e10, 2018.
 
7) Heckmann JG, et al : Increased frequency of cardioembolism and patent foramen ovale in patients with stroke and a positive travel history suggesting economy class stroke syndrome. Heart 92 : 1265-1268, 2006.
 
8) Ferrari E, et al : Travel as a risk factor for venous thromboembolic disease : a case-control study. Chest 115 : 440-444, 1999.
PubMed
9) Cruickshank JM, et al : Air travel and thrombotic episodes : the economy class syndrome. Lancet 332 : 497-498, 1988.
 
10) Scurr JH, et al : Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights : a randomised trial. Lancet 357 : 1485-1489, 2001.
PubMed
11) Cesarone MR, et al : Venous thrombosis from air travel : the LONFLIT3 study-prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects : a randomized trial. Angiology 53 : 1-6, 2002.
PubMed
12) 伊藤正明, ほか : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版), 2018.
 
P.335 掲載の参考文献
1) Babo FH, et al : Angiomas and angioma-like changes of the bronchial arteries. Forschr Roentgenstr 124 : 103-110, 1976.
 
2) Qian X, et al : Bronchial Dieulafoy's disease : a retrospective analysis of 73 cases. BMC Pulm Med 19 : 104, 2019.
 
3) 門松由佳 : 荒蕪肺を伴う続発性気管支動脈蔓状血管腫に対して左肺全摘術を施行した一例. 日本呼吸器外科学会雑誌 32 : 458-463, 2018.
 
4) Gziut AI, Gil RJ : Coronary aneurysms. Pol Arch Med Wewn 118 : 741-746, 2008.
PubMed
5) 大橋洋介, ほか : 喀血で発症した原発性気管支動脈蔓状血管腫の1例. 気管支学 43 : 60-65, 2021.
Medical*Online
6) Ishikawa H, et al : Efficacy and safety of super selective bronchial artery coil embolisation for haemoptysis : a single-centre retrospective observational study. BMJ Open 7 : e014805, 2017.
PubMed
7) Louey S, et al : Pediatric Racemose Hemangioma Treated with Angiographic Embolization. Am J Respir Crit Care Med 201 : e70-e71, 2020.
PubMed
8) Pua U, et al : Embolization of a Bronchial Artery-Pulmonary Artery Arterio-Venous Malformation. Ann Vasc Dis 12 : 253-255, 2019.
PubMed
9) Kitami A, et al : A Surgical Case of Bronchial Artery Aneurysm Directory Connecting with Pulmonary Artery. Ann Thorac Cardiovasc Surg 21 : 564-566, 2015.
PubMed
10) 石川秀雄 : 喀血/気管支動脈蔓状血管腫. 内科 127 : 544, 2021.
 
11) Kathuria H, et al : Management of life-threatening hemoptysis. J Intensive Care 8 : 23, 2020.
PubMed
12) Iwasaki M, et al : Primary racemose hemangioma of the bronchial artery. Intern Med 40 : 650-653, 2001.
PubMed
13) 成田欣史, ほか : 気管支動脈の著明な拡張, 蛇行を呈した原発性気管支動脈蔓状血管腫の1例. 気管支学 31 : 152-158, 2009.
Medical*Online
14) 石川秀雄, ほか : 呼吸器救急 大量喀血の治療戦略. 呼吸 33 : 252-258, 2014.
 
15) 蛇沢晶, ほか : 腐生性肺アスペルギルス症の病理-喀血源を含めて-. 日本胸部臨床 62 : 1070-1080, 2003.
 
16) Liao SX, et al : A rare and fatal respiratory disease : bronchial Dieulafoy's disease. Ther Adv Respir Dis 14 : 1753466620929236, 2020. (DOI : 10.1177/1753466620929236)
 
17) Panda A, et al : Bronchial artery embolization in hemoptysis : A systematic review. Diagn Interv Radiol 23 : 307-317, 2017.
PubMed
18) Omachi N, et al : The impact of bronchial artery embolisation on the quality of life of patients with haemoptysis : a prospective observational study. Eur Radiol 31 : 5351-5360, 2021.
PubMed
19) Ando T, et al : Early arterial embolization and mortality in mechanically ventilated patients with hemoptysis : A nationwide retrospective cohort study. Crit Care Med 48 : 1480-1486, 2020.
PubMed
20) Ishikawa H, et al : Spinal Cord Infarction after Bronchial Artery Embolization for Hemoptysis : A Nationwide Observational Study in Japan. Radiology 298 : 673-679, 2021.
PubMed
P.339 掲載の参考文献
1) Morita Y, et al : Bronchial artery anatomy : Preoperative 3D simulation with multidetector CT. Radiology 255 : 934-943, 2010.
PubMed
2) Suresh K, Shimoda LA : Lung Circulation. Compr Physiol 6 : 897-943, 2016.
PubMed
3) Fei QL, et al : An applied anatomical study of bronchial artery. Surg Radiol Anat 40 : 55-61, 2018.
PubMed
4) Cauldwell EW, et al : The bronchial arteries ; an anatomic study of 150 human cadavers. Surg Gynecol Obstet 86 : 395-412, 1948.
PubMed
5) McCullagh A, et al : The bronchial circulation-worth a closer look : areview of the relationship between the bronchial vasculature and airway inflammation. Pediatr Pulmonol 45 : 1-13, 2010.
 
6) Osaki S, et al : Prognosis of bronchial artery embolization in the management of hemoptysis. Respiration 67 : 412-416, 2000.
PubMed
7) San Norberto EM, et al : Endovascular treatment of bronchial aneurysms. J Thorac Cardiovasc Surg 156 : e109-e117, 2018.
PubMed
8) Di X, et al : Endovascular treatment of ectopic bronchial artery aneurysm with brachiocephalic artery stent placement and coil embolization A case report and literature review. Medicine (Balfimore) 95 : e4461, 2016.
PubMed
9) Mizuguchi S, et al : Ruptured bronchial artery aneurysm associated with bronchiectasis : a case report. Ann Thorac Cardiovasc Surg 15 : 115-118, 2009.
PubMed
10) Seo YH, Kwak JY : Spontaneous hemomediastinum and hemothorax caused by a ruptured bronchial artery aneurysm. Korean J Thorac Cardiovasc Surg 44 : 314-317, 2011.
PubMed
11) Ueda R, et al : A ruptured bronchial artery aneurysm with massive haemoptysis. BMJ Case Rep 2017 : bcr2017220392, 2017.
PubMed
12) Arici V, et al : Successful endovascular treatment of a bronchial artery aneurysm refractory to transcatheter embolization. Ann Vasc Surg 27 : 802.e13-802.e15, 2013.
 
13) Ishikawa H, et al : Spinal Cord Infarction after Bronchial Artery Embolization for Hemoptysis : A Nationwide Observational Study in Japan. Radiology 298 : 673-679, 2021.
PubMed
14) Ishikawa H, et al : Efficacy and safety of super selective bronchial artery coil embolisation for haemoptysis : A single-centre retrospective observational study. BMJ Open 7 : e014805, 2017.
PubMed
15) Omachi N, et al : The impact of bronchial artery embolisation on the quality of life of patients with haemoptysis : a prospective observational study. Eur Radiol 31 : 5351-5360, 2021.
PubMed
P.345 掲載の参考文献
1) 門間和夫 : 先天性肺動脈疾患 : 胎生期の形態と出生後のリモデリング. 日本小児循環器学会雑誌 16 : 96-103, 2000.
 
2) Pool PE, et al : Congenital Unilateral Absence of a Pulmonary Artery. The Importance of Flow in Pulmonary Hypertension. Am J Cardiol 10 : 706-732, 1962.
PubMed
3) Cucci CE, et al : Absence of a primary division of the pulmonary trunk. An ontogenetic theory. Circulation 29 : 124-131, 1964,
PubMed
4) 常本実 : 先天性肺血管異常. 血液と脈管 4 : 647-655, 1973.
 
5) Lucas PV Jr, et al : Anomalous Venous Connection, Pulmonary and Systemic. In : Heart Disease in Infants, Children and Adlescence (ed by Moss AJ, et al), The Williams & Willkins Co, Baltimore, 1968.
 
6) 白石公 : ここまで知っておきたい発生学 : 発生・形態形成の基礎知識. 日本小児循環器学会雑誌 34 : 88-98, 2018.
Medical*Online
7) 小児慢性特定疾病情報センター : 総動脈幹遺残症. [https://www.shouman.jp/disease/details/04_39_048/] (2021年7月閲覧)
 
8) Collett RW, Edwards JE : Persistent truncus arteriosus ; A classification according to anatomic types, Surg Clin North Amer 29 : 1245-1270, 1949.
 
9) Manhoff LJ, et al : Absence of the pulmonary artery ; a new classification for pulmonary arteries of anomalous origin ; report of a case of absence of the pulmonary artery with hypertrophied branchial arteries. Arch Pathol (Chic) 48 : 155-170, 1949.
PubMed
10) Van Praagh R, et al : The anatomy of common aorticopulmonary trunk (truncus arteriosus communis) and its embryologic implications. A study of 57 necropsy cases. Am J Cardiol 16 : 406-425, 1965.
PubMed
P.349 掲載の参考文献
1) 坂東政司 : 肺循環の異常 肺血管異常 特発性気道出血. 別冊日本臨牀 呼吸器症候群 II, p355-359, 日本臨牀社, 2009.
 
2) Herth F, et al : Long-term outcome and lung cancer incidence in patients with hemoptysis of unknown origin. Chest 120 : 1592-1594, 2001.
PubMed
3) Savale L, et al : Cryptogenic hemoptysis : from a benign to a life-threatening pathologic vascular condition. Am J Respir Crit Care Med 175 : 1181-1185, 2007.
PubMed
4) Ando T, et al : Clinical and Angiographic Characteristics of 35 Patients With Cryptogenic Hemoptysis. Chest 152 : 1008-1014, 2017.
PubMed
5) Nielsen K, et al : Bronchoscopy as a supplement to computed tomography in patients with haemoptysis may be unnecessary. Eur Clin Respir J 3 : 31802, 2016.
PubMed
6) Hamashima Y, Fujiwara H : Bronchoscopy in Hemoptysis. J Jpn Soc Resp Endoscopy 26 : 595-598, 2004.
 
7) 上野浩志, ほか : 特発性気道出血における喫煙と血圧の影響. 日本胸部臨床 75 : 914-921, 2016.
Medical*Online
8) Jean-Baptiste E : Clinical assessment and management of massive hemoptysis. Crit Care Med 28 : 1642-1647, 2000.
PubMed
9) Xia XD, et al : Massive cryptogenic hemoptysis undergoing pulmonary resection : clinical and pathological characteristics and management. Int J Clin Exp Med 8 : 18130-18136, 2015.
PubMed
10) Qian X, et al : Bronchial Dieulafoy's disease : a retrospective analysis of 73 cases. BMC Pulm Med 19 : 104, 2019.
 
11) 藤井亜希子, ほか : 繰り返す喀血に対しEndobronchial Watanabe Spigot (EWS) を用いた気管支充填術が奏功した症例. 日本呼吸器学会雑誌 46 : 416-419, 2008.
Medical*Online
12) Schmidt LH, et al : Blood clot removal by cryoextraction in critically ill patients with pulmonary hemorrhage. J Thorac Dis 11 : 4319-4327, 2019.
PubMed
13) 遠藤俊輔, ほか : 喀血症例に対する手術療法の適応と方法. 気管支学 26 : 614-620, 2004.
Medical*Online
14) Johnson JL : Manifestations of hemoptysis. How to manage minor, moderate, and massive bleeding. Postgrad Med 112 : 101-113, 2002.
PubMed
15) Petersen CL, et al : Five-year follow-up of hemoptysis with no malignancy suspected on chest computed tomography : recurrence, lung cancer and mortality, Eur Clin Respir J 6 : 1616519, 2019.
PubMed
P.355 掲載の参考文献
1) Ho SY, et al : Anomalies of venous connexions. In : Color Atlas of Congenital Heart Disease, Morphologic and Clinical Correlations (ed by Anderson RH), p35-43, Mosby-Wolfe, London, 1995.
 
2) 白石公 : 肺静脈の発生とその異常. 新 先天性心疾患を理解するための臨床心臓発生学 (山岸敬幸, 白石公編), p139-145, メジカルビュー社, 2021.
 
3) Craig JM, et al : Total pulmonary venous drainage into the right side of the heart : report of 17 autopsied cases not associated with other major cardiovascular anomalies. Lab Invest 6 : 44-64, 1957.
 
4) Brown DW, Geva T : Anomalies of the pulmonary veins. In : Moss and Adams' Heart Disease in Infants, Children, and Adolescents, Including the Fetus and Young Adult (ed by Allen HD, et al), p881-910, Wolters Kluwer, Philadelphia, 2016.
 
5) 白石修一 : 部分肺静脈還流異常. 小児・成育循環器病学 (日本小児循環器学会編), p465-468, 診断と治療社, 2018.
 
6) 関満, ほか : 小児期発生心疾患実態調査2019集計結果報告書. JSPCCS News Letter 3 : 15, 2020.
 
7) 角秀秋 : 肺静脈還流異常. 別冊日本臨牀 領域別症候群シリーズ No. 9 呼吸器症候群 第2版 II, p360-363, 日本臨牀社, 2009.
 
8) Gotsman MS, et al : Patial anomalous pulmonary venous drainage in association with atrial septal defect. Br Heart J 27 : 566-571, 1965.
PubMed
9) Gustafson RA, et al : Partial anomalous pulmonary venous connection to the right side of the heart. J Thorac Cardiovasc Surg 98 : 861-868, 1989.
 
10) McCormack RJ, et al : Partial anomalous pulmonary venous drainage and its surgical correction. Scott Med J 5 : 357-381, 1960.
PubMed
11) 樋口昌孝 : scimitar症候群. 小児科診療 79 (増刊号) : 157, 2016.
 
12) Harada T, et al : Surgical results of total anomalous pulmonary venous connection repair in 256 patients. Interact Cardiovasc Thorac Surg 28 : 421-426, 2019.
PubMed
13) Shi G, et al : Total Anomalous Pulmonary Venous Connection : The Current Management Strategies in a Pediatric Cohort of 768 Patients. Circulation 135 : 48-58, 2017.
 
14) Lacour-Gayet F, et al : Surgical management of progressive puimonary venous obstruction after repair of total anomalous pulmonary venous connection. J Thorac Cardiovasc Surg 117 : 679-687, 1999.
 
15) Ota N, et al : Improving outcomes of the surgical management of right atrial isomerism. Ann Thorac Surg 93 : 832-838 ; discussion 838-839, 2012.
 
P.359 掲載の参考文献
1) 福田恵一, ほか : 肺高血圧症治療ガイドライン (2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_fukuda_h.pdf] (2019年8月閲覧)
 
2) 日本肺高血圧・肺循環学会 : 肺静脈閉塞症 (PVOD) /肺毛細血管腫症 (PCH) 診療ガイドライン (2017年). [http://jpcphs.org/pdf/guideline/guideline.pdf] (2019年8月閲覧)
 
3) Simonneau G, et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53 : 1801913, 2019. [DOI : 10.1183/13993003.01913-2018].
 
4) Pietra GG, et al : Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80 : 1198-1206, 1989.
PubMed
5) Rubin LJ : Primary pulmonary hypertension. N Engl J Med 336 : 111-117, 1997.
PubMed
6) Montani D, et al : Pulmonary veno-occlusive disease. Eur Respir J 47 : 1518-1534, 2016.
PubMed
7) Eyries M, et al : EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 46 : 65-69, 2014.
PubMed
8) Dorfmuller P, et al : Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 38 : 893-902, 2007.
PubMed
9) 大郷恵子, ほか : 肺動脈性肺高血圧症および肺静脈閉塞症/肺毛細管腫症の病理-最近の知見から-. 日本呼吸器学会誌 3 : 471-477, 2014.
Medical*Online
10) Frazier AA, et al : From the Archives of the AFIP : pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Radiographics 27 : 867-882, 2007.
PubMed
11) 難病医学研究財団/難病情報センター : 肺静脈性閉塞症/肺毛細血管腫症 (指定難病87). [http://www.nanbyou.or.jp/entry/3869] (2021年8月閲覧)
 
12) Heath D, et al : Pulmonary veno-occlusive disease. Circulation 34 : 242-248, 1966.
PubMed
13) Wagenvoort CA, et al : Capillary haemangiomatosis of the lungs. Histopathology 2 : 401-406, 1978.
PubMed
14) Lantuejoul S, et al : Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis : a clinicopathologic study of 35 cases. Am J Surg Pathol 30 : 850-857, 2006.
PubMed
15) Best DH, et al : EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest 145 : 231-236, 2014.
PubMed
P.363 掲載の参考文献
1) Batram C, Strickland B : Pulmonary varices. Br J Radiol 44 : 927-935, 1971.
PubMed
2) Berecova Z, et al : A complex pulmonary vein varix-diagnosis with ECG gated MDCT, MRI and invasive pulmonary angiography. J Radiol Case Rep 6 : 9-16, 2012.
PubMed
3) Uyama T, et al : Pulmonary varices : acase report and review of the literature. JPn J Surg 18 : 359-362, 1988.
 
4) Emmert A, et al : Aneurysm of the pulmonary vein : an unusual cause of stroke. Ann Thorac Surg 98 : 1841-1843, 2014.
PubMed
5) 伊藤重範, ほか : 僧帽弁膜症に伴った肺静脈瘤の1例. 心臓 21 : 1356-1360, 1989.
 
6) Bryk D : Dilated right pulmonary veins in mitral insufficiency. Chest 58 : 24-27, 1970.
PubMed
7) Hayashi K, et al : Pulmonary venous aneurysm : Forming a glove balloon-like shape. Int J Surg Case Rep 28 : 139-141, 2016.
PubMed
8) 下川秀彦, ほか : 右肺静脈瘤に対し右S9, 10区域切除を施行した1例. 日本呼吸器外科学会雑誌 30 : 69-74, 2016.
 
9) Coffman J, et al : Management of asymptomatic pulmonary vein aneurysm. Respir Med Case Rep 20 : 7-9, 2017.
PubMed
10) AlNuaimi D, et al : Pulmonary venous varix associated with mitral regurgitation mimicking a mediastinal mass : A case report and review of the literature. Radiol Case Rep 13 : 404-407, 2018.
 
11) 辻本考平, ほか : 遺伝性出血性毛細血管拡張症において肺動静脈奇形を介し脳膿瘍を発症した1例. 臨床神経学 54 : 330-333, 2014.
 
12) Go T, et al : Aneurysm of right superior pulmonary vein. Ann Thorac Surg 89 : 987, 2010.
PubMed
13) Hayashi K, et al : Pulmonary venous aneurysm : Forming a glove balloon-like shape. Int J Surg Case Rep 28 : 139-141, 2016.
PubMed
14) Nauwerk C : Lungenvarix und Hernoptoe. Munch Med Wochenschr 70 : 1084, 1923.
 
15) Klinck GH Jr, Hunt HD : Pulmonary varix with spontaneous rupture and death. Arch Pathol 15 : 227-237, 1933.
 
P.367 掲載の参考文献
1) Pryce DM : Lower accessory pulmonary artery with intralobar sequestration of lung ; a report of seven cases. J Pathol Bacteriol 58 : 457-467, 1946.
 
2) Pryce DM, et al : Intralobar sequestration of lung associated with an abnormal pulmonary artery. Br J Surg 35 : 18-29, 1947.
PubMed
3) Campbell DC, et al : Systemic arterial blood supply to a normal lung. JAMA 182 : 497-499, 1962.
PubMed
4) 江崎紀浩, ほか : 肺底動脈大動脈起始症が高齢 (69歳) で発見された1例と本邦症例のまとめ. 日本呼吸器学会誌 49 : 528-533, 2011.
 
5) 増谷聡, ほか : 肺底区動脈大動脈起始症における肺内短絡の評価 選択的コントラストエコー, 選択的肺血流 シンチグラフィーを用いた検討. 日本小児循環器学会雑誌 17 : 732-737, 2001.
Medical*Online
6) 高森信吉, ほか : 肺底動脈大動脈起始症の1手術例. 日本呼吸器外科学会雑誌 30 : 236-242, 2016.
 
7) 後町杏子, ほか : 3D-CTにより診断し, 異常血管のみの切除にて治癒した肺底動脈大動脈起始症の1例. 日本呼吸器学会誌 49 : 221-225, 2011.
 
8) 多賀聡, ほか : 肺底区動脈体動脈起始症 (Pryce I型肺分画症) の一例. 日本呼吸器外科学会雑誌 11 : 74-80, 1997.
 
9) 窪倉浩俊, ほか : 左肺底区動脈大動脈起始症の2例. 日本医科大学医学会雑誌 4 : 118-122, 2008.
Medical*Online
10) 永瀬佑紀, ほか : 両側肺底動脈起始異常症の2例. 日本呼吸器学会誌 48 : 39-44, 2010.
 
11) Hessel EA, et al : High systemic origin of the sole artery to the basal segments of the left lung : findings, surgical treatment, and embryologic interpretation. Surgery 67 : 624-632, 1970.
 
12) Iizasa T, et al : Systemic arterial supply to the left basal segment without the pulmonary artery : four consecutive cases. Eur J Cardiothorac Surg 23 : 847-849, 2003.
 
13) Mori S, et al : Anomalous systemic arterial supply to the Basal segments of the lung : feasible thoracoscopic surgery. Ann Thorac Surg 96 : 990-994, 2013.
 
14) Letourneau-Guillon L, et al : Embolization of pulmonary arteriovenous malformations with amplatzer vascular plugs : safety and midterm effectiveness. J Vasc Interv Radiol 21 : 649-656, 2010.
PubMed
15) Jiang S, et al : Endovascular einbolization of the complete type of anomalous systemic arterial supply to normal basal lung segments : a report of four cases and literature review. Chest 139 : 1506-1513, 2011.
PubMed
P.372 掲載の参考文献
1) White RI, et al : Angioarchitecture of pulmonary arteriovenous malformations : an important consideration before embolotherapy. AJR Arn J Roentgenol 140 : 681-686, 1983.
 
2) Nakayama M, et al : Prevalence of pulmonary arteriovenous malformations as estimated by low-dose thoracic CT screening. Intern Med 51 : 1677-1681, 2012.
PubMed
3) 小宮山雅樹 : 遺伝性出血性毛細血管拡張症. 脳卒中の外科 43 : 193-200, 2015.
Medical*Online
4) Dakeishi M, et al : Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 19 : 140-148, 2002,
 
5) Shovlin CL, et al : Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91 : 66-67, 2000.
PubMed
6) Komiyama M, et al : Hereditary hemorrhagic telangiectasia in Japanese patients. J Hum Genet 59 : 37-41, 2014.
PubMed
7) Shovlin CL : Pulmonary arteriovenous malformations. Am J Respir Crit Care Med 190 : 1217-1228, 2014.
PubMed
8) Abdel-Aal AK, et al : Persistence of pulmonary arteriovenous malformations after successful embolotherapy with Amplatzer vascular plug : long-term results. Diagn Interv Radiol 22 : 358-364, 2016.
PubMed
9) Dinkel HP, Triller J : Pulmonary arteriovenous malformations : embolotherapy with superselective coaxial catheter placement and filling of venous sac with Guglielmi detachable coils. Radiology 223 : 709-714, 2002.
PubMed
10) Hayashi S, et al : Efficacy of venous sac embolization for pulmonary arteriovenous malformations : comparison with feeding artery embolization. J Vasc Interv Radiol 23 : 1566-1577, 2012.
PubMed
11) Kajiwara K, et al : Venous sac embolization of pulmonary arteriovenous malformation : safety and effectiveness at mid-term follow-up. Acta Radiol 55 : 1093-1098, 2014.
PubMed
12) Milic A, et al : Reperfusion of pulmonary arteriovenous malformations after embolotherapy. J Vasc Interv Radiol 16 : 1675-1683, 2005.
PubMed
P.378 掲載の参考文献
1) 門間和夫 : 先天性孤立性左肺動脈欠損症-名称, 成因, 肺高血圧, 縫合部狭窄-. 日本小児循環器学会雑誌 21 : 140, 2005.
Medical*Online
2) 新保秀人 : 先天性孤立性一側肺動脈欠損について. 日本小児循環器学会雑誌 21 : 139, 2005.
Medical*Online
3) 原澤寛, ほか : 稀な肺疾患 片側性肺動脈欠損症 (先天性). 呼吸 31 : 733-737, 2012.
 
4) Kruzliak P, et al : Unilateral absence of pulmonary artery : pathophysiology, symptoms, diagnosis and current treatment. Arch Cardiovasc Dis 106 : 448-454, 2013.
PubMed
5) Wang P, et al : Isolated unilateral absence of pulmonary artery in adulthood : a clinical analysis of 65 cases from a case series and systematic review. J Thorac Dis 9 : 4988-4996, 2017.
PubMed
6) Raymond A, et al : Neonatal diagnosis of isolated absence of the right pulmonary artery : a case report and review of the literature. Ital J pediatr 44 : 27, 2018.
PubMed
7) Kawada K, et al : Successful salvage of the left pulmonary artery in a neonate with isolated unilateral absence of the pulmonary artery. J Cardiol Cases 21 : 169-171, 2020.
 
8) 西畠信 : 小児の肺静脈狭窄性病変の病因と治療の選択. 日本小児循環器学会雑誌 25 : 153-155, 2009.
Medical*Online
9) Charlagorla P, et al : Congenital Pulmonary Vein Stenosis : Encouraging Mid-term Outcome. Pediatr Cardiol 37 : 125-130, 2016.
PubMed
10) 長友雄作, ほか : 孤立性片側肺静脈閉鎖症の3例. 日本小児循環器学会雑誌 33 : 318-325, 2017.
Medical*Online
11) Biradar B, et al : Unilateral pulmonary vein atresia : diagnostic dilemma unfolded on imaging. BMJ Case Rep 2018 : bcr2017224154, 2018.
PubMed
12) Levin TL, et al : Unilateral absence of the pulmonary veins : an unusual diagnosis with characteristic imaging findings. Clin Imaging 55 : 107-111, 2019.
PubMed
13) Okamoto R, et al : Mediastinal and hilar soft tissue mass-like lesions in congenital unilateral pulmonary vein atresia : A retrospective review of seven pediatric patients. Pediatr Int 62 : 1234-1240, 2020.
PubMed
P.383 掲載の参考文献
1) 血管炎症候群の診療ガイドライン (2017年改訂版). (日本循環器学会, ほか編), 2018. [https://www.j-circ.or.jp/old/guideline/pdf/JCS2017_isobe_h.pdf]
 
2) 薬剤性肺障害の診断・治療の手引き 第2版 2018 (日本呼吸器学会薬剤性肺障害診断・治療の手引き 第2版作成委員会編), メディカルレビュー社, 2018.
 
3) Gomez-Puerta JA, et al : Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest 136 : 1101-1111, 2009.
PubMed
4) Weng CH, Liu ZC : Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Chin Med J (Engl) 132 : 2848-2855, 2019.
PubMed
5) Radic M, et al : Drug-induced vascUlitis : a clinical and pathological review. Neth J Med 70 : 12-17, 2012.
PubMed
6) Almaani S, et al : ANCA-Associated Vasculitis : An Update. J Clin Med 10 : 1446, 2021.
PubMed
7) Gao Y, et al : Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatology (Oxford) 47 : 1515-1520, 2008.
 
8) Alidoost M, et al : Propylthiouracil-Induced Anti-Neutrophil Cytoplasmic Antibody Vasculitis Presenting with Red Eye Followed by Pulmonary Hemorrhage : Diagnostic and Management Considerations. Am J Case Rep 21 : e925200, 2020. (DOI : 10.12659/AJCR.925200)
 
9) Tieu J, et al : Rituximab for maintenance of remission in ANCA-associated vasculitis : expert consensus guidelines. Rheumatology (Oxford) 59 : e24-e32, 2020.
PubMed
10) Briasoulis E, Pavlidis N : Noncardiogenic pulmonary edema : an unusual and serious complication of anticancer therapy. Oncologist 6 : 153-161, 2001.
PubMed
11) 橋本修, 小林朋子 : 薬剤による肺血管病変 ; 肺循環の異常. 肺血管異常. 別冊日本臨牀新領域別症候群シリーズ No. 9 呼吸器症候群 (第2版) II-その他の呼吸器疾患を含めて-, p384-389, 日本臨牀社, 2009.
 
12) Assier E, et al : NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J Immunol 172 : 7661-7668, 2004.
PubMed
P.389 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vascuiitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Fujimoto S, et al : Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U. K. Rheumatology (Oxford) 50 : 1916-1920, 2011.
 
3) Wada N, et al : Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. Endocr J 49 : 329-334, 2002.
PubMed
4) Aloush V, et al : Propylthiouracil-induced autoimmune syndromes : two distinct clinical presentations with different course and management. Semin Arthritis Rheum 36 : 4-9, 2006.
PubMed
5) Tervaert JW, et al : Silicon exposure and vasculitis. Curr Opin Rheumatol 10 : 12-17, 1998.
PubMed
6) Yashiro M, et al : Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). Am J Kidney Dis 35 : 889-895, 2000.
PubMed
7) Xiao H, et al : Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110 : 955-963, 2002.
PubMed
8) Little MA, et al : Experimental autoimmune vasculitis : an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol 174 : 1212-1220, 2009.
PubMed
9) Nakazawa D, et al : Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol 25 : 990-997, 2014.
PubMed
10) Grayson PC, Kaplan M : At the Bench : Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases. J Leukoc Biol 99 : 253-264, 2016.
PubMed
11) Nakazawa D, et al : Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps : implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64 : 3779-3787, 2012.
 
12) Yoshida M, et al : Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis. Clin Exp Rheumatol 27 : S28-32, 2009.
 
13) Mukhtyar C, et al : Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68 : 1827-1832, 2009.
PubMed
14) Flaherty KR et al : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381 : 1718-1727, 2019.
PubMed
P.394 掲載の参考文献
1) Behcet H : Uber rezidivierende, aphthOse, durch ein Virus verusachet Geschwure am Mund, am Auge und an den Genitalien. Dermat Wochsch 105 : 1152-1157, 1937.
 
2) Takeno M, et al : Vascular involvement of Behcet's disease. In : Behcet's Disease : From Genetics to Therapies (ed by Ishigatsubo Y), 2015 edition, p79-100, Springer Tokyo, 2015.
 
3) Ideguchi H, et al : Characteristics of vascular involvement in Behcet's disease in Japan : a retrospective cohort study. Clin Exp Rheumatol 29 : S47-53, 2011.
PubMed
4) 石ヶ坪良明, ほか : 血管ベーチェット病の臨床像. 厚生労働省研究費補助金難治性疾患克服研究事業 ベーチェット病に関する調査研究 平成23年度総括・分担研究報告書, p76-82, 2012.
 
5) Ohno S, et al : HLA-Bw51 and Behcet's disease. JAMA 240 : 529, 1978.
PubMed
6) Meguro A, et al : Genetics of Behcet disease inside and outside the MHC. Ann Rheum Dis 69 : 747-754, 2010.
PubMed
7) Mizuki N, et al : Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 42 : 703-706, 2010.
PubMed
8) Kirino Y, et al : Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 45 : 202-207, 2013.
PubMed
9) Tascilar K, et al : Vascular involvement in Behcet's syndrome : a retrospective analysis of associations and the time course. Rheumatology (Oxford) 53 : 2018-2022, 2014.
PubMed
10) Seyahi E : Behcet's disease : how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol 30 : 279-295, 2016.
PubMed
11) Yazici H, et al : Behcet syndrome : a contemporary view. Nat Rev Rheumatol 14 : 107-119, 2018.
PubMed
12) Hamuryudan V, et al : The menacing pulmonary artery aneurysms of Behcet's syndrome. Clin Exp Rheumatol 22 (4 Suppl 34) : S1-3, 2004.
 
13) Kobayashi M, et al : Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease. Histopathology 36 : 362-371, 2000.
PubMed
14) Seyahi E, et al : Pulmonary artery involvement and associated lung disease in Behcet disease : a series of 47 patients. Medicine (Baltimore) 91 : 35-48, 2012.
PubMed
15) Tunaci M, et al : CT findings of pulmonary artery aneurysms during treatment for Behcet's disease. AJR Am J Roentgenol 172 : 729-733, 1999.
PubMed
16) Gul A, et al : Organizing pneumonia associated with pulmonary artery aneurysms in Behcet's disease. Rheumatology (Oxford) 38 : 1285-1289, 1999.
PubMed
17) Lakhanpal S, et al : Pathologic features of Behcet's syndrome : a review of Japanese autopsy registry data. Hum Pathol 16 : 790-795, 1985.
PubMed
18) Ozer Cm, et al : Inspiratory and expiratory HRCT findings in Behcet's disease and correlation with pulmonary function tests. Eur J Radiol 56 : 43-47, 2005.
 
19) Serra G, et al : Thoracic involvement in systemic primary vasculitis : radiological patterns and follow-up. JBR-BTR 97 : 57-68, 2014.
PubMed
20) Hatemi G, et al : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 77 : 808-818, 2018.
PubMed
21) Kingston M, et al : Aneurysm after arterial puncture in Behcet's disease. Br Med J 1 : 1766-1767, 1979.
PubMed
22) Tuzun H, et al : Management and prognosis of nonpulmonary large arterial disease in patients with Behcet disease. J Vasc Surg 55 : 157-163, 2012.
PubMed
23) Ha YJ, et al : Long-term clinical outcomes and risk factors for the occurrence of post-operative complications after cardiovascular surgery in patients with Behcet's disease. Clin Exp Rheumatol 30 (3 Suppl 72) : S18-26, 2012.
 
24) Saadoun D, et al : Mortality in Behcet's disease. Arthritis Rheum 62 : 2806-2812, 2010.
PubMed
P.400 掲載の参考文献
1) Jennette JC, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
PubMed
2) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
3) Takahashi K, et al : Kawasaki disease as a systemic vasculitis in childhood. Ann Vasc Dis 3 : 173-181, 2010.
PubMed
4) Hirayama K, et al : Anti-glomerular basement membrane antibody disease in Japan : part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol 12 : 339-347, 2008.
PubMed
5) 松尾清一, ほか : 厚生労働省特定疾患進行性腎障害に関する調査研究班報告 急速進行性腎炎症候群の診療指針 第2版. 日本腎臓学会誌 53 : 509-555, 2011.
 
6) Borza DB, et al : Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am J Kidney Dis 45 : 397-406, 2005.
PubMed
7) 磯部光章, ほか : 血管炎症候群の診療ガイドライン (2017年改訂版). p71-75, 2018. [https://www.j-circ.or.jp/old/guideline/pdf/JCS2017_isobe_h.pdf]
 
8) 住田孝之 : 血管炎 小型血管炎 免疫複合体性血管炎 抗GBM抗体病 (抗糸球体基底膜腎炎). 日本臨牀 75 (増刊 : 動脈・静脈の疾患, (下)) : 984-987, 2017.
 
9) Saulsbury FT : Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 78 : 395-409, 1999.
PubMed
10) 磯部光章, ほか : 血管炎症候群の診療ガイドライン (2017年改訂版). p78-83, 2018. [https://www.j-circ.or.jp/old/guideline/pdf/JCS2017_isobe_h.pdf]
 
11) 渡邊俊之 : 特集血管炎症候群のupdate, IgA血管炎-ガラクトース欠損IgA1など. リウマチ科 61 : 555-562, 2019.
 
12) 循環器病の診断と治療に関するガイドライン. 血管炎症候群の診療ガイドライン. Circ J 72 (Suppl IV) : 1303-1305, 2008.
 
13) Mills JA, et al : The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 33 : 1114-1121, 1990.
PubMed
14) Counahan R, et al : Prognosis of Henoch-Schonlein nephritis in children. Br Med J 2 : 11-14, 1977.
PubMed
15) Wright WK, et al : Pulmonary vasculitis with hemorrhage in anaphylactoid purpura. Pediatr Pulmonol 17 : 269-271, 1994.
PubMed
16) Medcalf JF, et al : Pulmonary haemorrhage in association with IgA nephropathy. Nephrol Dial Transplant 11 : 1148-1149, 1996.
PubMed
17) Ren X, et al : A case of anaphylactoid purpura nephritis accompanied by pulmonary hemorrhage and review of the literature. Exp Ther Med 5 : 1385-1388, 2013.
 
18) Ito Y, et al : Diffuse Alveolar Hemorrhage in IgA Vasculitis with an Atypical Presentation. Intern Med 57 : 81-84, 2018.
PubMed
19) Miyoshi S, et al : Pulmonary Hemorrhaging as a Fatal Complication of IgA Vasculitis. Intern Med 57 : 3141-3147, 2018.
PubMed
P.406 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Pagnoux C, et al : Clinical features and outcomes in 348 patients with polyarteritis nodosa : a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62 : 616-626, 2010.
 
3) Kastner D, et al : Polyarteritis nodosa and myocardial infarction. Can J Cardiol 16 : 515-518, 2000.
PubMed
4) Adams TN, et al : Pulmonary manifestations of large, medium, and variable vessel vasculitis. Respir Med 145 : 182-191, 2018.
PubMed
5) Lee YJ, et al : A case of systemic polyarteritis nodosa involving bronchial artery. Sarcoidosis Vasc Diffuse Lung Dis 27 : 164-168, 2010.
PubMed
6) Matsumoto T, et al : The lung in polyarteritis nodosa : a pathologic study of 10 cases. Hum Pathol 24 : 717-724, 1993.
PubMed
7) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
PubMed
8) 磯部光章, ほか : 血管炎症候群の診療ガイドライン (2017年改訂版), 2018.
 
9) Guillevin L, et al : Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors : a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 49 : 93-100, 2003.
PubMed
10) Ribi C, et al : Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors : A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62 : 1186-1197, 2010.
PubMed
11) Bourgarit A, et al : Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome : aretrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 84 : 323-330, 2005.
 
12) Guillevin L, et al : The Five-Factor Score revisited : assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90 : 19-27, 2011.
 
P.411 掲載の参考文献
1) 本間栄 : ANCA関連血管炎における間質性肺炎. 日本内科学会雑誌 108 : 1954-1961, 2019.
 
2) Sada K, et al ; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 : R101, 2014.
 
3) Alba MA, et al : Interstital lung disease in ANCA vasculitis. Autoimmun Rev 16 : 722-729, 2017.
PubMed
4) Katsumata Y, et al : Interstitial Lung Disease with ANCA-associated Vasculitis. Clin Med Insights Circ Respir Pulm Med 9 : 51-56, 2015.
PubMed
5) Kawasaki A, Tsuchiya N : Advances in the genomics of ANCA-associated vasculitis-a view from East Asia. Genes Immun 22 : 1-11, 2021. (DOI : 10.1038/s41435-021-00123-x)
 
6) Namba N, et al : Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis 78 : 1144-1146, 2019.
PubMed
7) 高田秀人, 針谷正祥 : ANCA関連血管炎. Evidence based medicineを活かす膠原病・リウマチ診療 (東京女子医科大学病院膠原病リウマチ痛風センター編), p496-515, メジカルビュー社, 2020.
 
8) Giorgiutti S, et al : Prevalence of antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis and spatial association with quarries in a French Northeast region. Arthritis Rheumatol 2021. (DOI : 10.1002/art.41767)
 
9) 黒崎敦子 : (10) 放射線科 ; ANCA関連血管炎 ; 専門領域の視点から. 日本臨牀増刊号血管炎 (第2版), p365-370, 日本臨牀社, 2018.
 
10) Yamagata M, et al : Prevalence and Responsiveness to Treatment of Lung Abnormalities on Chest Computed Tomography in Patients With Microscopic Polyangiitis : A Multicenter, Longitudinal, Retrospective Study of One Hundred Fifty Consecutive Hospital-Based Japanese Patients. Arthritis Rheumatol 68 : 713-723, 2016.
PubMed
11) ANCA関連血管炎診療ガイドライン 2017 (有村義宏, ほか編), 診断と治療社, 2017.
 
12) 勝又康弘 : 【膠原病・自己免疫疾患を「見える化」する】臨床から見える化する 血管炎 血管炎 を見える化する. Medicina 57 : 2119-2125, 2020.
 
13) Hirayama K, et al ; Japanese RPGN Study Group of Progressive Renal Disease : Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. Nephrol Dial Transplant 30 (Suppl 1) : i83-93, 2015.
 
14) Comarmond C, et al : Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA) -associated vasculitis : a series of 49 patients and review of the literature. Medicine (Baltimore) 93 : 340-349, 2014.
PubMed
P.416 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Monti S, et al : Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis : focus on giant cell arteritis. RMD Open 5 : e001003, 2019.
PubMed
3) Kobayashi S, et al : Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan : the first government-supported nationwide survey. Arthritis Rheum 49 : 594-598, 2003.
PubMed
4) Yoshifuji H : Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy. Mod Rheumatol 29 : 287-293, 2019.
PubMed
5) Ponte C, et al : Diagnosis of giant cell arteritis. Rheumatology (Oxford) 59 (suppl 3) : iii5-iii16, 2020.
 
6) Isobe M, et al : JCS 2017 Guideline on Management of Vasculitis Syndrome-Digest Version. Circ J 84 : 299-359, 2020.
PubMed
7) Ladanyi M, Fraser RS : Pulmonary involvement in giant cell arteritis. Arch Pathol Lab Med 111 : 1178-1180, 1987.
PubMed
8) Larson TS, et al : Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med 101 : 594-597, 1984.
PubMed
9) Karagiannis A, et al : Dry cough as first manifestation of giant-cell arteritis. J Am Geriatr Soc 54 : 1957-1958, 2006.
PubMed
10) Kramer MR, et al : Pulmonary manifestations of temporal arteritis. Eur J Respir Dis 71 : 430-433, 1987.
PubMed
11) Glover MU, et al : Pulmonary artery obstruction due to giant cell arteritis. Chest 91 : 924-925, 1987.
PubMed
12) Marie I, et al : Pleural effusion revealing giant cell arteritis. Eur J Intern Med 15 : 125-127, 2004.
PubMed
13) Roddy E, et al : Follicular bronchiolitis, an unusual cause of haemoptysis in giant cell arteritis. Clin Rheumatol 25 : 433-435, 2006.
PubMed
14) Weyand CM, et al : Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 371 : 50-57, 2014.
PubMed
15) Stone JH, et al : Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 377 : 1494-1495, 2017.
PubMed
P.420 掲載の参考文献
1) 高安右人 : 奇異ナル網膜血管之変状二就テ. 十全會雜誌 50 : 1-4, 1908.
 
2) Numano F, Kakuta T : Takayasu arteritis-five doctors in the history of Takayasu arteritis. Int J Cardiol 54 (Suppl) : S1-10, 1996.
 
3) 難病情報センター : 特定疾患医療受給者証所持者数. [http://www.nanbyou.or.jp/entry/1356]
 
4) 毛利昌史, ほか : 大動脈炎症候群における肺血流スキャン所見について. 核医学 7 : 59-60, 1970.
Medical*Online
5) Lupi E, et al : Pulmonary artery involvement in Takayasu's arteritis. Chest 67 : 69-74, 1975.
PubMed
6) Kong X, et al : Involvement of the pulmonary arteries in patients with Takayasu arteritis : a prospective study from a single centre in China. Arthritis Res Ther 22 : 131, 2020.
 
7) Kimura A, et al : Comprehensive analysis of HLA genes in Takayasu arteritis in Japan. Int J Cardiol 54 (Suppl) : S61-S69, 1996.
 
8) Hotchi M : Pathological studies on Takayasu arteritis. Heart Vessels 7 : 11-17, 1992.
PubMed
9) Watanabe Y, et al : Current Clinical Features of New Patients With Takayasu Arteritis Observed From Cross-Country Research in Japan : Age and Sex Specificity. Circulation 132 : 1701-1709, 2015.
PubMed
10) 血管炎症候群の診療ガイドライン (2017年改訂版). (日本循環器学会, ほか編), 2018. [https://j-circ.or.jp/old/guideline/pdf/JCS2017_isobe_h.pdf]
 
11) Ishikawa K, Maetani S : Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation 90 : 1855-1860, 1994.
PubMed
12) Ohigashi H, et al : Improved prognosis of Takayasu arteritis over the past decade-comprehensive analysis of 106 patients. Circ J 76 : 1004-1011, 2012.
PubMed
13) Nakaoka Y, et al : Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis : results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77 : 348-354, 2018.
PubMed
14) Saadoun D, et al : Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis : a multicenter experience. Circulation 125 : 813-819, 2012.
PubMed

書評

最近チェックした商品履歴

Loading...